<SEC-DOCUMENT>0001213900-15-007437.txt : 20151002
<SEC-HEADER>0001213900-15-007437.hdr.sgml : 20151002
<ACCEPTANCE-DATETIME>20151002162556
ACCESSION NUMBER:		0001213900-15-007437
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20151002
DATE AS OF CHANGE:		20151002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RELMADA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001553643
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				455401931
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-207248
		FILM NUMBER:		151140690

	BUSINESS ADDRESS:	
		STREET 1:		546 FIFTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-702-7163

	MAIL ADDRESS:	
		STREET 1:		546 FIFTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CAMP NINE, INC.
		DATE OF NAME CHANGE:	20120706
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>fs32015_relmadathera.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As
filed with the Securities and Exchange Commission on October 2, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Registration
No. 333-</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FORM
S-3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>Relmada
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></td>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>45-5401931</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State
        or other jurisdiction of</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">incorporation
        or organization)</FONT></P></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S.
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Identification
        Number)</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>757
Third Avenue, Suite 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>New
York, NY 10017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(212)
376-5776</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address,
including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Sergio
Traversa</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Relmada
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>757
3rd Avenue, Suite 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>New
York, New York 10017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(212)
376-5771</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Copies
of all communications, including communications sent to agent for service, should be sent to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Thomas
Slusarczyk, Esq.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Barclay
Damon, LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>One
Park Place</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>300
South State Street</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Syracuse,
New York 13202</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Tel.
(315) 235-2299</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fax
(315) 624-7359</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Approximate
date of commencement of proposed sale to the public:</B> From time to time after this Registration Statement becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box: &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box: &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462 I under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
this Form is a registration statement filed pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer</FONT></td>
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif">&#9744;</td>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer</FONT></td>
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif">&#9746;</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accelerated
    filer</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9744; </td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting
    company</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">(Do not check if a smaller reporting company)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title of each class of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>securities to be registered</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>Amount
    to be</B> </FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>registered<SUP>(1)</SUP></B> </FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>Proposed
    maximum</B> <B>offering </B></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>price</B> <B>per </B></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>security<SUP>(2)</SUP></B> </FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>Proposed
    </B></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>maximum</B></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <B>aggregate</B> <B>offering</B></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>price<SUP>(1)</SUP></B><SUP> </SUP></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Amount
    of</B> </FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>registration </B></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>fee<SUP>(3)</SUP> </B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Common Stock, $0.001 par value per share<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Preferred Stock, $0.001 par value per share<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Debt Securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Rights</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchase Contracts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Units</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 4pt">Total Offering</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 4pt double">200,000,000</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 4pt double">&mdash;</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 4pt double">200,000,000</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,140</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 4pt"><SUP>(3)</SUP></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    securities being registered hereunder consist of such indeterminate number of shares of common stock, and preferred stock,
    such indeterminate principal amount of debt securities, such indeterminate number of warrants to purchase common stock, preferred
    stock or debt securities, and such indeterminate number of rights, purchase contracts, or units as shall have an aggregate
    initial offering price not to exceed $200,000,000, less the aggregate dollar amount of all securities previously sold hereunder.
    If any debt securities are issued at an original issue discount, then the offering price of such debt securities shall be
    in such greater principal amount as shall result in an aggregate initial offering price not to exceed $200,000,000, less the
    aggregate dollar amount of all securities previously issued hereunder. Any securities registered hereunder may be sold separately
    or as units with other securities registered hereunder. Any securities registered hereunder may be sold separately or as units
    with the other securities registered hereunder. The proposed maximum offering price per share or unit will be determined,
    from time to time, by the registrant in connection with the issuance by the registrant of the securities registered hereunder.
    The securities registered hereunder also include such indeterminate number of shares of common stock, preferred stock and
    principal amounts of debt securities as may be issued upon conversion of or exchange for preferred stock or debt securities
    that provide for conversion or exchange, upon exercise of warrants or pursuant to the anti-dilution provisions of any of such
    securities. In addition, pursuant to Rule 416 under the Securities Act, the shares being registered hereunder include such
    indeterminate number of shares of common stock, preferred stock or debt securities as may be issuable with respect to the
    shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. </FONT></td></tr>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    proposed maximum offering price per security will be determined from time to time by the registrant in connection with, and
    at the time of, the issuance of the securities and is not specified as to each class of security pursuant to General Instruction
    II.D. of Form S-3 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).</FONT></td></tr>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Calculated
    pursuant to Rule 457(o) under the Securities Act based on the proposed maximum aggregate offering price of all securities
    listed.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THE
REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL
THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME
EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL
BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXPLANATORY
NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Registration Statement contains two prospectuses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;   </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
    base prospectus which covers the offering, issuance and sale by us of up to a maximum aggregate offering price of $200,000,000
    of our shares of common stock, shares of preferred stock, debt securities, warrants, rights, purchase contracts, and/or units;
    and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
        sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price
        of $75,000,000 of our common stock that may be issued and sold under a sales agreement with Cantor Fitzgerald &amp; Co.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The base
prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base
prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows
the base prospectus. The $75,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus
is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we
are not soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SUBJECT
TO COMPLETION, DATED OCTOBER 2, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$200,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Purchase
Contracts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering,
any combination of the securities described in this prospectus, up to an aggregate amount of $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or
change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement
as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of
the securities offered hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THIS
PROSPECTUS MAY NOT BE USED TO OFFER AND SELL SECURITIES UNLESS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents;
or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation
and any over-allotment options held by them will be described in the applicable prospectus supplement. See &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Our common stock is presently traded on the OTCQB under the symbol
&ldquo;RLMD.&rdquo; On September 30, 2015, the last reported sale price of our common stock was $4.90 per share. We recommend
that you obtain current market quotations for our common stock prior to making an investment decision. We will provide information
in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock on any securities
exchange.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INVESTING
IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY READ AND CONSIDER THE RISK FACTORS DESCRIBED IN THIS PROSPECTUS,
ANY ACCOMPANYING PROSPECTUS SUPPLEMENT, AND IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS. SEE &ldquo;RISK FACTORS&rdquo;
BEGINNING ON PAGE  6 AND IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
date of this prospectus is October &nbsp;&nbsp;&nbsp;, 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="toc"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_1"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUMMARY</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_4"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_5"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_6"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RATIO OF EARNINGS TO FIXED CHARGES AND PREFERENCE DIVIDENDS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">8</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_7"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF CAPITAL STOCK</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_8"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF DEBT SECURITIES</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_9"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF WARRANTS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_10"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF RIGHTS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_11"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF PURCHASE CONTRACTS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_12"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF UNITS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">26</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_13"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">27</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_14"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">29</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_15"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">29</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_16"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">29</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_17"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">30</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<DIV STYLE="padding: 2px; width: 100%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_1"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus
is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may, from time to time, issue and
sell to the public any combination of the securities described in this prospectus in one or more offerings up to a total dollar
amount of $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus
provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add to,
update or change information contained in this prospectus or in documents incorporated by reference in this prospectus and, accordingly,
to the extent inconsistent, information in this prospectus will be deemed modified or superseded by the information in the prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The prospectus
supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities offered; the
public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the offering of
the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You should
only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or issuer
free writing prospectus relating to a particular offering. No person has been authorized to give any information or make any representations
in connection with this offering other than those contained or incorporated by reference in this prospectus, any accompanying
prospectus supplement and any related issuer free writing prospectus in connection with the offering described herein and therein,
and, if given or made, such information or representations must not be relied upon as having been authorized by us. Neither this
prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an offer to sell or a
solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an
offering or solicitation. This prospectus does not contain all of the information included in the registration statement. For
a more complete understanding of the offering of the securities, you should refer to the registration statement, including its
exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You should
carefully read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as
the documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus,
before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free
writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated
by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to
the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the
information appearing in this prospectus, any prospectus supplement or any document incorporated by reference is accurate only
as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our
business, financial condition, results of operations and prospects may have changed since that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THIS
PROSPECTUS MAY NOT BE USED TO OFFER AND SELL SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registration
statement containing this prospectus, including exhibits to the registration statement, provides additional information about
us and the securities offered under this prospectus. The registration statement can be read at the SEC&rsquo;s website or at the
SEC offices mentioned under the heading &ldquo;Where You Can Find More Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>




<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_2"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>This
summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does
not contain all of the information you should consider before investing in our securities. You should carefully read the prospectus,
the information incorporated by reference and the registration statement of which this prospectus is a part in their entirety
before investing in our securities, including the information discussed under &ldquo;Risk Factors&rdquo; in this prospectus and
the documents incorporated by reference and our financial statements and notes thereto that are incorporated by reference in this
prospectus. As used in this prospectus, unless the context otherwise indicates, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo;
&ldquo;us,&rdquo; or &ldquo;the Company&rdquo; refer to Relmada Therapeutics, Inc., a Nevada corporation, and its subsidiary taken
as a whole.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
Therapeutics, Inc. (&ldquo;Relmada&rdquo; or the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company focused
on developing a pipeline of drug candidates to treat chronic pain. Chronic pain is often defined as any pain lasting more than
12 weeks. Whereas acute pain is a normal sensation that alerts us to possible injury, chronic pain persists &ndash; often for
months or even longer. Chronic pain may arise from an initial injury, such as back sprain, or there may be an ongoing cause, such
as an illness. Sometimes there is no clear cause. According to the National Institutes of Health, approximately 100 million people
in the U.S. are living with chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We intend
to realize our business objectives by implementing two core strategies to address unmet medical needs in the treatment of chronic
pain: a) developing improved versions of proven drug candidates and b) developing new chemical entities. This two tiered approach
is expected to reduce overall clinical development investment, time and risks. Our drug candidates are designed to improve the
overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics,
half-life and/or bioavailability of drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>d-Methadone
(dextromethadone, REL-1017)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our most-advanced
new chemical entity, d-Methadone (dextromethadone, REL-1017), is a novel, N-methyl-D-aspartate (&ldquo;NMDA&rdquo;) receptor antagonist
being developed for the treatment of neuropathic pain. As a single isomer of racemic methadone, d-Methadone has been shown to
possess NMDA antagonist properties with virtually no opioid activity at the expected therapeutic doses. The activation of NMDA
receptors has been associated with neuropathic pain and it is expected that d-Methadone will have a role in pain management by
blocking this activity. In contrast, racemic methadone is a long-acting narcotic producing typical opioid side effects used in
the treatment of various pain states and as a substitution therapy in opioid addiction. In November 2014, Health Canada approved
a Clinical Trial Application (&ldquo;CTA&rdquo;) to conduct the first Phase I study with d-Methadone. This is a Single Ascending
Dose (&ldquo;SAD&rdquo;) study that will be followed by a Multiple Ascending Dose (&ldquo;MAD&rdquo;) study, both in healthy volunteers.
The two studies are designed to assess the safety, tolerability and pharmacokinetics of d-Methadone in healthy subjects. The SAD
study includes single escalating oral doses of d-Methadone to determine the maximum tolerated dose. In the MAD study, healthy
subjects are to receive daily oral doses of d-Methadone for several days to assess its safety, pharmacokinetics and tolerability.
In March 2015, d-Methadone demonstrated a safe profile with no dose limiting side effects after four cohorts were exposed to increasing
higher doses. In April 2015, we received clearance from Health Canada to continue with dose escalation and explore higher doses
of d-Methadone. In June 2015, we successfully completed the SAD study and subsequently received a No Objection Letter (&ldquo;NOL&rdquo;)
from Health Canada to conduct the MAD clinical study in August 2015. The data from these studies will inform the design of a subsequent
Phase II proof of concept study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ketamine
hydrochloride (&ldquo;ketamine&rdquo;), an NMDA receptor antagonist, is a U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)-approved,
rapid-acting general anesthetic that also produces strong analgesia in neuropathic pain states. The NMDA receptor is an excitatory
glutamatergic receptor present at spinal and supraspinal sites and involved in the afferent transmission of nociceptive signals.
In chronic pain states, prolonged nociceptive stimulation causes activation and upregulation of the NMDA receptor at dorsal horn
synapses resulting in enhanced and amplified trafficking of pain signals to the brain, or central sensitization. This phenomenon
is an important factor in the process of perseverance of pain. There is now evidence that NMDA receptor antagonists that block
the NMDA receptor, such as ketamine, are able to halt the excessive barrage of nociceptive input to the brain and are therefore
potential alternatives to existing treatments of chronic pain syndromes. The potential for widespread therapeutic use of ketamine
is severely limited by its potential for abuse, dissociative and psychosis-like side effects. Orally-available d-Methadone is
among the new generation of pain medications with the potential to deliver ketamine-like palliative effects, without side effects
typically associated with ketamine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LevoCap
ER (REL-1015)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our most
advanced novel version of a proven drug product, LevoCap ER (REL-1015), is an extended release, abuse deterrent, proprietary formulation
of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other strong opioids
for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. In particular, levorphanol
binds to all three opioid receptor subtypes involved in analgesia (mu, kappa, and delta), the NMDA receptor and the norepinephrine
and serotonin uptake pumps, whereas morphine is relatively selective for mu sites. The dual mechanism of action of levorphanol,
combining opioid receptor agonism with noradrenaline reuptake inhibition in the same molecule makes levorphanol a useful analgesic
to treat chronic and neuropathic pain in addition to providing pain relief in patients resistant to other strong opioids. Levorphanol
is a strong opioid first synthesized decades ago and is considered equal in potency to hydromorphone, oxycodone, fentanyl and
methadone. In clinical studies, it has demonstrated a remarkably broad spectrum of analgesic activity against many different types
of pain, including neuropathic pain, post-surgical pain and chronic pain in patients refractory to other opioids. We continue
to scale up manufacturing and prepare for Phase III development program and are planning to submit a request to the FDA to discuss
the final regulatory and clinical plan for this product. In preparation for pivotal trial(s) that we plan to perform under the
U.S. Investigational New Drug (&ldquo;IND&rdquo;) program, we are selecting the final formulation and are planning to generate
the necessary good manufacturing practices (&ldquo;GMP&rdquo;) batches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BuTab
(REL-1028)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our second
most advanced novel version of a proven drug product, BuTab (REL-1028), represents novel formulations of oral, modified release
buprenorphine being developed for both chronic pain and opioid dependence indications. Buprenorphine is a partial opioid agonist
that has been widely used by the sublingual and transdermal routes of administration, but was believed to be ineffective by the
oral route. We have completed a preclinical program to better define the pharmacokinetic profile of BuTab and to assess the time
course of systemic absorption of buprenorphine using several different oral modified release formulations of buprenorphine in
dogs, compared to an intravenous administration. Based on the results of this work, we have obtained approval from Health Canada
to initiate a Phase I pharmacokinetic study in healthy volunteers in the second quarter of 2015. This trial is ongoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>MepiGel
(REL-1021)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our third
most advanced novel version of a proven drug product, MepiGel (REL-1021), is a proprietary topical dosage form of the local anesthetic
mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia
and painful human immunodeficiency virus (&ldquo;HIV&rdquo;)-associated neuropathy. Mepivacaine is an anesthetic, or numbing medicine,
that blocks the nerve impulses that send pain signals to the brain. It is chemically related to bupivacaine, but pharmacologically
related to lidocaine. Mepivacaine is currently indicated for infiltration, nerve block and epidural anesthesia. We have received
two FDA Orphan Drug Designations for mepivacaine, one for the treatment of painful HIV-associated neuropathy and one for the management
of postherpetic neuralgia (&ldquo;PHN&rdquo;). We have selected the formulations to be advanced into clinical studies for MepiGel
after the evaluation of results from in vitro and ex vivo studies conducted by MedPharm Ltd. comparing various topical prototypes
of mepivacaine. We are planning single and multiple dose Phase I studies in healthy subjects with the selected MepiGel formulations.
The data from these studies will inform the design of a subsequent Phase II proof of concept study in patients suffering from
neuropathic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Along
with antidepressants, antiepileptic drugs (&ldquo;AEDs&rdquo;) are often used as a first-line therapy for PHN. The most commonly
prescribed AEDs for PHN are gabapentin and pregabalin (Lyrica). Physicians typically prefer pregabalin because of its more-favorable
dosing attributes (less-frequent daily dosing, faster titration) in balance with price and accessibility. AEDs are commonly associated
with side effects, including somnolence, dizziness and weight gain. If first-line AEDs or antidepressant monotherapy fails to
provide acceptable pain relief, physicians initiate combination therapy. If AED/antidepressant combination therapy is not effective,
physicians typically add a dual-acting opioid, such as tramadol, to the treatment. For more-severe pain, physicians may add or
switch to tapentadol ER (Nucynta ER). If pain persists with the addition of tramadol or tapentadol, physicians often switch to
a more potent opioid analgesic, such asoxycodone, while maintaining AED and/or antidepressant therapy. Although some experts acknowledge
that strong opioids can be quite effective for PHN, they generally reserve this drug class for refractory cases and/or patients
with high pain intensity. For some PHN patients, particularly those experiencing highly localized pain, physicians may prescribe
the lidocaine 5% patch (Lidoderm). Pain specialists generally consider that lidocaine is particularly beneficial for localized
pain, and many physicians prefer it to oral agents because it does not cause systemic side effects and is easy to administer.
In many cases, the patch is used in combination with an oral first-line AED and/or antidepressant therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Acorda
Therapeutics, Inc. (&ldquo;Acorda&rdquo;) is developing a concentrated (20%) topical liquid formulation of capsaicin (NP-1998,
formerly NGX-1998) for the treatment of neuropathic pain. The product was formerly in development by NeurogesX, Inc. (&ldquo;NerogesX&rdquo;),
which licensed all U.S. rights as well as those of its 8% capsaicin patch (Qutenza) to Acorda in July 2013. Acorda is planning
to launch a Phase III clinical trial of NP-1998 in painful HIV peripheral neuropathy as the first potential indication for NP-1998.
Acorda is also exploring the potential for additional indications, including painful diabetic neuropathy. In 2011, NeurogesX completed
a Phase II trial in post-herpetic neuralgia and results from the trial confirmed efficacy and safety. Teva Pharmaceutical Industries
Ltd. (&ldquo;Teva&rdquo;) and Xenon Pharmaceuticals Inc. (&ldquo;Xenon&rdquo;) are developing TV-45070 (formerly XEN402), a subtype
selective ion channel inhibitor. TV-45070 has potentially broad application in nociceptive pain, including inflammatory pain,
and neuropathic pain indications. Xenon is partnered with Teva in a milestone, royalty and co-promotion partnership. Using a topical
(ointment) formulation of TV-45070, Teva has initiated a 300-patient Phase IIb clinical trial in osteoarthritis (&ldquo;OA&rdquo;)
of the knee. In July 2015, Teva reported that TV-45070 4% and 8% did not demonstrate statistically significant difference from
placebo in efficacy endpoints in the Phase IIb study in pain due to osteoarthritis of the knee. Teva is also developing topical
TV-45070 in neuropathic pain indications, and is currently planning a Phase IIb clinical trial in patients with post-herpetic
neuralgia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A significant
portion of our operating expenses is related to research and development and we intend to maintain our strong commitment to research
and development. Research and development expense for our fiscal year ended June 30, 2015, for the six months ended June 30, 2014
and for the year ended December 31, 2013 was approximately $7.9 million, $0.8 million and $5.3 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our
Corporate History and Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We are
a clinical stage biopharmaceutical company focused on developing a pipeline of drug candidates to treat chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
Therapeutics, Inc. (&ldquo;RTI&rdquo;) was incorporated in May 2004 as a privately held company. On December 31, 2014, RTI entered
into a merger agreement with Medeor Inc. (&ldquo;Medeor&rdquo;), through which all of Medeor&rsquo;s shares of common stock were
exchanged for shares of RTI&rsquo;s common stock, based upon a negotiated exchange ratio. Following the transaction, the corporate
existence of Medeor ceased and RTI continued as the surviving corporation. Prior to the merger, Medeor had been developing d-Methadone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In May
2014, RTI completed a share exchange with Camp Nine, Inc., a publicly traded Nevada corporation that was formed in May 2012. In
July 2014, we changed the name of Camp Nine, Inc. to Relmada Therapeutics, Inc. Pursuant to the share exchange, RTI shareholders
exchanged 10 shares of RTI&rsquo;s common stock for one share of our common stock. Following the share exchange, RTI&rsquo;s shareholders
acquired the majority of our issued and outstanding capital stock and RTI became our subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The share
exchange was accounted for as a &ldquo;reverse merger&quot; rather than a business combination, wherein we are considered the
acquirer for accounting and financial reporting purposes. The statement of operations reflects the activities of RTI from the
commencement of its operations since inception. Unless the context suggests otherwise, when we refer to business and financial
information for periods prior to the consummation of the share exchange, we are referring to the business and financial information
of RTI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2014, we changed our fiscal year end to June 30 and increased our authorized common stock to 500,000,000
shares and our authorized preferred stock to 200,000,000 shares, of which 3,500,000 is designated as Class A preferred stock.
On August 12, 2015, we completed a one-for-five reverse stock split in preparation for our proposed up-listing to the NASDAQ Capital
Markets or the NYSE MKT, reducing the authorized common share to 100,000,000 common shares. This prospectus reflects a retroactive
adjustment for the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Currently,
none of our drugs have been approved for sale in the United States or elsewhere. We have no commercial products nor do we have
a sales or marketing infrastructure. In order to market and sell our products we must conduct clinical trials on patients and
obtain regulatory approvals from appropriate regulatory agencies, like the FDA in the United States, and similar organizations
elsewhere in the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have
not generated revenues and do not anticipate generating revenues for the foreseeable future. We had a net loss of approximately
$20.8 million, $21.3 million and $19.9 million for our fiscal year ended June 30, 2015, for the six months ended June 30, 2014
and for the year ended December 31, 2013, respectively. At June 30, 2015, we had an accumulated deficit of approximately $76.1
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In August 2015, we filed an application to list our shares
of common stock on the NASDAQ Capital Market. Although we hope that our common stock will be accepted for listing on the NASDAQ
Capital Market, we cannot assure you that our application will be accepted or that we will be able to sustain such listing. Assuming
that our application is accepted, we expect to continue trading under the symbol &ldquo;RLMD&rdquo; and discontinue quotation
on the OTCQB.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Corporate
and Other Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our principal
executive offices are located at 757 3rd Avenue, Suite 2018, New York, New York 10017. Our telephone number is (212) 376-5776.
Our website address is www.relmada.com. Information accessed through our website is not incorporated into this prospectus and
is not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
Securities We May Offer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
offer our shares of common stock, shares of preferred stock, debt securities, warrants, rights, purchase contracts or units, or
any combination of the foregoing, with a total value of up to $200,000,000 from time to time under this prospectus at prices and
on terms to be determined by market conditions at the time of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In this
prospectus, we refer to the common stock, preferred stock, debt securities, warrants, rights, purchase contracts or units, or
any combination of the foregoing securities to be sold by us in a primary offering collectively as &ldquo;securities.&rdquo; This
prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities,
we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities,
as described below under &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus
may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_3"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An investment
in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities will
contain a discussion of the risks applicable to an investment in our securities. Before deciding whether to invest in our securities,
you should carefully consider the specific factors discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus
supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or
appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed
under Item 1A, &ldquo;Risk Factors,&rdquo; in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015, all of which
are incorporated herein by reference, as updated or superseded by the risks and uncertainties described under similar headings
in the other documents that are filed after the date hereof and incorporated by reference into this prospectus and any prospectus
supplement related to a particular offering. The risks and uncertainties we have described are not the only ones we face. Additional
risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. Past financial
performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results
or trends in future periods. If any of these risks actually occurs, our business, business prospects, financial condition or results
of operations could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss
of all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_4"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus,
each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement contain
&ldquo;forward-looking statements,&rdquo; which include information relating to future events, future financial performance, strategies,
expectations, competitive environment and regulation. Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo;
&ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar
expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not
be read as a guarantee of future performance or results and will probably not be accurate indications of when such performance
or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our
management&rsquo;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties
that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Important factors that could cause such differences include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty
    regarding the adequacy of our liquidity to pursue our complete business objectives;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to
    complete clinical trials as anticipated and obtain and maintain regulatory approvals for our products;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to
    adequately protect our intellectual property;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">disputes over
    ownership of intellectual property;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the risk that
    the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our products is
    an attractive alternative to other products;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">intense competition
    in our industry, with competitors having substantially greater financial, technological, research and development, regulatory
    and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">entry of new competitors
    and products and potential technological obsolescence of our products;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss of a key
    customer or supplier;</FONT></td></tr>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">technical
    problems with our research and products and potential product liability claims;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse economic
    conditions;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse federal,
    state and local government regulation, in the United States;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">price increases
    for supplies;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">inability to carry
    out research, development and commercialization plans; and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss or retirement
    of key executives and research scientists.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You should
review carefully the section entitled &ldquo;Risk Factors&rdquo; beginning on page  6 of this prospectus for a discussion of
these and other risks that relate to our business and investing in our securities. The forward-looking statements contained or
incorporated by reference in this prospectus or any prospectus supplement are expressly qualified in their entirety by this cautionary
statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances
after the date on which any such statement is made or to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_5"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We intend
to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_6"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RATIO
OF EARNINGS TO FIXED CHARGES AND PREFERENCE DIVIDENDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth our ratio of fixed charges and preference dividends to earnings for each of the periods indicated.
You should read this table in conjunction with the financial statements and notes incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif"><B>Year&nbsp;Ended
                                         June 30,</B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><BR> <FONT STYLE="line-height: 107%"><B>2015</B></FONT></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif"><B>Six&nbsp;Months&nbsp;Ended
June 30,</B></FONT><BR><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="line-height: 107%"><B>2014</B></FONT></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif"><B>Year
                                         Ended</B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><BR>
                                         <FONT STYLE="line-height: 107%"><B>December&nbsp;31,</B></FONT><BR>
                                         <FONT STYLE="line-height: 107%"><B>2013</B></FONT></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ratios
    of fixed charges and preference dividends to earnings</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have computed the ratio of fixed charges and preference dividends to earnings set forth above by dividing pre-tax loss before
fixed charges and preference dividends by fixed charges and preference dividends. Fixed charges are the sum of the following:</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 0.25in; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif">interest
    expensed and capitalized; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 0.25in; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif">amortized
    premiums related to indebtedness; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 0.25in; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0pt; line-height: 107%; text-indent: 0pt"><FONT STYLE="font: 10pt/107% Times New Roman, Times, Serif">an
    estimate of the interest within rental expense. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have not paid any cash dividends on any shares of our capital stock during the periods set forth above.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
has not recorded earnings for the fiscal years ended June 30, 2015, for the six months ended June 30, and for the year ended December&nbsp;31,
2014. Accordingly, the Company was insufficient to cover fixed charges for such periods and we are unable to disclose a ratio
of fixed charges and preference dividends to earnings for such periods. The dollar amount of the deficiency in earnings available
for fixed charges and preference dividends for the f the fiscal years ended June 30, 2015, for the six months ended June 30, December&nbsp;31,
2014 and for the fiscal year ended December 31, 2013 was approximately $20.8 million and $19.9 million, respectively.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_7"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The following
description of common stock and preferred stock summarizes the material terms and provisions of the common stock and preferred
stock that we may offer under this prospectus, but is not complete. For the complete terms of our common stock and preferred stock,
please refer to our amended and restated certificate of incorporation and our bylaws, which have been filed with the SEC as exhibits
to our registration statement, of which this prospectus forms a part. While the terms we have summarized below will apply generally
to any future common stock or preferred stock that we may offer, we will describe the specific terms of any series of preferred
stock in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any preferred
stock we offer under that prospectus supplement may differ from the terms we describe below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">We have authorized 300,000,000 shares of capital stock, par value
$0.001 per share, of which 100,000,000 are shares of common stock and 200,000,000 are shares of preferred stock, 3,500,000 of
which are designated Class A Convertible Preferred Stock. On October 2, 2015, there were 11,014,155 shares of common stock issued
and outstanding and 71,672 shares of Class A convertible preferred stock issued and outstanding. There are no preferred issued
and outstanding. The authorized and unissued shares of common stock and the authorized and undesignated shares of preferred stock
are available for issuance without further action by our stockholders, unless such action is required by applicable law or the
rules of any stock exchange on which our securities may be listed. Unless approval of our stockholders is so required, our board
of directors does not intend to seek stockholder approval for the issuance and sale of our common stock or preferred stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We also
have warrants that are outstanding, which are described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The following
is a summary of the material provisions of the common stock and preferred stock provided for in our amended and restated certificate
of incorporation and bylaws. For additional detail about our capital stock, please refer to our certificate of incorporation and
bylaws, each as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The holders
of our common stock are entitled to one vote per share. Our certificate of incorporation does not provide for cumulative voting.
Our directors are divided into three classes. At each annual meeting of stockholders, directors elected to succeed those directors
whose terms expire are elected for a term of office to expire at the third succeeding annual meeting of stockholders after their
election. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board
of directors out of legally available funds. However, the current policy of our board of directors is to retain earnings, if any,
for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share
ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription
or conversion rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences
and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any
series of preferred stock, which may be designated solely by action of our board of directors and issued in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Our common stock is listed on the OTCQB under the symbol &ldquo;RLMD.&rdquo;
We have applied to list our common stock on the NASDAQ Capital Market. There can be no assurance, however, that our application
will be approved.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">As of October 2, 2015, there were 71,672 shares of Class A Convertible
Preferred Stock issued and outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The rights
and preferences of our Class A Convertible Preferred Stock include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Liquidation
Preference</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the event of any dissolution, liquidation or winding up of our Company, whether voluntary or involuntary, the holders of our Class A
Convertible Preferred Stock are entitled to participate in any distribution out of our assets of on an equal basis per share
with the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Class
A Convertible Preferred Stock is, with respect to dividend rights, entitled to two times the amount of any dividend granted by
our board of directors to the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Optional
Conversion. </I>Subject to certain exceptions, each share of Class A Convertible Preferred Stock is convertible at the option
of the holder and without the payment of additional consideration by the holder, at any time, into shares of our common stock
at a conversion rate of one share of our common stock for every one share of our Class A Convertible Preferred Stock. However,
a holder of our Class A Convertible Preferred Stock cannot convert shares of our Class A Convertible Preferred Stock to shares
of our common stock if such conversion would cause the holder or any &ldquo;group&rdquo; (within the meaning of Section 13(d)
of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)) of which such holder is or deemed to be a part, to &ldquo;beneficially
own&rdquo; (within the meaning of Rule 13d-3 under the Exchange Act) more than 9.9% of the number of shares of our common stock
listed as outstanding by in our most recent public filing with the SEC prior to us receiving the conversion demand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Automatic
Conversion. </I>Subject to the limitation on conversion described above, on the first day of each month until there are no shares
of our Class A Convertible Preferred Stock outstanding, each share of our Class A Convertible Preferred Stock will convert without
the payment of additional consideration by a holder into shares of our common stock on the automatic conversion date at a conversion
rate of one share of our common stock for every one share of our Class A Convertible Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Voting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The holders
of our Class A Convertible Preferred Stock are not entitled to vote on any matter submitted to a vote of the holders of our common
stock, including the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The board
of directors is authorized, subject to any limitations prescribed by law, without further vote or action by our stockholders,
to issue from time to time shares of preferred stock in one or more series. Each such series of preferred stock shall have such
number of shares, designations, preferences, voting powers, qualifications and special or relative rights or privileges as determined
by our board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion
rights and preemptive rights. Issuance of preferred stock by our board of directors may result in such shares having dividend
and/or liquidation preferences senior to the rights of the holders of our common stock and could dilute the voting rights of the
holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prior
to the issuance of shares of each series of preferred stock, our board of directors is required by the Nevada Revised Law and
our amended and restated certificate of incorporation to adopt resolutions and file a certificate of designation with the Secretary
of State of the State of Nevada. The certificate of designation fixes for each class or series the designations, powers, preferences,
rights, qualifications, limitations and restrictions, including, but not limited to, some or all of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    number of shares constituting that series and the distinctive designation of that series, which number may be increased or
    decreased (but not below the number of shares then outstanding) from time to time by action of our board of directors;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the dividend rate
    and the manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative, and,
    if so, from which date;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether that series
    will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights;</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether that series
    will have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment
    of the conversion rate in such events as our board of directors may determine;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether or not
    the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether that series
    will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such
    sinking fund;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether or not
    the shares of the series will have priority over or be on a parity with or be junior to the shares of any other series or
    class in any respect;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the rights of
    the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation,
    and the relative rights or priority, if any, of payment of shares of that series; and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any other relative
    rights, preferences and limitations of that series.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Once designated
by our board of directors, each series of preferred stock may have specific financial and other terms that will be described in
a prospectus supplement. The description of the preferred stock that is set forth in any prospectus supplement is not complete
without reference to the documents that govern the preferred stock. These include our amended and restated certificate of incorporation
and any certificates of designation that our board of directors may adopt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All shares
of our preferred stock will, when issued, be fully paid and non-assessable, including shares of our preferred stock issued upon
the exercise of preferred stock warrants or subscription rights, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
our board of directors has no intention at the present time of doing so, it could authorize the issuance of a series of preferred
stock that could, depending on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Series
A Preferred Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">In connection with our sale of Series A preferred stock and 8%
senior subordinated unsecured convertible notes in 2012 and 2013, we sold to the purchasers 498,437 warrants to purchase common
stock at an exercise price of $4.00 per share (the &ldquo;Series A Preferred Warrants&rdquo;). The Series A Preferred Warrants
have a seven-year term from their issuance dates, which occurred between July 10, 2012 and September 26, 2013. The exercise price
of the Series A Preferred Warrants is subject to adjustment upon certain events. If we at any time while the Series A Preferred
Warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding common stock payable
in shares of its capital stock, or split, subdivide or combine the common stock into a different number of securities of the same
class, the exercise price for the Series A Preferred Warrants shall be proportionately decreased in the case of a dividend, split
or subdivision or proportionately increased in the case of a combination. The Series A Preferred Warrants contained an anti-dilution
provision that was eliminated upon the Company going public.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Notes
Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">In connection with our 2013 notes financing, we sold to the purchasers
42,750 warrants to purchase common stock at an exercise price of $4.00 per share. The note warrants have a seven-year term from
their issuance dates and have substantially the same terms as the Series A Preferred Warrants (as described above).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Advisory
Firm Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">In connection with an agreement with an advisory firm,
we issued to such advisory firm warrants (&quot;Advisory Firm Warrants&quot;) to purchase 12% of the fully diluted shares
of Relmada, or 1,731,157 shares of common stock. As of October 1, 2015 there were 1,539,980 Advisory Firm Warrants
outstanding. The Advisory Firm Warrants are exercisable at $0.001 per share, provide for cashless exercise and expire seven
years after the date of issuance. Shares purchased by exercise of the Advisory Firm Warrants have unlimited piggyback
registration rights should we have a public offering registered with the SEC and are subject to lock-ups, if any, required by
SEC regulations or other applicable law, or by investors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Series
B Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">In connection with our sale of units in 2014, we sold to the
purchasers &lrm;an aggregate of 1,716,379 Series B warrants to purchase common stock at an exercise price of $11.25 per share
(the &quot;Series B Warrants&quot;). The Series B Warrants have a five-year term from their respective issuance dates. There is
a cashless exercise provision. We may call these Series B Warrants for redemption upon written notice to all purchasers at any
time the closing price of the common stock exceeds $18.75 for 20 consecutive trading days, as reported by Bloomberg, provided
at such time there is an effective registration statement covering the resale of the shares. In the 60 business days following
the date the redemption notice is deemed given, investors may choose to exercise their respective Series B Warrant or a portion
of their Series B Warrant by paying the then applicable exercise price. Any shares not exercised on the last day of the exercise
period will be redeemed by us at $0.001 per share. The Series B Warrants have an anti-dilution provision, which will terminate
upon the issuance of a clearance letter for the up-listing of our common stock to a senior stock exchange such as NASDAQ Capital
Market or the NYSE MKT.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Placement
Agent Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In connection with our sale of Series A preferred
stock and 8% senior subordinated unsecured convertible notes in 2012 and 2013, we issued to a placement agent warrants to
purchase 250,000 shares of common stock at an exercise price of $4.00 per share (the &ldquo;Placement Agent Warrants&rdquo;).
As of October 1, 2015 there are 183,863 warrants to purchase common stock outstanding. These Placement Agent Warrants include
a cashless exercise provision and have substantially the same terms as the Series A Preferred Warrants. In connection with
the 2013 notes financing, the placement agent or its designees also received five-year warrants to purchase 28,125 shares of
our common stock at a price of $4.00 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In connection with our merger with Medeor in December 2013,
we issued to a placement agent 40,000 warrants exercisable for shares of our common stock at an exercise price of $5.50 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In connection with our May 2014 offering, we also issued
to a placement agent warrants to purchase 858,190 shares of common stock at an exercise price of $7.50 per share (the &ldquo;2014
Placement Agent Warrants&rdquo;). The 2014 Placement Agent Warrants issued have substantially the same proportional adjustment
provisions as the Series A Preferred Warrants described above. The 2014 Placement Agent Warrants have an anti-dilution provision,
which will terminate upon the issuance of a clearance letter for the up-listing of our common stock to a senior stock exchange
such as NASDAQ Capital Market or the NYSE MKT.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Founder
Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">During 2012, we issued our founder 173,643 warrants to purchase
common stock in connection with a transaction that exchanged debt for stock. The warrants have an exercise price of $4.00 per
share and will expire five years from their respective issuance dates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In connection
with our May 2014 private placement offering that closed on May 15, 2014, we were obligated to file within 45 days of the final
closing of the offering a registration statement registering for resale all shares of our common stock issued as part of the units
and all of our common shares issuable upon exercise of the Series A and Series B Warrants issued in the offering. In connection
with Camp Nine, Inc.&rsquo;s May 2014 private placement offering that closed on June 10, 2014, we were obligated to file within
45 days of the final closing of the offering a registration statement registering for resale of all shares of Camp Nine, Inc.&rsquo;s
common stock issued as part of the units and all of Camp Nine, Inc.&rsquo;s common shares issuable upon exercise of the Series
A and Series B Warrants issued in the offering. We were also obligated to include in the registration statement (i) our Series
A Preferred Stock that converted into shares of our common stock at the share exchange, (ii) our Notes that converted into shares
of our common stock at the share exchange, (iii) underlying shares of our common stock included with the Series A Preferred Warrants
and Notes Warrants, (iv) underlying shares of our common stock in connection with warrants issued to the placement agent in our
Series A Preferred financing and (v) Notes financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Anti-takeover
Effects of Our Articles of Incorporation and By-laws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our amended
and restated articles of incorporation and bylaws contain certain provisions that may have anti-takeover effects, making it more
difficult for or preventing a third party from acquiring control of us or changing our board of directors and management. According
to our amended and restated articles of incorporation and bylaws, neither the holders of our common stock nor the holders of our
preferred stock have cumulative voting rights in the election of our directors. The combination of the present ownership by a
few stockholders of a significant portion of the issued and outstanding shares of our common stock and lack of cumulative voting
makes it more difficult for other stockholders to replace our board of directors or for a third party to obtain control of us
by replacing our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Anti-takeover
Effects of Nevada Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Business
Combinations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The &ldquo;business
combination&rdquo; provisions of Sections 78.411 to 78.444, inclusive, of the Nevada Revised Statutes (&ldquo;NRS&rdquo;), generally
prohibit a Nevada corporation with at least 200 stockholders of record, a &ldquo;resident domestic corporation,&rdquo; from engaging
in various &ldquo;combination&rdquo; transactions with any &ldquo;interested stockholder&rdquo; unless certain conditions are
met or the corporation has elected in its articles of incorporation to not be subject to these provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A &ldquo;combination&rdquo;
is generally defined to include (a) a merger or consolidation of the resident domestic corporation or any subsidiary of the resident
domestic corporation with the interested stockholder or affiliate or associate of the interested stockholder, (b) any sale, lease,
exchange, mortgage, pledge, transfer or other disposition, in one transaction or a series of transactions, by the resident domestic
corporation or any subsidiary of the resident domestic corporation to or with the interested stockholder or affiliate or associate
of the interested stockholder having: (i) an aggregate market value equal to 5% or more of the aggregate market value of the assets
of the resident domestic corporation, (ii) an aggregate market value equal to 5% or more of the aggregate market value of all
outstanding shares of the resident domestic corporation or (iii) 10% or more of the earning power or net income of the resident
domestic corporation, (c) the issuance or transfer in one transaction or series of transactions of shares of the resident domestic
corporation or any subsidiary of the resident domestic corporation having an aggregate market value equal to 5% or more of the
resident domestic corporation to the interested stockholder or affiliate or associate of the interested stockholder and (d) certain
other transactions with an interested stockholder or affiliate or associate of the interested stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An &ldquo;interested
stockholder&rdquo; is generally defined as a person who, together with affiliates and associates, owns (or within three years,
did own) 10% or more of a corporation&rsquo;s voting stock. An &ldquo;affiliate&rdquo; of the interested stockholder is any person
that directly or indirectly through one or more intermediaries is controlled by or is under common control with the interested
stockholder. An &ldquo;associate&rdquo; of an interested stockholder is any (a) corporation or organization of which the interested
stockholder is an officer or partner or is directly or indirectly the beneficial owner of 10% or more of any class of voting shares
of such corporation or organization, (b) trust or other estate in which the interested stockholder has a substantial beneficial
interest or as to which the interested stockholder serves as trustee or in a similar fiduciary capacity or (c) relative or spouse
of the interested stockholder, or any relative of the spouse of the interested stockholder, who has the same home as the interested
stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If applicable,
the prohibition is for a period of two years after the date of the transaction in which the person became an interested stockholder,
unless such transaction is approved by the board of directors prior to the date the interested stockholder obtained such status;
or the combination is approved by the board of directors and thereafter is approved at a meeting of the stockholders by the affirmative
vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders; and extends
beyond the expiration of the two-year period, unless (a) the combination was approved by the board of directors prior to the person
becoming an interested stockholder, (b) the transaction by which the person first became an interested stockholder was approved
by the board of directors before the person became an interested stockholder, (c) the transaction is approved by the affirmative
vote of a majority of the voting power held by disinterested stockholders at a meeting called for that purpose no earlier than
two years after the date the person first became an interested stockholder or (d) if the consideration to be paid to all stockholders
other than the interested stockholder is, generally, at least equal to the highest of: (i) the highest price per share paid by
the interested stockholder within the three years immediately preceding the date of the announcement of the combination or in
the transaction in which it became an interested stockholder, whichever is higher, plus compounded interest and less dividends
paid, (ii) the market value per share of common shares on the date of announcement of the combination and the date the interested
stockholder acquired the shares, whichever is higher, plus compounded interest and less dividends paid or (iii) for holders of
preferred stock, the highest liquidation value of the preferred stock, plus accrued dividends, if not included in the liquidation
value. With respect to (i) and (ii) above, the interest is compounded at the rate for one-year United States Treasury obligations
from time to time in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Applicability
of the Nevada business combination law would discourage parties interested in taking control of our company if they cannot obtain
the approval of our board of directors. These provisions could prohibit or delay a merger or other takeover or change in control
attempt and, accordingly, may discourage attempts to acquire our company even though such a transaction may offer our stockholders
the opportunity to sell their stock at a price above the prevailing market price. We have elected to not be governed by the Nevada
business combination provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Control
Share Acquisitions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The &ldquo;control
share&rdquo; provisions of Sections 78.378 to 78.3793, inclusive, of the NRS, apply to &ldquo;issuing corporations,&rdquo; which
are Nevada corporations with at least 200 stockholders of record, including at least 100 stockholders of record who are Nevada
residents, and which conduct business directly or indirectly in Nevada, unless the corporation has elected to not be subject to
these provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The control
share statute prohibits an acquirer of shares of an issuing corporation, under certain circumstances, from voting its shares of
a corporation&rsquo;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the
target corporation&rsquo;s disinterested stockholders. The statute specifies three thresholds: (a) one-fifth or more but less
than one-third, (b) one-third but less than a majority and (c) a majority or more, of the outstanding voting power. Generally,
once a person acquires shares in excess of any of the thresholds, those shares and any additional shares acquired within 90 days
thereof become &ldquo;control shares&rdquo; and such control shares are deprived of the right to vote until disinterested stockholders
restore the right. These provisions also provide that if control shares are accorded full voting rights and the acquiring person
has acquired a majority or more of all voting power, all other stockholders who do not vote in favor of authorizing voting rights
to the control shares are entitled to demand payment for the fair value of their shares in accordance with statutory procedures
established for dissenters&rsquo; rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A corporation
may elect to not be governed by, or &ldquo;opt out&rdquo; of, the control share provisions by making an election in its articles
of incorporation or bylaws, provided that the opt-out election must be in place on the 10th day following the date an acquiring
person has acquired a controlling interest, that is, crossing any of the three thresholds described above. We have opted out of
the control share statutes, and, provided the &ldquo;opt out&rdquo; election remains in place, we will not be subject to the control
share statutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The effect
of the Nevada control share statute is that the acquiring person, and those acting in association with the acquiring person, will
obtain only such voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or special
meeting. The Nevada control share law, if applicable, could have the effect of discouraging takeovers of us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_8"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under
this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable
prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described
below. Unless the context requires otherwise, whenever we refer to the indenture, we are also referring to any supplemental indentures
that specify the terms of a particular series of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will
be qualified under the Trust Indenture Act of 1939, as amended (&quot;Trust Indenture Act&quot;). We have filed the form of indenture
as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt
securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of
which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The following
summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference
to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus,
as well as the complete indenture that contains the terms of the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General
Terms of the Indenture</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The indenture
does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal
amount that we may authorize and may be in any currency or currency unit designated by us. Except for the limitations on consolidation,
merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain
any covenants or other provisions designed to afford holders of any debt securities protection with respect to our operations,
financial condition or transactions involving us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
issue the debt securities issued under the indenture as &quot;discount securities,&quot; which means they may be sold at a discount
below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount,
may, for U.S. federal income tax purposes, be treated as if they were issued with &quot;original issue discount&quot; (&quot;OID&quot;)
because of interest payment and other characteristics. Special U.S. federal income tax considerations applicable to debt securities
issued with original issue discount will be described in more detail in any applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    title of the series of debt securities; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    limit upon the aggregate principal amount that may be issued; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    maturity date or dates; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    form of the debt securities of the series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    applicability of any guarantees; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    or not the debt securities will be secured or unsecured, and the terms of any secured debt; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms
    of any subordination; </FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued
    is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of
    acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is
    convertible into another security or the method by which any such portion will be determined; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will
    begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method
    for determining such dates; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    right, if any, to defer payment of interest and the maximum length of any such deferral period; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may,
    at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the
    terms of those redemption provisions; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund
    or analogous fund provisions or otherwise, to redeem, or at the holder's option to purchase, the series of debt securities
    and the currency or currency unit in which the debt securities are payable; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    denominations in which we will issue the series of debt securities, if other than denominations of $1,000, and any integral
    multiple thereof; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security
    for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the
    marketing of debt securities of that series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    the debt securities of the series will be issued in whole or in part in the form of a global security or securities; the terms
    and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual
    securities; and the depositary for such global security or securities; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions
    upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable,
    or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders' option) conversion
    or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;
    </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which will
    be payable upon declaration of acceleration of the maturity thereof; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additions
    to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation,
    merger or sale covenant; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additions
    to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders
    to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additions
    to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additions
    to or changes in the provisions relating to satisfaction and discharge of the indenture; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additions
    to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders
    of debt securities issued under the indenture; </FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S.
    dollars; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    interest will be payable in cash or additional debt securities at our or the holders' option and the terms and conditions
    upon which the election may be made; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal
    amounts of the debt securities of the series to any holder that is not a &quot;United States person&quot; for federal tax
    purposes; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    restrictions on transfer, sale or assignment of the debt securities of the series; and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions
    or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws
    or regulations. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Conversion
or Exchange Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
set forth in the prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable
for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether
conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which
the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would
be subject to adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidation,
Merger or Sale</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will
not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose
of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets, other
than a subsidiary of ours, must assume all of our obligations under the indenture or the debt securities, as
appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Events
of Default Under the Indenture</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events
of default under the indenture with respect to any series of debt securities that we may issue:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    we fail to pay any installment of interest on any debt securities of that series, as and when the same will become due and
    payable, and such default continues for a period of 90 days, provided that a valid extension of an interest payment period
    by us in accordance with the terms of any indenture supplemental thereto will not constitute a default in the payment of interest
    for this purpose; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    we fail to pay the principal of (or premium, if any) on any debt securities of that series as and when the same will become
    due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking
    or analogous fund established with respect to that series, provided, that a valid extension of the maturity of such debt securities
    in accordance with the terms of any indenture supplemental thereto will not constitute a default in the payment of principal
    or premium, if any; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    we fail to observe or perform any other covenant or agreement with respect to that series contained in the indenture or otherwise
    established with respect to that series pursuant to the indenture, other than a covenant or agreement specifically included
    solely for the benefit of one or more debt securities other than that series, and our failure continues for 90 days after
    we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default
    thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of
    the applicable series; and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    specified events of bankruptcy, insolvency or reorganization occur. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If an
event of default with respect to debt securities of any series occurs and is continuing, other than an event of default described
in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt
securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the
unpaid principal of (premium, if any) and accrued and unpaid interest, if any, due and payable immediately. If an event of default
specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of that
series will be automatically due and payable without any declaration or other action on the part of the trustee or any holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The holders
of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default
with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium,
if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver will cure
the default or event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subject
to the terms of the indenture, if an event of default under an indenture occurs and is continuing, the trustee will be under no
obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the
applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority
in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place
of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee,
with respect to the debt securities of that series, provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    direction so given by the holder is not in conflict with any law or the applicable indenture; and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">subject
    to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability
    or might be unduly prejudicial to the holders not involved in the proceeding. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a
receiver or trustee, or to seek other remedies only if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    holder has given written notice to the trustee of a continuing event of default with respect to that series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written
    request; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">such
    holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred
    by the trustee in compliance with the request; and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount
    of the outstanding debt securities of that series other inconsistent directions within 90 days after the notice, request and
    offer. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium,
if any, or interest on, the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Modification
of Indenture; Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We and
the trustee may change an indenture without the consent of any holders with respect to specific matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    comply with the provisions described above under &quot;Description of Debt Securities&mdash;Consolidation, Merger or Sale&rdquo;;
    </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    provide for uncertificated debt securities in addition to or in place of certificated debt securities; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for
    the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance,
    of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender
    any right or power conferred upon us in the indenture; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of
    issue, authentication and delivery of debt securities, as set forth in the indenture; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    make any change that does not adversely affect the interests of any holder of debt securities of any series in any material
    respect; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided
    above under &quot;Description of Debt Securities&mdash;General&quot; to establish the form of any certifications required
    to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders
    of any series of debt securities; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">to
    comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.
    </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In addition,
under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written
consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series
that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt
securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities
affected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">extending
    the fixed maturity of any debt securities of any series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reducing
    the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon
    the redemption of any series of any debt securities; or </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reducing
    the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification
    or waiver. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Discharge</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each indenture
provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">provide
    for payment; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">register
    the transfer or exchange of debt securities of the series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">replace
    stolen, lost or mutilated debt securities of the series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">pay
    principal of and premium and interest on any debt securities of the series; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">maintain
    paying agencies; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">hold
    monies for payment in trust; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">recover
    excess money held by the trustee; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">compensate
    and indemnify the trustee; and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">appoint
    any successor trustee. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In order
to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all
the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Form,
Exchange and Transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we
may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited
with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in a prospectus
supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry,
a description of terms relating will be set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At the
option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt
securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subject
to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or
with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the
security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the
debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer
or exchange, but we may require payment of any taxes or other governmental charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar,
that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation
of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required
to maintain a transfer agent in each place of payment for the debt securities of each series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If we
elect to redeem the debt securities of any series, we will not be required to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">issue,
    register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business
    15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and
    ending at the close of business on the day of the mailing; or </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">register
    the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion
    of any debt securities we are redeeming in part. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Information
Concerning the Trustee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The trustee,
other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties
as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the
same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision,
the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt
securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Payment
and Paying Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on
any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered
at the close of business on the regular record date for the interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments
by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable
prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with
respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we
initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for
the debt securities of a particular series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All money
we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities
that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable (or such shorter
period set forth in applicable escheat, abandoned or unclaimed property law) will be repaid to us, and the holder of the debt
security thereafter may look only to us for payment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The indenture
and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the
extent that the Trust Indenture Act is applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_9"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">As of October 2, 2015, there were 5,104,867 shares of our common
stock that may be issued upon exercise of outstanding warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
issue warrants for the purchase of our debt securities, common stock or preferred stock in one or more series. We may issue warrants
independently or together with our debt securities, common stock or preferred stock, and the warrants may be attached to or separate
from these securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
evidence each series of warrants by warrant certificates that we may issue under a separate agreement. We may enter into a warrant
agreement with a warrant agent. Each warrant agent may be a bank that we select which has its principal office in the United States.
We may also choose to act as our own warrant agent. We will indicate the name and address of any such warrant agent in the applicable
prospectus supplement relating to a particular series of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
describe in the applicable prospectus supplement the terms of the series of warrants, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    offering price and aggregate number of warrants offered;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued
    with each such security or each principal amount of such security;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    applicable, the date on and after which the warrants and the related securities will be separately transferable;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">in
    the case of warrants to debt securities, purchase common stock or preferred stock, the number or amount of shares of common
    stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which and currency
    in which these shares may be purchased upon such exercise; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    manner of exercise of the warrants, including any cashless exercise rights;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    warrant agreement under which the warrants will be issued;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">anti-dilution
    provisions of the warrants, if any;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    terms of any rights to redeem or call the warrants;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    dates on which the right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable
    during that period, the specific date or dates on which the warrants will be exercisable;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    manner in which the warrant agreement and warrants may be modified;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    identities of the warrant agent and any calculation or other agent for the warrants;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">federal
    income tax consequences of holding or exercising the warrants;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    terms of the securities issuable upon exercise of the warrants;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants
    may be listed or quoted; and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    other specific terms, preferences, rights or limitations of or restrictions on the warrants.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such
exercise, including, in the case of warrants to purchase shares of our common stock or preferred stock, the right to receive dividends,
if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exercise
of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each warrant
will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement,
holders of the warrants may exercise the warrants at any time up to 5:00 P.M. eastern time, the close of business, on the expiration
date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holders
of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together
with specified information, and paying the required exercise price by the methods provided in the applicable prospectus supplement.
We will set forth on the reverse side of the warrant certificate, and in the applicable prospectus supplement, the information
that the holder of the warrant will be required to deliver to the warrant agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Upon receipt
of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities
purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we
will issue a new warrant certificate for the remaining amount of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Enforceability
of Rights By Holders of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any warrant
agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue
of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement
or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us.
Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate
legal action the holder&rsquo;s right to exercise, and receive the securities purchasable upon exercise of, its warrants in accordance
with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrant
Agreement Will Not Be Qualified Under Trust Indenture Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No warrant
agreement will be qualified as an indenture, and no warrant agent will be required to qualify as a trustee, under the Trust Indenture
Act. Therefore, holders of warrants issued under a warrant agreement will not have the protection of the Trust Indenture Act with
respect to their warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each warrant
agreement and any warrants issued under the warrant agreements will be governed by New York law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_10"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
issue rights to our stockholders to purchase shares of our common stock or preferred stock. We may offer rights separately or
together with one or more additional rights, debt securities, preferred stock, common stock or warrants or any combination of
those securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will be issued
under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent. The rights agent
will act solely as our agent in connection with the certificates relating to the rights of the series of certificates and will
not assume any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial owners
of rights. The following description sets forth certain general terms and provisions of the rights to which any prospectus supplement
may relate. The particular terms of the rights to which any prospectus supplement may relate and the extent, if any, to which
the general provisions may apply to the rights so offered will be described in the applicable prospectus supplement. To the extent
that any particular terms of the rights, rights agreement or rights certificates described in a prospectus supplement differ from
any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus supplement.
We encourage you to read the applicable rights agreement and rights certificate for additional information before you decide whether
to purchase any of our rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
provide in a prospectus supplement the following terms of the rights being issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    date on which stockholders entitled to the rights distribution will be determined; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    aggregate number of shares of common stock or preferred stock purchasable upon exercise of the rights; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    exercise price; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    aggregate number of rights issued; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    date, if any, on and after which the rights will be separately transferable; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    date on which the ability to exercise the rights will commence, and the date on which such ability will expire; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    conditions to the completion of the offering, if any; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    withdrawal, termination and cancellation rights, if any; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    applicable material U.S. federal income tax considerations; and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange and exercise
    of the rights. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each right
will entitle the holder of rights to purchase, for cash, the number of shares of our common stock or preferred stock at the exercise
price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close of business on the
expiration date for the rights provided in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holders
may exercise rights as described in the applicable prospectus supplement. Upon receipt of payment and the rights certificate properly
completed and duly executed at the corporate trust office of the rights agent or any other office indicated in the prospectus
supplement, we will, as soon as practicable, forward the shares of our common stock or preferred stock, as applicable, purchasable
upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed
securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination
of such methods, including pursuant to standby arrangements, as described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_11"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF PURCHASE CONTRACTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
issue purchase contracts, including contracts obligating holders to purchase from us, and for us to sell to holders, a specific
or variable number of our debt securities, shares of common stock, preferred stock, warrants or rights, or securities of an entity
unaffiliated with us, or any combination of the above, at a future date or dates. Alternatively, the purchase contracts may obligate
us to purchase from holders, and obligate holders to sell to us, a specific or variable number of our debt securities, shares
of common stock, preferred stock, warrants, rights or other property, or any combination of the above. The price of the securities
or other property subject to the purchase contracts may be fixed at the time the purchase contracts are issued or may be determined
by reference to a specific formula described in the purchase contracts. We may issue purchase contracts separately or as a part
of units each consisting of a purchase contract and one or more of our other securities described in this prospectus or securities
of third parties, including U.S. Treasury securities, securing the holder&rsquo;s obligations under the purchase contract. The
purchase contracts may require us to make periodic payments to holders or vice versa and the payments may be unsecured or pre-funded
on some basis. The purchase contracts may require holders to secure the holder&rsquo;s obligations in a manner specified in the
applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The applicable
prospectus supplement will describe the terms of any purchase contracts in respect of which this prospectus is being delivered,
including, to the extent applicable, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to
    purchase under the purchase contract, and the nature and amount of each of those securities, or the method of determining
    those amounts; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    the purchase contracts are to be prepaid; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance or level of the
    securities subject to purchase under the purchase contract; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    acceleration, cancellation, termination or other provisions relating to the settlement of the purchase contracts; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    applicable federal income tax considerations; and </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
    </FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    the purchase contracts will be issued in fully registered or global form. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The preceding
description sets forth certain general terms and provisions of the purchase contracts to which any prospectus supplement may relate.
The particular terms of the purchase contracts to which any prospectus supplement may relate and the extent, if any, to which
the general provisions may apply to the purchase contracts so offered will be described in the applicable prospectus supplement.
To the extent that any particular terms of the purchase contracts described in a prospectus supplement differ from any of the
terms described above, then the terms described above will be deemed to have been superseded by that prospectus supplement. We
encourage you to read the applicable purchase contract for additional information before you decide whether to purchase any of
our purchase contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_12"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
issue units comprised of one or more of the other securities described in this prospectus or any prospectus supplement in any
combination. Each unit will be issued so that the holder of the unit is also the holder, with the rights and obligations of a
holder, of each security included in the unit. The unit agreement under which a unit is issued may provide that the securities
included in the unit may not be held or transferred separately, at any time or at any times before a specified date or upon the
occurrence of a specified event or occurrence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
applicable prospectus supplement will describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    designation and the terms of the units and of the securities comprising the units, including whether and under what circumstances
    those securities may be held or transferred separately;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    unit agreement under which the units will be issued;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units;
    and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
    the units will be issued in fully registered or global form.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_13"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
sell the securities being offered pursuant to this prospectus to or through underwriters, through dealers, through agents, or
directly to one or more purchasers or through a combination of these methods. The securities may be distributed at a fixed price
or prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices,
or negotiated prices. The applicable prospectus supplement will describe the terms of the offering of the securities, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    name or names of any underwriters, if any, and if required, any dealers or agents;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    name or names of any managing underwriter or underwriters;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    purchase price of the securities and the net proceeds we will receive from the sale;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    delayed delivery arrangements;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    underwriting discounts, commissions and other items constituting underwriters&rsquo; compensation;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    discounts or concessions allowed or re-allowed or paid to dealers; </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    commissions paid to agents; and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding-right: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    securities exchange or market on which the securities may be listed or traded.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Only underwriters
named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Sale
Through Underwriters or Dealers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If underwriters
are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter
and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters
and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates
represented by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting
syndicate is used, the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are
used in the sale, the offered securities will be acquired by the underwriters for their own accounts and may be resold from time
to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices
determined at the time of sale. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers
may be changed from time to time. Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters
to purchase the offered securities will be subject to conditions precedent, and the underwriters will be obligated to purchase
all of the offered securities, if any are purchased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price,
with additional underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any
over-allotment option will be set forth in the prospectus supplement for those securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If we
use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell
the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined
by the dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified in a prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Direct
Sales and Sales Through Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
sell the securities directly or through agents we designate from time to time. We will name any agent involved in the offering
and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus
supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering
price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified
date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these
contracts in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>At-the-Market
Offerings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To the
extent that we make sales through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the
terms of a sales agency financing agreement or other at-the-market offering arrangement between us, on the one hand, and the underwriters
or agents, on the other. If we engage in at-the-market sales pursuant to any such agreement, we will issue and sell our securities
through one or more underwriters or agents, which may act on an agency basis or a principal basis. During the term of any such
agreement, we may sell securities on a daily basis in exchange transactions or otherwise as we agree with the underwriters or
agents. Any such agreement will provide that any securities sold will be sold at prices related to the then prevailing market
prices for our securities. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be
determined at this time. Pursuant to the terms of the agreement, we may agree to sell, and the relevant underwriters or agents
may agree to solicit offers to purchase blocks of our common stock or other securities. The terms of any such agreement will be
set forth in more detail in the applicable prospectus or prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Market
Making, Stabilization and Other Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
otherwise specified in the applicable prospectus supplement, any common stock sold pursuant to a prospectus supplement will be
eligible for listing on a national securities exchange, such as the NYSE MKT or NASDAQ, subject to official notice of issuance.
Any underwriters to whom securities are sold by us for public offering and sale may make a market in the securities, but such
underwriters will not be obligated to do so and may discontinue any market making at any time without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To facilitate
a public offering of a series of securities, persons participating in the offering may engage in transactions that stabilize,
maintain, or otherwise affect the market price of the securities. This may include over-allotments or short sales of the securities,
which involves the sale by persons participating in the offering of more securities than have been sold to them by us. In addition,
those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market
or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such offering
may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these
transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail
in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation or prediction
as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of
our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In connection
with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the securities
for whom they act as agents, in the form of discounts, concessions or commissions. Underwriters may sell the securities to or
through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters
or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution
of the securities, and any institutional investors or others that purchase securities directly for the purpose of resale or distribution,
may be deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the
common stock by them may be deemed to be underwriting discounts and commissions under the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We may
provide agents, underwriters and other purchasers with indemnification against particular civil liabilities, including liabilities
under the Securities Act of 1933, as amended, or contribution with respect to payments that the agents, underwriters or other
purchasers may make with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services
for, us in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In order
to comply with the securities laws of some states, if applicable, the securities offered pursuant to this prospectus will be sold
in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not be sold
unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_14"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The validity
of the securities offered by this prospectus will be passed upon by Fennemore Craig, P.C., Reno, Nevada. Additional legal matters
may be passed upon for us or any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_15"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The financial
statements incorporated in this prospectus by reference to the Annual Report on Form 10-K for the fiscal year ended June 30, 2015
have been so incorporated in reliance on the report of GBH CPAs, PC, an independent registered public accounting firm, given on
the authority of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_16"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We are
subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith file
annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission (the
&ldquo;SEC&rdquo;). Such reports, proxy statements and other information can be read and copied at the SEC&rsquo;s public reference
facilities at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-732-0330 for further information on the
operation of the public reference facilities. In addition, the SEC maintains a website that contains reports, proxy and information
statements and other information regarding registrants that file electronically with the SEC. The address of the SEC&rsquo;s website
is www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We make
available free of charge on or through our website at www.relmada.com, our Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with
or otherwise furnish it to the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have
filed with the SEC a registration statement under the Securities Act of 1933, as amended, relating to the offering of these securities.
The registration statement, including the attached exhibits, contains additional relevant information about us and the securities.
This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the
registration statement, at prescribed rates, from the SEC at the address listed above, or for free at www.sec.gov. The registration
statement and the documents referred to below under &ldquo;Incorporation of Certain Information By Reference&rdquo; are also available
on our website, www.relmada.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have
not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part
of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="a_17"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The SEC
allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be
a part of this prospectus, and information that we later file with the SEC will automatically update and supersede information
contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below
and any future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the SEC pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the date of this prospectus
and prior to the termination of the offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
    Annual Report on Form 10-K as of June 30, 2015 and 2014 and for the year ended June 30, 2015, for the six months ended June 30,
2014, and for the year ended December 31, 2013, filed with the SEC on September 11, 2015; and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    description of our common stock, which is contained in our Current Report on Form 8-K, filed with the SEC on May 27, 2014.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All filings
filed by us pursuant to the Securities Exchange Act of 1934, as amended, after the date of the initial filing of this registration
statement and prior to the effectiveness of such registration statement (excluding information furnished pursuant to Items 2.02
and 7.01 of Form 8-K) shall also be deemed to be incorporated by reference into the prospectus. Any statements contained in a
previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of
this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated
by reference herein, modifies or supersedes that statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus
may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by reference
in this prospectus. You should rely only on the information incorporated by reference or provided in this prospectus. We have
not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus
is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written
or oral request, a copy of any or all of the information that has been incorporated by reference in this prospectus but not delivered
with this prospectus (other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference
in this prospectus). Any such request should be addressed to us at: 757 3rd Avenue, Suite 2018, New York, New York 10017, Attention:
Sergio Traversa, Chief Executive Officer, or made by phone at (212) 376-5771. You may also access the documents incorporated by
reference in this prospectus through our website at www.relmada.com. Except for the specific incorporated documents listed above,
no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement
of which it forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we
are not soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SUBJECT
TO COMPLETION, DATED OCTOBER 2, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #DE1A1E"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: Red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>Up
to $75,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have
entered into a Controlled Equity Offering<B><SUP>SM</SUP></B> sales agreement with Cantor Fitzgerald &amp; Co. relating to shares
of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the
sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $75,000,000 from
time to time through Cantor Fitzgerald &amp; Co., acting as agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Our common stock is listed on the OTCQB under the symbol &ldquo;RLMD.&rdquo;
On September 30, 2015, the last reported sale price of our common stock on the OTCQB was $4.90 per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be
&ldquo;at-the-market&rdquo; equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended,
or the Securities Act, including sales made directly on or through the NASDAQ Capital Market, the existing trading market for
our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at
market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted
by law. Cantor Fitzgerald &amp; Co. will act as sales agent on a best effort basis and use commercially reasonable efforts to
sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales
practices, on mutually agreed terms between Cantor Fitzgerald &amp; Co. and us. There is no arrangement for funds to be received
in any escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cantor
Fitzgerald &amp; Co. will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold.
In connection with the sale of the common stock on our behalf, Cantor Fitzgerald &amp; Co. will be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act, and the compensation of Cantor Fitzgerald &amp; Co. will be deemed to be underwriting
commissions or discounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Investing
in our securities involves a high degree of risk. Before making an investment decision, please read the information
contained in or incorporated by reference under the heading &ldquo;Risk Factors&rdquo; beginning on page S-6 of this
prospectus supplement, on page  6 of the accompanying prospectus and in the documents incorporated by reference into this
prospectus supplement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="img_005.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
date of this prospectus supplement is &nbsp;&nbsp;&nbsp;, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 27pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="toc1"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_1"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-2</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE OFFERING</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-5</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_4"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-6</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_5"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-7</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_6"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-8</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_7"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DILUTION</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-9</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_8"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIVIDENDS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-10</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_9"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-11</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_10"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-12</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_11"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-12</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_12"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-12</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S_13"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-13</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<DIV STYLE="padding: 2px; width: 100%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_1"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus
supplement and the accompanying prospectus relates to the offering of our common stock. Before buying any of the common stock
that we are offering, we urge you to carefully read this prospectus supplement, the accompanying prospectus, any free writing
prospectus that we have authorized for use in connection with this offering, together with the information incorporated by reference
as described under the heading &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information
by Reference.&rdquo; These documents contain important information that you should consider when making your investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This document
is comprised of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and
also adds to, and updates information contained in, the accompanying prospectus and the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, including the documents
incorporated by reference into the accompanying prospectus, provides more general information, some of which may not apply to
this offering. Generally, when we refer to this prospectus, we are referring to the combined document consisting of this prospectus
supplement and the accompanying prospectus. In this prospectus supplement, as permitted by law, we &ldquo;incorporate by reference&rdquo;
information from other documents that we file with the Securities and Exchange Commission, or the Commission. This means that
we can disclose important information to you by referring to those documents. The information incorporated by reference is considered
to be a part of this prospectus supplement and the accompanying prospectus and should be read with the same care. When we make
future filings with the Commission to update the information contained in documents that have been incorporated by reference,
the information included or incorporated by reference in this prospectus supplement is considered to be automatically updated
and superseded. In other words, in case of a conflict or inconsistency between information contained in this prospectus supplement
and information in the accompanying prospectus or incorporated by reference into this prospectus supplement, you should rely on
the information contained in the document that was filed later.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You should
only rely on the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus,
and any free writing prospectus that we have authorized for use in connection with this offering. No person has been authorized
to give any information or make any representations in connection with this offering other than those contained or incorporated
by reference in this prospectus supplement, the accompanying prospectus, and any related free writing prospectus in connection
with the offering described herein and therein, and, if given or made, such information or representations must not be relied
upon as having been authorized by us. This prospectus supplement, the accompanying prospectus and any related free writing prospectus
shall not constitute offers to sell or solicitations of an offer to buy offered securities in any jurisdiction in which it is
unlawful for such person to make such an offering or solicitation. This prospectus supplement does not contain all of the information
included in the registration statement. For a more complete understanding of the offering of the securities, you should refer
to the registration statement, including its exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You should
read the entire prospectus supplement, the accompanying prospectus and any related free writing prospectus, as well as the documents
incorporated by reference into this prospectus supplement, the accompanying prospectus or any related free writing prospectus,
before making an investment decision. You should assume that the information appearing in this prospectus supplement, the accompanying
prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and in any
free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those
respective documents, regardless of the time of delivery of this prospectus supplement and accompanying prospectus or any sale
of securities. Our business, financial condition, results of operations and prospects may have changed since that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
the context otherwise requires, as used in this prospectus supplement, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;Relmada,&rdquo;
&ldquo;the Company&rdquo; and &ldquo;our&rdquo; refer to Relmada Therapeutics, Inc., a Nevada corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>




<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_2"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>This
summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does
not contain all of the information you should consider before investing in our common stock. You should carefully read the prospectus,
the information incorporated by reference and the registration statement of which this prospectus is a part in their entirety
before investing in our common stock, including the information discussed under &ldquo;Risk Factors&rdquo; in this prospectus
and the documents incorporated by reference and our financial statements and notes thereto that are incorporated by reference
in this prospectus. As used in this prospectus, unless the context otherwise indicates, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo;
&ldquo;us,&rdquo; or &ldquo;the Company&rdquo; refer to Relmada Therapeutics, Inc., a Nevada corporation, and its subsidiaries
taken as a whole.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
Therapeutics, Inc. (&ldquo;Relmada&rdquo; or the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company focused
on developing a pipeline of drug candidates to treat chronic pain. Chronic pain is often defined as any pain lasting more than
12 weeks. Whereas acute pain is a normal sensation that alerts us to possible injury, chronic pain persists &ndash; often for
months or even longer. Chronic pain may arise from an initial injury, such as back sprain, or there may be an ongoing cause, such
as an illness. Sometimes there is no clear cause. According to the National Institutes of Health, approximately 100 million people
in the U.S. are living with chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We intend
to realize our business objectives by implementing two core strategies to address unmet medical needs in the treatment of chronic
pain: a) developing improved versions of proven drug candidates and b) developing new chemical entities. This two tiered approach
is expected to reduce overall clinical development investment, time and risks. Our drug candidates are designed to improve the
overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics,
half-life and/or bioavailability of drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>d-Methadone
(dextromethadone, REL-1017)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our most-advanced
new chemical entity, d-Methadone (dextromethadone, REL-1017), is a novel, N-methyl-D-aspartate (&ldquo;NMDA&rdquo;) receptor antagonist
being developed for the treatment of neuropathic pain. As a single isomer of racemic methadone, d-Methadone has been shown to
possess NMDA antagonist properties with virtually no opioid activity at the expected therapeutic doses. The activation of NMDA
receptors has been associated with neuropathic pain and it is expected that d-Methadone will have a role in pain management by
blocking this activity. In contrast, racemic methadone is a long-acting narcotic producing typical opioid side effects used in
the treatment of various pain states and as a substitution therapy in opioid addiction. In November 2014, Health Canada approved
a Clinical Trial Application (&ldquo;CTA&rdquo;) to conduct the first Phase I study with d-Methadone. This is a Single Ascending
Dose (&ldquo;SAD&rdquo;) study that will be followed by a Multiple Ascending Dose (&ldquo;MAD&rdquo;) study, both in healthy volunteers.
The two studies are designed to assess the safety, tolerability and pharmacokinetics of d-Methadone in healthy subjects. The SAD
study includes single escalating oral doses of d-Methadone to determine the maximum tolerated dose. In the MAD study, healthy
subjects are to receive daily oral doses of d-Methadone for several days to assess its safety, pharmacokinetics and tolerability.
In March 2015, d-Methadone demonstrated a safe profile with no dose limiting side effects after four cohorts were exposed to increasing
higher doses. In April 2015, we received clearance from Health Canada to continue with dose escalation and explore higher doses
of d-Methadone. In June 2015, we successfully completed the SAD study and subsequently received a No Objection Letter (&ldquo;NOL&rdquo;)
from Health Canada to conduct the MAD clinical study in August 2015. The data from these studies will inform the design of a subsequent
Phase II proof of concept study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ketamine
hydrochloride (&ldquo;ketamine&rdquo;), an NMDA receptor antagonist, is a U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)-approved,
rapid-acting general anesthetic that also produces strong analgesia in neuropathic pain states. The NMDA receptor is an excitatory
glutamatergic receptor present at spinal and supraspinal sites and involved in the afferent transmission of nociceptive signals.
In chronic pain states, prolonged nociceptive stimulation causes activation and upregulation of the NMDA receptor at dorsal horn
synapses resulting in enhanced and amplified trafficking of pain signals to the brain, or central sensitization. This phenomenon
is an important factor in the process of perseverance of pain. There is now evidence that NMDA receptor antagonists that block
the NMDA receptor, such as ketamine, are able to halt the excessive barrage of nociceptive input to the brain and are therefore
potential alternatives to existing treatments of chronic pain syndromes. The potential for widespread therapeutic use of ketamine
is severely limited by its potential for abuse, dissociative and psychosis-like side effects. Orally-available d-Methadone is
among the new generation of pain medications with the potential to deliver ketamine-like palliative effects, without side effects
typically associated with ketamine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LevoCap
ER (REL-1015)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our most
advanced novel version of a proven drug product, LevoCap ER (REL-1015), is an extended release, abuse deterrent, proprietary formulation
of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other strong opioids
for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. In particular, levorphanol
binds to all three opioid receptor subtypes involved in analgesia (mu, kappa, and delta), the NMDA receptor and the norepinephrine
and serotonin uptake pumps, whereas morphine is relatively selective for mu sites. The dual mechanism of action of levorphanol,
combining opioid receptor agonism with noradrenaline reuptake inhibition in the same molecule makes levorphanol a useful analgesic
to treat chronic and neuropathic pain in addition to providing pain relief in patients resistant to other strong opioids. Levorphanol
is a strong opioid first synthesized decades ago and is considered equal in potency to hydromorphone, oxycodone, fentanyl and
methadone. In clinical studies, it has demonstrated a remarkably broad spectrum of analgesic activity against many different types
of pain, including neuropathic pain, post-surgical pain and chronic pain in patients refractory to other opioids. We continue
to scale up manufacturing and prepare for Phase III development program and are planning to submit a request to the FDA to discuss
the final regulatory and clinical plan for this product. In preparation for pivotal trial(s) that we plan to perform under the
U.S. Investigational New Drug (&ldquo;IND&rdquo;) program, we are selecting the final formulation and are planning to generate
the necessary good manufacturing practices (&ldquo;GMP&rdquo;) batches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BuTab
(REL-1028)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our second
most advanced novel version of a proven drug product, BuTab (REL-1028), represents novel formulations of oral, modified release
buprenorphine being developed for both chronic pain and opioid dependence indications. Buprenorphine is a partial opioid agonist
that has been widely used by the sublingual and transdermal routes of administration, but was believed to be ineffective by the
oral route. We have completed a preclinical program to better define the pharmacokinetic profile of BuTab and to assess the time
course of systemic absorption of buprenorphine using several different oral modified release formulations of buprenorphine in
dogs, compared to an intravenous administration. Based on the results of this work, we have obtained approval from Health Canada
to initiate a Phase I pharmacokinetic study in healthy volunteers in the second quarter of 2015. This trial is ongoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>MepiGel
(REL-1021)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our third
most advanced novel version of a proven drug product, MepiGel (REL-1021), is a proprietary topical dosage form of the local anesthetic
mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia
and painful human immunodeficiency virus (&ldquo;HIV&rdquo;)-associated neuropathy. Mepivacaine is an anesthetic, or numbing medicine,
that blocks the nerve impulses that send pain signals to the brain. It is chemically related to bupivacaine, but pharmacologically
related to lidocaine. Mepivacaine is currently indicated for infiltration, nerve block and epidural anesthesia. We have received
two FDA Orphan Drug Designations for mepivacaine, one for the treatment of painful HIV-associated neuropathy and one for the management
of postherpetic neuralgia (&ldquo;PHN&rdquo;). We have selected the formulations to be advanced into clinical studies for MepiGel
after the evaluation of results from in vitro and ex vivo studies conducted by MedPharm Ltd. comparing various topical prototypes
of mepivacaine. We are planning single and multiple dose Phase I studies in healthy subjects with the selected MepiGel formulations.
The data from these studies will inform the design of a subsequent Phase II proof of concept study in patients suffering from
neuropathic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Along
with antidepressants, antiepileptic drugs (&ldquo;AEDs&rdquo;) are often used as a first-line therapy for PHN. The most commonly
prescribed AEDs for PHN are gabapentin and pregabalin (Lyrica). Physicians typically prefer pregabalin because of its more-favorable
dosing attributes (less-frequent daily dosing, faster titration) in balance with price and accessibility. AEDs are commonly associated
with side effects, including somnolence, dizziness and weight gain. If first-line AEDs or antidepressant monotherapy fails to
provide acceptable pain relief, physicians initiate combination therapy. If AED/antidepressant combination therapy is not effective,
physicians typically add a dual-acting opioid, such as tramadol, to the treatment. For more-severe pain, physicians may add or
switch to tapentadol ER (Nucynta ER). If pain persists with the addition of tramadol or tapentadol, physicians often switch to
a more potent opioid analgesic, such asoxycodone, while maintaining AED and/or antidepressant therapy. Although some experts acknowledge
that strong opioids can be quite effective for PHN, they generally reserve this drug class for refractory cases and/or patients
with high pain intensity. For some PHN patients, particularly those experiencing highly localized pain, physicians may prescribe
the lidocaine 5% patch (Lidoderm). Pain specialists generally consider that lidocaine is particularly beneficial for localized
pain, and many physicians prefer it to oral agents because it does not cause systemic side effects and is easy to administer.
In many cases, the patch is used in combination with an oral first-line AED and/or antidepressant therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Acorda
Therapeutics, Inc. (&ldquo;Acorda&rdquo;) is developing a concentrated (20%) topical liquid formulation of capsaicin (NP-1998,
formerly NGX-1998) for the treatment of neuropathic pain. The product was formerly in development by NeurogesX, Inc. (&ldquo;NerogesX&rdquo;),
which licensed all U.S. rights as well as those of its 8% capsaicin patch (Qutenza) to Acorda in July 2013. Acorda is planning
to launch a Phase III clinical trial of NP-1998 in painful HIV peripheral neuropathy as the first potential indication for NP-1998.
Acorda is also exploring the potential for additional indications, including painful diabetic neuropathy. In 2011, NeurogesX completed
a Phase II trial in post-herpetic neuralgia and results from the trial confirmed efficacy and safety. Teva Pharmaceutical Industries
Ltd. (&ldquo;Teva&rdquo;) and Xenon Pharmaceuticals Inc. (&ldquo;Xenon&rdquo;) are developing TV-45070 (formerly XEN402), a subtype
selective ion channel inhibitor. TV-45070 has potentially broad application in nociceptive pain, including inflammatory pain,
and neuropathic pain indications. Xenon is partnered with Teva in a milestone, royalty and co-promotion partnership. Using a topical
(ointment) formulation of TV-45070, Teva has initiated a 300-patient Phase IIb clinical trial in osteoarthritis (&ldquo;OA&rdquo;)
of the knee. In July 2015, Teva reported that TV-45070 4% and 8% did not demonstrate statistically significant difference from
placebo in efficacy endpoints in the Phase IIb study in pain due to osteoarthritis of the knee. Teva is also developing topical
TV-45070 in neuropathic pain indications, and is currently planning a Phase IIb clinical trial in patients with post-herpetic
neuralgia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A significant
portion of our operating expenses is related to research and development and we intend to maintain our strong commitment to research
and development. Research and development expense for our fiscal year ended June 30, 2015, for the six months ended June 30, 2014
and for the year ended December 31, 2013 was approximately $7.9 million, $0.8 million and $5.3 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In August 2015 we filed an application to list our shares
of common stock on the NASDAQ Capital Market. Although we hope that our common stock will be accepted for listing on the NASDAQ
Capital Market, we cannot assure you that our application will be accepted or that we will be able to sustain such listing. Assuming
that our application is accepted, we expect to continue trading under the symbol &ldquo;RLMD&rdquo; and discontinue quotation
on the OTCQB.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Corporate
and Other Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our principal
executive offices are located at 757 3rd Avenue, Suite 2018, New York, New York 10017. Our telephone number is (212) 376-5776.
Our website address is www.relmada.com. Information accessed through our website is not incorporated into this prospectus and
is not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_3"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common
                                         stock offered by us pursuant to this prospectus supplement</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shares
                                         of our common stock having an aggregate offering price of up to $75,000,000.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common stock to
    be outstanding after this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Up to 26,320,277 shares (as more fully described in the notes
    following this table), assuming sales of 15,306,122 shares of our common stock in this offering at an offering price of
    $4.90     per share, which was the last reported sale price of our common stock on The OTCQB on September 30, 2015. The
    actual number of     shares issued will vary depending on the sales price under this offering.</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Manner of offering</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;At-the-market
    offering&rdquo; that may be made from time to time through our sales agent, Cantor Fitzgerald &amp; Co. See &ldquo;Plan of
    Distribution&rdquo; on page S-11.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use of Proceeds</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
                                         currently intend to use the net proceeds from this offering, if any, for general corporate
                                         purposes, including capital expenditures, the advancement of our drug candidates in clinical
                                         trials, preclinical trials and working capital.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
        the section entitled &ldquo;Use of Proceeds&rdquo; on page S-8.</FONT></P></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Investing in our
securities involves a high degree of risk. Before making an investment decision, you should read the information contained in
or incorporated by reference under the heading &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus supplement,
on page 6 of the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OTCQB symbol </FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0">Our common stock currently trades on the OTCQB under the symbol &ldquo;RLMD&rdquo;. We have applied to list
our common stock on the NASDAQ Capital Market under the same symbol. There can be no assurance, however, that our application will
be accepted.</P> </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">The number of shares of common stock to be outstanding after
this offering is based on 11,014,155 shares of common stock outstanding as of October 1, 2015, and excludes, in each case as of
October 1, 2015:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">753,147
                                         shares of common stock issuable upon the exercise of outstanding stock options having
                                         a weighted-average exercise price of $7.47 per share;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,104,807
                                         shares of common stock issuable upon the exercise of outstanding stock warrants having
                                         a weighted-average exercise price of $5.83 per share;</FONT></P>



</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">94,000
                                         shares of common stock issuable upon vesting of outstanding restricted stock units; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">764,622
                                         shares of common stock reserved for issuance pursuant to future awards under our Amended
                                         2014 Stock Option and Equity Incentive Plan, as well as any automatic increases in the
                                         number of shares of our common stock reserved for future issuance under this plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 20pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Unless otherwise stated, all information contained in this sales
agreement prospectus supplement reflects an assumed public offering price of $4.90 per share, which was the last reported sale
price of our common stock on The OTCQB on September 30, 2015.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_4"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>An
investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should
carefully consider the risks and uncertainties described below, together with the information under the heading &ldquo;Risk Factors&rdquo;
in our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2015, all of which are incorporated herein by
reference, as updated or superseded by the risks and uncertainties described under similar headings in the other documents that
are filed after the date hereof and incorporated by reference into this prospectus, together with all of the other information
contained or incorporated by reference in this prospectus. The risks and uncertainties we have described are not the only ones
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our
operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should not
be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business prospects,
financial condition or results of operations could be seriously harmed. This could cause the trading price of our common stock
to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled &ldquo;Special
Note Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Additional
Risks Relating to this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
management team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not
yield a significant return.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our management
will have broad discretion over the use of proceeds from this offering. Our management will have broad discretion in the application
of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance
the value of our common stock. The failure by management to apply these funds effectively could result in financial losses that
could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development
of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Purchasers in this offering will likely experience
immediate and substantial dilution in the book value of their investment.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Because the prices per share at which shares of our common
stock are sold in this offering may be substantially higher than the book value per share of our common stock, you may suffer immediate
and substantial dilution in the net tangible book value of the common stock you purchase in this offering. The shares sold in this
offering, if any, will be sold from time to time at various prices. After giving effect to the sale of our common stock in the
maximum aggregate offering amount of $75,000,000 at an assumed offering price of $4.90 per share, the last reported sale price
of our common stock on the OTCQB on September 30, 2015, and after deducting estimated offering commissions payable by us, our net
tangible book value as of June 30, 2015 would have been $74.7 million, or $2.66 per share of common stock and Class A convertible
preferred stock. This represents an immediate increase in the net tangible book value of $2.04 per share to our existing stockholders
and an immediate and substantial dilution in net tangible book value of $2.05 per share to new investors who purchase our common
stock in the offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Sales of a substantial number of shares of our common
stock, or the perception that such sales may occur, may adversely impact the price of our common stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Almost all of the 11,014,155<B> </B>outstanding shares of
our common stock and 71,672 shares of Class A preferred stock as of October 2, 2015, as well as a substantial number of shares
of our common stock underlying outstanding options and warrants, are available for sale in the public market, either pursuant to
Rule 144 under the Securities Act of 1933, as amended, or an effective registration statement. Pursuant to our shelf registration
statement on Form S-3, we may sell up to $200,000,000 of our equity securities over the next several years. Sales of a substantial
number of shares of our common stock, or the perception that such sales may occur, may adversely impact the price of our common
stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risks
Related to Our Organization and Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
articles of incorporation and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders
may consider favorable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our board
of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences
and other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference
over our common stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adversely
affect the voting or other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences
and designations of the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if
that change of control might benefit our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_5"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus
supplement, the accompanying prospectus, the documents we have filed with the Commission that are incorporated by reference and
any free writing prospectus that we have authorized for use in connection with this offering contain &ldquo;forward-looking statements,&rdquo;
within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or
the Exchange Act, that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect,
could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements
contained in this prospectus supplement other than statements of historical fact, including statements relating to future events,
future financial performance, strategies, expectations, competitive environment and regulation, are forward-looking statements.
Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and will probably not
be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information
we have when those statements are made or our management&rsquo;s good faith belief as of that time with respect to future events,
and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty
    regarding the adequacy of our liquidity to pursue our complete business objectives;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    ability to complete clinical trials as anticipated and obtain and maintain regulatory approvals for our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    ability to adequately protect our intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">disputes
    over ownership of intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and
    to increase production as necessary;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our products
    are an attractive alternative to other procedures and products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">intense
    competition in our industry, with competitors having substantially greater financial, technological, research and development,
    regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">entry
    of new competitors and products and potential technological obsolescence of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss
    of a key customer or supplier;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse
    economic conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse
    federal, state and local government regulation, in the United States;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">price
    increases for supplies and components;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">inability
    to carry out research, development and commercialization plans; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss
    or retirement of key executives and research scientists.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">We discuss in greater detail, and incorporate by reference into
this prospectus supplement and the accompanying prospectus in their entirety, many of these risks and uncertainties under the
heading &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus supplement. The forward-looking statements contained
or incorporated by reference in this prospectus are expressly qualified in their entirety by this cautionary statement. We do
not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date
on which any such statement is made or to reflect the occurrence of unanticipated events.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_6"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The amount
of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they
are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Cantor
Fitzgerald &amp; Co. as a source of financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
otherwise indicated in the prospectus supplement, we currently intend to use the net proceeds from this offering, if any, for
general corporate purposes, including capital expenditures, the advancement of our drug candidates in clinical trials, preclinical
trials, and working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Investors
are cautioned, however, that expenditures may vary substantially from these uses. Investors will be relying on the judgment of
our management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing
of our actual expenditures will depend upon numerous factors, including the amount of cash generated by our operations, the amount
of competition and other operational factors. We may find it necessary or advisable to use portions of the proceeds from this
offering for other purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From time
to time, we evaluate these and other factors and we anticipate continuing to make such evaluations to determine if the existing
allocation of resources, including the proceeds of this offering, is being optimized. Circumstances that may give rise to a change
in the use of proceeds include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
    change in development plan or strategy;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    addition of new products or applications;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">technical
    delays;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays
    or difficulties with our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">negative
    results from our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">difficulty
    obtaining U.S. Food and Drug Administration approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure
    to achieve sales as anticipated; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    availability of other sources of cash including cash flow from operations and new bank debt financing arrangements, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pending
other uses, we intend to invest the proceeds to us in investment-grade, interest-bearing securities such as money market funds,
certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether
the proceeds invested will yield a favorable, or any, return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_7"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If you invest in our common stock, your interest will be
diluted immediately to the extent of the difference between the public offering price per share of our common stock you pay in
this offering and the as adjusted net tangible book value per share of our common stock immediately after this offering. Our net
tangible book value of our common stock and Class A convertible preferred stock as of June 30, 2015 was approximately $8.8 million,
or approximately $0.81 per share of common stock based upon 10,778,474 shares and 71,772 shares outstanding at that time, respectively.
Net tangible book value represents the amount of our total tangible assets less the sum of our total liabilities and intangible
assets. Net tangible book value per share represents the net tangible book value divided by the total number of shares of our common
stock outstanding and Class A convertible preferred stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">After giving effect to the sale of shares of our common stock,
$0.001 par value per share, in the aggregate amount of $75,000,000 at an assumed offering price of $4.90 per share, the last reported
sale price of our common stock on the OTCQB on September 30, 2015, and after deducting estimated aggregate offering expenses payable
by us, our as adjusted net tangible book value as of June 30, 2015 would have been approximately $74.7 million, or approximately
$2.85 per share of common stock. This represents an immediate increase in net tangible book value of approximately $2.04 per share
to our existing stockholders and an immediate dilution in as adjusted net tangible book value of approximately $2.05 per share
to purchasers of our common stock in this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following table illustrates this calculation on a per
share basis as of June 30, 2015:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 81%">Assumed public offering price per share of common stock</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">4.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share of common stock</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">081</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Increase in net tangible book value per share of common stock attributable to investors purchasing our common stock in this offering</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">$</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">2.04</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"></TD><TD STYLE="text-align: right; padding-bottom: 1.5pt"></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">As adjusted net tangible book value per share of common stock after giving effect to the offering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">2.85</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Dilution in net tangible book value per share of common stock to investors purchasing our common stock in this offering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">(2.05</TD><TD STYLE="text-align: left; padding-bottom: 4pt">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The foregoing table and calculations are based on the number
of shares of our common stock outstanding as of June 30, 2015.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_8"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DIVIDENDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In the
past, we have not declared or paid cash dividends on our common stock, and we do not intend to pay any cash dividends on our common
stock. Rather, we intend to retain future earnings, if any, to fund the operation and expansion of our business and for general
corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_9"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">On October 2, 2015, we entered into a Controlled Equity Offering<SUP>SM
</SUP>Sales Agreement, or the sales agreement, with Cantor Fitzgerald &amp; Co., or Cantor, under which we may issue and sell
shares of our common stock through Cantor acting as agent. We may issue and sell shares through this prospectus supplement having
an aggregate gross sales price of up to $75,000,000. The following summary of the material provisions of the sales agreement does
not purport to be a complete statement of its terms and conditions. The sales agreement has been filed as an exhibit to our registration
statement on Form S-3 of which this prospectus forms a part.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Upon delivery
of a placement notice and subject to the terms and conditions of the sales agreement, Cantor may sell our common stock by any
method permitted by law that is deemed to be an &ldquo;at-the-market&rdquo; offering as defined in Rule 415 promulgated under
the Securities Act, including sales made directly on or through the NASDAQ Capital Market or any other existing trading market
for our common stock in the United States or to or through a market maker. Subject to the terms of a Placement Notice, Cantor
may also sell our common stock by any other method permitted by law, including in privately negotiated transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each time
we wish to issue and sell common stock under the sales agreement, we will notify Cantor of the number of shares to be issued,
the dates on which such sales are anticipated to be made, any limitation on the number of shares that may be sold in any one day
and any minimum price below which sales may not be made. Once we have so instructed Cantor, unless Cantor declines to accept the
terms of such notice, Cantor has agreed to use its commercially reasonable efforts consistent with its normal trading and sales
practices to sell such shares up to the amount specified on such terms. The obligations of Cantor under the sales agreement, to
sell our common stock are subject to a number of conditions that we must meet. We or Cantor may suspend the offering of our common
stock upon notice and, subject to other conditions, our prior approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The settlement
between us and Cantor is generally anticipated to occur on the third trading day following the date on which any sales are made,
or on some other date that is agreed upon by us and Cantor in connection with a particular transaction, in return for payment
of the net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement will be settled through the
facilities of The Depository Trust Company or by such other means as we and Cantor may agree upon. There is no arrangement for
funds to be received in an escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">We will pay Cantor a commission equal to an aggregate of 3.0%
of the gross proceeds we receive from the sales of our common stock. Because there is no minimum offering amount required as a
condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable
at this time. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act, and the compensation of Cantor will be deemed to be underwriting commissions or discounts.
We have agreed to provide indemnification and contribution to Cantor with respect to certain civil liabilities, including liabilities
under the Securities Act. We have also agreed to reimburse Cantor for certain specified expenses, including the fees and disbursements
of its legal counsel, in an amount not to exceed $50,000. We estimate that the total expenses for the offering, but excluding
any underwriter fees or expense reimbursement payable to Cantor under the terms of the sales agreement, will be approximately
$150,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The offering
of our common stock pursuant to this prospectus will terminate upon the termination of the sales agreement as permitted therein.
We and Cantor may each terminate the sales agreement at any time upon ten days&rsquo; prior notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any portion
of the $75,000,000 included in this sales agreement prospectus supplement that is not previously sold or included in an active
placement notice pursuant to the sales agreement is available for sale in other offerings pursuant to the base prospectus, and
if no shares are sold under the sales agreement, the full $75,000,000 of securities may be sold in other offerings pursuant to
the base prospectus and a corresponding prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cantor
and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us
and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M under
the Exchange Act, Cantor will not engage in any market making activities involving our common stock while the offering is ongoing
under this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This prospectus
supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Cantor, and Cantor
may distribute this prospectus supplement and the accompanying prospectus electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_10"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
validity of the securities offered by this prospectus will be passed upon by Fennemore Craig, P.C., Reno, Nevada. Cantor is being
represented in connection with this offering by Cooley, LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_11"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The financial
statements incorporated in this prospectus by reference to the Annual Report on Form 10-K for the fiscal year ended June 30, 2015
have been so incorporated in reliance on the report of GBH CPAs, PC an independent registered public accounting firm, given on
the authority of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_12"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We are
subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith file
annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission, or
the Commission. Such reports, proxy statements and other information can be read and copied at the Commission&rsquo;s public reference
facilities at 100 F Street, N.E., Washington, D.C. 20549. Please call the Commission at 1-800-732-0330 for further information
on the operation of the public reference facilities. In addition, the Commission maintains a website that contains reports, proxy
and information statements and other information regarding registrants that file electronically with the Commission. The address
of the Commission&rsquo;s website is www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We make
available free of charge on or through our website at www.relmada.com, our Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with
or otherwise furnish it to the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have
filed with the Commission a registration statement under the Securities Act of 1933, as amended, relating to the offering of these
securities. The registration statement, including the attached exhibits, contains additional relevant information about us and
the securities. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in
the registration statement. You can obtain a copy of the registration statement, at prescribed rates, from the Commission at the
address listed above, or for free at www.sec.gov. The registration statement and the documents referred to below under &ldquo;Incorporation
of Certain Information By Reference&rdquo; are also available on our website, www.relmada.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We have
not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part
of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="S_13"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Commission
allows us to &ldquo;incorporate by reference&rdquo; the information we have filed with it, which means that we can disclose important
information to you by referring you to those documents instead of having to repeat the information in this prospectus supplement.
The information incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus,
and later information that we file with the Commission will automatically update and supersede prior information. We incorporate
by reference the documents listed below and any future documents (excluding information furnished pursuant to Items 2.02 and 7.01
of Form 8-K) we file with the Commission pursuant to Sections l3(a), l3(c), 14 or l5(d) of the Securities Exchange Act of 1934,
as amended, or the Exchange Act, subsequent to the date of this prospectus supplement and before the sale of all the securities
covered by this prospectus supplement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
    Annual Report on Form 10-K for the fiscal year ended June 30, 2015, filed with the Commission on September 11, 2015;</FONT> and</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    description of our common stock, which is contained in our Current Report on Form 8-K, filed with the Commission on May 27,
    2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To the
extent that any information contained in any filings we have made or will make with the Commission under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, or any exhibit thereto, was furnished, rather than filed with the Commission, such information
or exhibit is specifically not incorporated by reference in this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will
provide without charge to each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of
any or all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus
(other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus).
Any such request should be addressed to us at: 757 3rd Avenue, Suite 2018, New York, New York 10017, Attention: Sergio Traversa,
Chief Executive Officer, or made by phone at (212) 376-5771. You may also access the documents incorporated by reference in this
prospectus through our website at www.relmada.com. Except for the specific incorporated documents listed above, no information
available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which
it forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B><IMG SRC="image_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: Red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: Red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Up
to $75,000,000</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Common
Stock</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: Red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><IMG SRC="img_005.jpg" ALT=""><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>,
2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>




































<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INFORMATION
NOT REQUIRED IN THE PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
    14.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other
    Expenses of Issuance and Distribution.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
fees and expenses, other than underwriting discounts and commissions, payable by us in connection with this registration statement
are estimated as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Securities
    and Exchange Commission registration fee</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,140</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINRA filing fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">30,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The supplemental
    listing fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounting fees
    and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal fees and
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Printing fees
    and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Transfer Agent
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Miscellaneous
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">* These
fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
    15.</B></FONT></TD>
    <TD STYLE="width: 92%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Indemnification
    of Directors and Officers.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a Nevada corporation and generally governed by the Nevada Private Corporations Code, Title 78 of the Nevada Revised Statutes,
or NRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section
78.138 of the NRS provides that, unless the corporation&rsquo;s articles of incorporation provide otherwise, a director or officer
will not be individually liable unless it is proven that (i) the director&rsquo;s or officer&rsquo;s acts or omissions constituted
a breach of his or her fiduciary duties, and (ii) such breach involved intentional misconduct, fraud, or a knowing violation of
the law. Our amended and restated articles of incorporation provide that no director or officer shall be personally liable to
the corporation or any of its stockholders for damages for any breach of fiduciary duty as a director or officer except for liability
of a director or officer for (i) acts or omissions involving intentional misconduct, fraud, or a knowing violation of law or (ii)
payment of dividends in violation of Section 78-300 of the NRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section
78.7502 of the NRS permits a company to indemnify its directors and officers against expenses, judgments, fines, and amounts paid
in settlement actually and reasonably incurred in connection with a threatened, pending, or completed action, suit, or proceeding,
if the officer or director (i) is not liable pursuant to NRS 78.138, or (ii) acted in good faith and in a manner the officer or
director reasonably believed to be in or not opposed to the best interests of the corporation and, if a criminal action or proceeding,
had no reasonable cause to believe the conduct of the officer or director was unlawful. Section 78.7502 of the NRS also precludes
indemnification by the corporation if the officer or director has been adjudged by a court of competent jurisdiction, after exhaustion
of all appeals, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent
that the court determines that in view of all the circumstances, the person is fairly and reasonably entitled to indemnity for
such expenses and requires a corporation to indemnify its officers and directors if they have been successful on the merits or
otherwise in defense of any claim, issue, or matter resulting from their service as a director or officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section
78.751 of the NRS permits a Nevada company to indemnify its officers and directors against expenses incurred by them in defending
a civil or criminal action, suit, or proceeding as they are incurred and in advance of final disposition thereof, upon determination
by the stockholders, the disinterested board members, or by independent legal counsel. Section 78.751 of NRS requires a corporation
to advance expenses as incurred upon receipt of an undertaking by or on behalf of the officer or director to repay the amount
if it is ultimately determined by a court of competent jurisdiction that such officer or director is not entitled to be indemnified
by the company if so provided in the corporations articles of incorporation, bylaws, or other agreement. Section 78.751 of the
NRS further permits the company to grant its directors and officers, additional rights of indemnification under its articles of
incorporation, bylaws, or other agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section
78.752 of the NRS provides that a Nevada company may purchase and maintain insurance or make other financial arrangements on behalf
of any person who is or was a director, officer, employee, or agent of the company, or is or was serving at the request of the
company as a director, officer, employee, or agent of another company, partnership, joint venture, trust, or other enterprise,
for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee,
or agent, or arising out of his status as such, whether or not the company has the authority to indemnify him against such liability
and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
amended and restated bylaws implement the indemnification and insurance provisions permitted by Chapter 78 of the NRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter
acquire under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&rsquo;s
official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased
to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such
person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
maintain a general liability insurance policy that covers liabilities of directors and officers of our corporation arising out
of claims based on acts or omissions in their capacities as directors or officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
16.&#9; Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A list
of exhibits filed herewith is contained in the exhibit index that immediately precedes such exhibits and is incorporated herein
by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
17. Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The undersigned registrant hereby undertakes:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
                                         file, during any period in which offers or sales are being made, a post-effective amendment
                                         to this registration statement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
                                         include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
                                         reflect in the prospectus any facts or events arising after the effective date of the
                                         registration statement (or the most recent post-effective amendment thereof) which, individually
                                         or in the aggregate, represent a fundamental change in the information set forth in the
                                         registration statement. Notwithstanding the foregoing, any increase or decrease in volume
                                         of securities offered (if the total dollar value of securities offered would not exceed
                                         that which was registered) and any deviation from the low or high end of the estimated
                                         maximum offering range may be reflected in the form of prospectus filed with the SEC
                                         pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
                                         no more than a 20 percent change in the maximum aggregate offering price set forth in
                                         the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration
                                         statement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
                                         include any material information with respect to the plan of distribution not previously
                                         disclosed in the registration statement or any material change to such information in
                                         the registration statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>provided,
however</I>, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included
in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">That,
                                         for the purpose of determining any liability under the Securities Act of 1933, each such
                                         post-effective amendment shall be deemed to be a new registration statement relating
                                         to the securities offered therein, and the offering of such securities at that time shall
                                         be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
                                         remove from registration by means of a post-effective amendment any of the securities
                                         being registered which remain unsold at the termination of the offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">That,
                                         for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
                                         the registrant is relying on Rule 430B,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 108pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(A)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
                                         prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part
                                         of the registration statement as of the date the filed prospectus was deemed part of
                                         and included in the registration statement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 108pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(B)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
                                         prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part
                                         of a registration statement in reliance on Rule 430B relating to an offering made pursuant
                                         to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required
                                         by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included
                                         in the registration statement as of the earlier of the date such form of prospectus is
                                         first used after effectiveness or the date of the first contract of sale of securities
                                         in the offering described in the prospectus. As provided in Rule 430B, for liability
                                         purposes of the issuer and any person that is at that date an underwriter, such date
                                         shall be deemed to be a new effective date of the registration statement relating to
                                         the securities in the registration statement to which that prospectus relates, and the
                                         offering of such securities at that time shall be deemed to be the initial bona fide
                                         offering thereof. Provided, however, that no statement made in a registration statement
                                         or prospectus that is part of the registration statement or made in a document incorporated
                                         or deemed incorporated by reference into the registration statement or prospectus that
                                         is part of the registration statement will, as to a purchaser with a time of contract
                                         of sale prior to such effective date, supersede or modify any statement that was made
                                         in the registration statement or prospectus that was part of the registration statement
                                         or made in any such document immediately prior to the effective date; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
                                         the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b)
                                         as part of a registration statement relating to an offering, other than registration
                                         statements relying on Rule 430B or other than prospectuses filed in reliance on Rule
                                         430A, shall be deemed to be part of and included in the registration statement as of
                                         the date it is first used after effectiveness. Provided, however, that no statement made
                                         in a registration statement or prospectus that is part of the registration statement
                                         or made in a document incorporated or deemed incorporated by reference into the registration
                                         statement or prospectus that is part of the registration statement will, as to a purchaser
                                         with a time of contract of sale prior to such first use, supersede or modify any statement
                                         that was made in the registration statement or prospectus that was part of the registration
                                         statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">That,
                                         for the purpose of determining liability of the registrant under the Securities Act of
                                         1933 to any purchaser in the initial distribution of the securities, the undersigned
                                         registrant undertakes that in a primary offering of securities of the undersigned registrant
                                         pursuant to this registration statement, regardless of the underwriting method used to
                                         sell the securities to the purchaser, if the securities are offered or sold to such purchaser
                                         by means of any of the following communications, the undersigned registrant will be a
                                         seller to the purchaser and will be considered to offer and sell such securities to such
                                         purchaser:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
                                         preliminary prospectus or prospectus of the undersigned registrant relating to the offering
                                         required to be filed pursuant to Rule 424;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
                                         free writing prospectus relating to the offering prepared by or on behalf of the undersigned
                                         registrant or used or referred to by the undersigned registrant;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         portion of any other free writing prospectus relating to the offering containing material
                                         information about the undersigned registrant or its securities provided by or on behalf
                                         of the undersigned registrant; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 72pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
                                         other communication that is an offer in the offering made by the undersigned registrant
                                         to the purchaser.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         undersigned registrant hereby undertakes that, for purposes of determining any liability
                                         under the Securities Act of 1933, each filing of the registrant&rsquo;s annual report
                                         pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and,
                                         where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant
                                         to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference
                                         in the registration statement shall be deemed to be a new registration statement relating
                                         to the securities offered therein, and the offering of such securities at that time shall
                                         be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Insofar
                                         as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
                                         to directors, officers and controlling persons of the registrant pursuant to the foregoing
                                         provisions, or otherwise, the registrant has been advised that in the opinion of the
                                         Securities and Exchange Commission such indemnification is against public policy as expressed
                                         in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim
                                         for indemnification against such liabilities (other than the payment by the registrant
                                         of expenses incurred or paid by a director, officer or controlling person of the registrant
                                         in the successful defense of any action, suit or proceeding), is asserted by such director,
                                         officer or controlling person in connection with the securities being registered, the
                                         registrant will, unless in the opinion of its counsel the matter has been settled by
                                         controlling precedent, submit to a court of appropriate jurisdiction the question whether
                                         such indemnification by it is against public policy as expressed in the Securities Act
                                         of 1933 and will be governed by the final adjudication of such issue.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 36pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         undersigned registrant hereby undertakes to file an application for the purpose of determining
                                         the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust
                                         Indenture Act in accordance with the rules and regulations prescribed by the SEC under
                                         Section 305(b)(2) of the Trust Indenture Act.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on October 2, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RELMADA
    THERAPEUTICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Sergio Traversa</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sergio Traversa</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive
    Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Power
of Attorney</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">KNOW ALL
PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sandesh Seth and Sergio Traversa,
and each of them individually, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and
resubstitution, for him or her and in his or her name, place and stead, in any and all capacities to sign the Registration Statement
filed herewith and any or all amendments to said Registration Statement (including post-effective amendments and registration
statements filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and otherwise), and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission granting unto said
attorneys-in-fact and agents the full power and authority to do and perform each and every act and thing requisite and necessary
to be done in and about the foregoing, as full to all intents and purposes as he might or could do in person, hereby ratifying
and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute, may lawfully do or cause to
be done by virtue thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 29%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Signature
    </B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title
    </B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date
    </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Sergio Traversa </FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer and Director </FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October
    2, 2015 </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sergio Traversa</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(principal executive
    officer) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Douglas Beck </FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer </FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October
    2, 2015 </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Douglas Beck</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(principal financial
    and accounting officer) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Sheeram Agharkar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October
    2, 2015 </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sheeram Agharkar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Charles J. Casamento</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October
    2, 2015 </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Charles J. Casamento</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Sandesh Seth </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman of the
    Board </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October
    2,      2015 </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandesh Seth </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Nabil Yazgi </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October
    2,      2015 </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nabil Yazgi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
Index</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top; width: 0.7in; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>No.</B></P></TD>
    <TD STYLE="vertical-align: top; width: 0.1in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.1*</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Underwriting Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.2**</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controlled Equity Offering Sales Agreement<SUP>SM</SUP>, dated October 2, 2015, by and between Relmada Therapeutics, Inc. and Cantor Fitzgerald &amp; Co.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">i) Articles of Incorporation of Camp Nine, Inc. (incorporated by reference to Exhibit 3.1 of Relmada&rsquo;s Registration Statement on Form S-1 filed with the SEC on November 13, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ii) Certificate of Designation dated May 13, 2014 (incorporated by reference to Exhibit 4.1 to Relmada&rsquo;s Report on Form 8-K filed with the SEC on May 19, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii) Nevada Certificate of Amendment to Articles of Incorporation of Camp Nine, Inc., effective May 30, 2014 (incorporated by reference to Exhibit 3.1 of Relmada&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iv) Nevada Certificate of Amendment to Articles of Incorporation of Camp Nine, Inc., effective July 8, 2014 (incorporated by reference to Exhibit 3.1 of Relmada&rsquo;s Form 8-K filed with the SEC on July 14, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(v) Certificate of Amendment to Articles of Incorporation of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 of Relmada&rsquo;s Form 10-Q filed with the SEC on February 13, 2015).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(vi) Certificate of Change of Relmada Therapeutics, Inc. dated August 4, 2015 (incorporated by reference to Exhibit 3.1 of Relmada&rsquo;s Form 8-K filed with the SEC on August 10, 2015).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Bylaws of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 of Relmada&rsquo;s Form 8-K filed with the SEC on August 7, 2015).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1**</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Certificate</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2*</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Designation of Preferred Stock</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3* </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Indenture </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.4* </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Warrant Agreement and Warrant Certificate </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.5* </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Preferred Stock Warrant Agreement and Warrant Certificate </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.6* </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Debt Securities Warrant Agreement and Warrant Certificate </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.7* </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Subscription Rights Agreement and Certificate </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.8* </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Purchase Contract </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.9* </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Unit Agreement </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1**</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Opinion of Fennemore Craig, P.C. </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12.1**</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement Regarding the Computation of Ratio of Earnings to Fixed Charges.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1**</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of GBH CPAs, PC</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2**</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of Fennemore Craig, P.C. (included in Exhibit 5.1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.1</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Power of Attorney (included in signature page)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25.1*</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the trustee, as trustee under the indenture filed herewith.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">* To be
filed as an exhibit to a Current Report of the registrant on Form 8-K or other document to be incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">** Filed
herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;II-6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>2
<FILENAME>fs32015ex1ii_relmadathera.htm
<DESCRIPTION>CONTROLLED EQUITY OFFERING SALES AGREEMENTSM, DATED OCTOBER 2, 2015, BY AND BETWEEN RELMADA THERAPEUTICS, INC. AND CANTOR FITZGERALD & CO.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
1.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RELMADA
THERAPEUTICS, INC.</B><BR>
Shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(par
value $0.001 per share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Controlled
Equity Offering<SUP>SM</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Sales
Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October
2, 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 288pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cantor
Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 288pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">499
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 288pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 324pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
Therapeutics, Inc., a Nevada corporation (the &ldquo;<B><U>Company</U></B>&rdquo;), confirms its agreement (this &ldquo;<B><U>Agreement</U></B>&rdquo;)
with Cantor Fitzgerald &amp; Co. (the &ldquo;<B><U>Agent</U></B>&rdquo;), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject
to the conditions set forth herein, it may issue and sell through the Agent, shares of common stock (the &ldquo;<B><U>Placement
Shares</U></B>&rdquo;) of the Company, par value $0.001 per share (the &ldquo;<B><U>Common Stock</U></B>&rdquo;); <I>provided</I>,
<I>however</I>, that in no event shall the Company issue or sell through the Agent such number or dollar amount of Placement Shares
that would (a) exceed the number or dollar amount of shares of Common Stock registered on the effective Registration Statement
(defined below) pursuant to which the offering is being made, (b) exceed the number of authorized but unissued shares of Common
Stock, (c) exceed the number or dollar amount of shares of Common Stock permitted to be sold under Form S-3 (including General
Instruction I.B.6 thereof, if applicable) or (d) exceed the number or dollar amount of shares of Common Stock for which the Company
has filed a Prospectus Supplement (defined below) (the lesser of (a), (b), (c) and (d), the &ldquo;<B><U>Maximum Amount</U></B>&rdquo;).
Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth
in this <U>Section 1</U> on the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility
of the Company and that Agent shall have no obligation in connection with such compliance. The issuance and sale of Placement
Shares through Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company and which
will be declared effective by the Securities and Exchange Commission (the &ldquo;<B><U>Commission</U></B>&rdquo;), although nothing
in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has filed or will file, in accordance with the provisions of the Securities Act of 1933 (the &ldquo;<B><U>Securities Act</U></B>&rdquo;)
and the rules and regulations thereunder (the &ldquo;<B><U>Securities Act Regulations</U></B>&rdquo;), with the Commission a registration
statement on Form S-3, including a base prospectus, relating to certain securities, including the Placement Shares to be issued
from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance
with the provisions of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><U>Exchange Act</U></B>&rdquo;), and the
rules and regulations thereunder. The Company has prepared a prospectus or a prospectus supplement to the base prospectus included
as part of the registration statement, which prospectus or prospectus supplement relates to the Placement Shares to be issued
from time to time by the Company (the &ldquo;<B><U>Prospectus Supplement</U></B>&rdquo;). The Company will furnish to the Agent,
for use by the Agent, copies of the prospectus included as part of such registration statement, as supplemented, by the Prospectus
Supplement, relating to the Placement Shares to be issued from time to time by the Company. The Company may file one or more additional
registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement,
if applicable (which shall be a Prospectus Supplement), with respect to the Placement Shares. Except where the context otherwise
requires, such registration statement(s), including all documents filed as part thereof or incorporated by reference therein,
and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to
Rule&nbsp;424(b) under the Securities Act Regulations or deemed to be a part of such registration statement pursuant to Rule&nbsp;430B
of the Securities Act Regulations, is herein called the &ldquo;<B><U>Registration Statement</U></B>.&rdquo; The base prospectus
or base prospectuses, including all documents incorporated therein by reference, included in the Registration Statement, as it
may be supplemented, if necessary, by the Prospectus Supplement, in the form in which such prospectus or prospectuses and/or Prospectus
Supplement have most recently been filed by the Company with the Commission pursuant to Rule&nbsp;424(b) under the Securities
Act Regulations, together with the then issued Issuer Free Writing Prospectus(es), is herein called the &ldquo;<B><U>Prospectus</U></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
reference herein to the Registration Statement, any Prospectus Supplement, Prospectus or any Issuer Free Writing Prospectus (defined
below) shall be deemed to refer to and include the documents, if any, incorporated by reference therein (the &ldquo;<B><U>Incorporated
Documents</U></B>&rdquo;), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such
Incorporated Documents. Any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo;
with respect to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall
be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date
of the Registration Statement, or the date of the Prospectus Supplement, Prospectus or such Issuer Free Writing Prospectus, as
the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement,
the Prospectus or to any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission
pursuant to its Electronic Data Gathering Analysis and Retrieval System, or if applicable, the Interactive Data Electronic Application
system when used by the Commission (collectively, &ldquo;<B><U>EDGAR</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Placements</U>.
Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a &ldquo;<B><U>Placement</U></B>&rdquo;),
it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) of the number of Placement
Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement Shares
that may be sold in any one day and any minimum price below which sales may not be made (a &ldquo;<B><U>Placement Notice</U></B>&rdquo;),
the form of which is attached hereto as <U>Schedule 1</U>. The Placement Notice shall originate from any of the individuals from
the Company set forth on <U>Schedule 3</U> (with a copy to each of the other individuals from the Company listed on such schedule),
and shall be addressed to each of the individuals from the Agent set forth on <U>Schedule 3</U>, as such <U>Schedule 3</U> may
be amended from time to time. The Placement Notice shall be effective unless and until (i)&nbsp;the Agent declines to accept the
terms contained therein for any reason, in its sole discretion, (ii)&nbsp;the entire amount of the Placement Shares thereunder
have been sold, (iii)&nbsp;the Company suspends or terminates the Placement Notice or (iv)&nbsp;this Agreement has been terminated
under the provisions of <U>Section 13</U>. The amount of any discount, commission or other compensation to be paid by the Company
to Agent in connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in <U>Schedule
2</U>. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation whatsoever with
respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Agent and the Agent
does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and
herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement
Notice will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sale of Placement Shares by Agent</U>.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Placement
Shares</U>. Subject to the provisions of <U>Section 5(a)</U>, the Agent, for the period specified in the Placement Notice, will
use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal
laws, rules and regulations and the rules of the NASDAQ Capital Market or NYSE MKT (the &ldquo;<B><U>Exchange</U></B>&rdquo;),
to sell the Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice.
The Agent will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) immediately
following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares
sold on such day, the compensation payable by the Company to the Agent pursuant to <U>Section 2</U> with respect to such sales,
and the Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Agent (as set
forth in <U>Section 5(b)</U>) from the gross proceeds that it receives from such sales. Subject to the terms of the Placement
Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an &ldquo;at the market&rdquo; offering
as defined in Rule&nbsp;415 of the Securities Act Regulations, including without limitation sales made directly on the Exchange,
on any other existing trading market for the Common Stock or to or through a market maker. Subject to the terms of a Placement
Notice, the Agent may also sell Placement Shares by any other method permitted by law, including but not limited to in privately
negotiated transactions, with the Company&rsquo;s prior written consent. &ldquo;<B><U>Trading Day</U></B>&rdquo; means any day
on which Common Stock is traded on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Short Sales</U>. During the term of this Agreement, the Agent shall not engage in (i) any short sale of any security of the Company,
as defined in Regulation SHO, (ii) any sale of any security of the Company that Agent does not own or any sale which is consummated
by the delivery of a security of the Company borrowed by, or for the account of, Agent or (iii) any market making, bidding, stabilization
or other trading activity with regard to the Common Stock or related derivative securities if such activity would be prohibited
under Regulation M or other anti-manipulation rules under the Securities Act or any other law applicable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Suspension
of Sales</U>. The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each
of the individuals of the other party set forth on <U>Schedule 3</U>, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
facsimile transmission or email correspondence to each of the individuals of the other party set forth on <U>Schedule 3</U>),
suspend any sale of Placement Shares (a &ldquo;<B><U>Suspension</U></B>&rdquo;); <I>provided</I>, <I>however</I>, that such suspension
shall not affect or impair any party&rsquo;s obligations with respect to any Placement Shares sold hereunder prior to the receipt
of such notice. While a Suspension is in effect any obligation under <U>Sections 7(l)</U>, <U>7(m)</U>, and <U>7(n)</U> with respect
to the delivery of certificates, opinions, or comfort letters to the Agent, shall be waived. Each of the parties agrees that no
such notice under this <U>Section 4</U> shall be effective against any other party unless it is made to one of the individuals
named on <U>Schedule 3</U> hereto, as such Schedule may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Sale
    and Delivery to the Agent; Settlement</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sale
of Placement Shares</U><I>. </I>On the basis of the representations and warranties herein contained and subject to the terms and
conditions herein set forth, upon the Agent&rsquo;s acceptance of the terms of a Placement Notice, and unless the sale of the
Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this
Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent
with its normal trading and sales practices and applicable law and regulations to sell such Placement Shares up to the amount
specified, and otherwise in accordance with the terms of such Placement Notice. The Company acknowledges and agrees that (i) there
can be no assurance that the Agent will be successful in selling Placement Shares, (ii) the Agent will incur no liability or obligation
to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent
to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations
to sell such Placement Shares as required under this Agreement and (iii) the Agent shall be under no obligation to purchase Placement
Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by the Agent and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement
of Placement Shares</U><I>. </I>Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement
Shares will occur on the third (3<SUP>rd</SUP>) Trading Day (or such earlier day as is industry practice for regular-way trading)
following the date on which such sales are made (each, a &ldquo;<B><U>Settlement Date</U></B>&rdquo;). The Agent shall notify
the Company of each sale of Placement Shares no later than the opening of the Trading Day immediately following the Trading Day
on which it has made sales of Placement Shares hereunder. The amount of proceeds to be delivered to the Company on a Settlement
Date against receipt of the Placement Shares sold (the &ldquo;<B><U>Net Proceeds</U></B>&rdquo;) will be equal to the aggregate
sales price received by the Agent, after deduction for (i) the Agent&rsquo;s commission, discount or other compensation for such
sales payable by the Company pursuant to <U>Section 2</U> hereof, and (ii) any transaction fees imposed by any governmental or
self-regulatory organization in respect of such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Placement Shares</U>. On or before each Settlement Date, the Company will, or will cause its transfer agent to,
electronically transfer the Placement Shares being sold by crediting the Agent&rsquo;s or its designee&rsquo;s account (provided
the Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date)
at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may
be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in
good deliverable form. On each Settlement Date, the Agent will deliver the related Net Proceeds in same day funds to an account
designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent
(if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date, the Company agrees that in addition
to and in no way limiting the rights and obligations set forth in <U>Section 10(a)</U> hereto, it will (i) hold the Agent harmless
against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in
connection with such default by the Company or its transfer agent (if applicable) and (ii) pay to the Agent any commission, discount,
or other compensation to which it would otherwise have been entitled absent such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Denominations;
Registration</U><I>. </I>Certificates for the Placement Shares, if any, shall be in such denominations and registered in such
names as the Agent may request in writing at least one full Business Day (as defined below) before the Settlement Date. The certificates
for the Placement Shares, if any, will be made available by the Company for examination and packaging by the Agent in The City
of New York not later than&nbsp;noon (New York time) on the Business Day prior to the Settlement Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations
on Offering Size</U><I>. </I>Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares
if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant
to this Agreement would exceed the lesser of (A)&nbsp;together with all sales of Placement Shares under this Agreement, the Maximum
Amount, (B)&nbsp;the amount available for offer and sale under the currently effective Registration Statement and (C)&nbsp;the
amount authorized from time to time to be issued and sold under this Agreement by the Company&rsquo;s board of directors, a duly
authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances
shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than
the minimum price authorized from time to time by the Company&rsquo;s board of directors, a duly authorized committee thereof
or a duly authorized executive committee, and notified to the Agent in writing. Further, under no circumstances shall the Company
cause or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to, and agrees with Agent that as of the date of this Agreement
and as of each Applicable Time (as defined below), unless such representation, warranty or agreement specifies a different date
or time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Statement and Prospectus</U>. The Company and the transactions contemplated by this Agreement meet the requirements for and comply
with the applicable conditions set forth in Form S-3 (including General Instruction I.A and I.B) under the Securities Act. The
Registration Statement has been or will be filed with the Commission and will be declared effective by the Commission under the
Securities Act prior to the issuance of any Placement Notices by the Company. The Prospectus Supplement will name the Agent as
the agent in the section entitled &ldquo;Plan of Distribution.&rdquo; The Company has not received, and has no notice of, any
order of the Commission preventing or suspending the use of the Registration Statement, or threatening or instituting proceedings
for that purpose. The Registration Statement and the offer and sale of Placement Shares as contemplated hereby meet the requirements
of Rule&nbsp;415 under the Securities Act and comply in all material respects with said Rule. Any statutes, regulations, contracts
or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits
to the Registration Statement have been so described or filed. Copies of the Registration Statement, the Prospectus, and any such
amendments or supplements and all documents incorporated by reference therein that were filed with the Commission on or prior
to the date of this Agreement have been delivered, or are available through EDGAR, to Agent and its counsel. The Company has not
distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of the Placement Shares,
will not distribute any offering material in connection with the offering or sale of the Placement Shares other than the Registration
Statement and the Prospectus and any Issuer Free Writing Prospectus (as defined below) to which the Agent has consented, such
consent not to be unreasonably withheld, conditioned or delayed. The Common Stock is registered pursuant to Section 12(b) of the
Exchange Act and is currently listed on the Exchange under the trading symbol &ldquo;RLMD.&rdquo; The Company has taken no action
designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act, delisting
the Common Stock from the Exchange, nor has the Company received any notification that the Commission or the Exchange is contemplating
terminating such registration or listing. To the Company&rsquo;s knowledge, it is in compliance in all material respects with
all applicable listing requirements of the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Misstatement or Omission</U>. The Registration Statement, when it became or becomes effective, and the Prospectus, and any amendment
or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects
with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such
date, will conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became
or becomes effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement
thereto, on the date thereof and at each Applicable Time (defined below), did not or will not include an untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading. The documents incorporated by reference in the Prospectus or any Prospectus Supplement did not,
and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue
statement of a material fact or omit to state a material fact required to be stated in such document or necessary to make the
statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall not
apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished
to the Company by Agent specifically for use in the preparation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conformity
with Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or any
amendment or supplement thereto, and the documents incorporated by reference in the Registration Statement, the Prospectus or
any amendment or supplement thereto, when such documents were or are filed with the Commission under the Securities Act or the
Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or will conform in all material
respects with the requirements of the Securities Act and the Exchange Act, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Information</U>. The consolidated financial statements of the Company included or incorporated by reference in the Registration
Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, together with the related notes and schedules, present
fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries (as defined below) as
of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the
Company for the periods specified and have been prepared in all material respects in compliance with the requirements of the Securities
Act and Exchange Act, as applicable, and in conformity with GAAP (as defined below) applied on a consistent basis (except for
such adjustments to accounting standards and practices as are noted therein) during the periods involved (subject, in the case
of unaudited financial statements, to normal recurring adjustments and to the extent they may exclude footnotes or may be condensed
or summarized statements); the other financial and statistical data with respect to the Company and the Subsidiaries (as defined
below) contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses,
if any, are accurately and fairly presented and prepared on a basis consistent with the financial statements and books and records
of the Company; there are no financial statements (historical or pro forma) that are required to be included or incorporated by
reference in the Registration Statement or the Prospectus that are not included or incorporated by reference as required; the
Company and the Subsidiaries (as defined below) do not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto) or the Prospectus
which are required to be described in the Registration Statement or the Prospectus; and all disclosures contained or incorporated
by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, regarding &ldquo;non-GAAP
financial measures&rdquo; (as such term is defined by the rules and regulations of the Commission) comply in all material respects
with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conformity
with EDGAR Filing</U>. The Prospectus delivered to Agent for use in connection with the sale of the Placement Shares pursuant
to this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing via
EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization</U>.
The Company and each of its Subsidiaries are duly organized, validly existing as a corporation and in good standing under the
laws of their respective jurisdictions of organization. The Company and each of its Subsidiaries are duly licensed or qualified
as a foreign corporation for transaction of business and in good standing under the laws of each other jurisdiction in which their
respective ownership or lease of property or the conduct of their respective businesses requires such license or qualification,
and have all corporate power and authority necessary to own or hold their respective properties and to conduct their respective
businesses as described in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good
standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would
reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties,
condition (financial or otherwise), prospects, stockholders&rsquo; equity or results of operations of the Company and the Subsidiaries
taken as a whole, or prevent or materially interfere with consummation of the transactions contemplated hereby (a &ldquo;<B><U>Material
Adverse Effect</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
The subsidiaries set forth on <U>Schedule 4</U> (collectively, the &ldquo;<B><U>Subsidiaries</U></B>&rdquo;), are the Company&rsquo;s
only significant subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the Commission). Except as
set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly, all of the equity interests
of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction,
and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and
similar rights. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from
making any other distribution on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to
such Subsidiary from the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the Company or any
other Subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Violation or Default</U>. Neither the Company nor any of its Subsidiaries is (i)&nbsp;in violation of its charter or by-laws or
similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both,
would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a
party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or
any of its Subsidiaries are subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation
of any court or arbitrator or governmental or regulatory authority, except, in the case of each of clauses (ii) and (iii) above,
for any such violation or default that would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&rsquo;s
knowledge, no other party under any material contract or other agreement to which it or any of its Subsidiaries is a party is
in default in any respect thereunder where such default would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Change</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Prospectus and the Free Writing Prospectuses, if any (including any document deemed incorporated by reference therein), there
has not been (i) any Material Adverse Effect or the occurrence of any development that the Company reasonably expects will result
in a Material Adverse Effect, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii)
any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or any
Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock
(other than (A) the grant of additional options or other awards under or outside the Company&rsquo;s existing stock incentive
plans, (B) changes in the number of outstanding shares of Common Stock of the Company due to the issuance of shares upon the exercise
or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof, (C) as a result
of the issuance of Placement Shares, (D) any repurchases of capital stock of the Company, (E) as described in a proxy statement
filed on Schedule 14A or a Registration Statement on Form S-4, or (F) otherwise publicly announced) of the Company or any of its
Subsidiaries or (v) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company or any
Subsidiary, other than in each case above (1) in the ordinary course of business, (2) as otherwise disclosed in the Registration
Statement or Prospectus or (3) where such matter, item, change, or development, individually or in the aggregate, would not make
the statements in the Registration Statement or the Prospectus contain an untrue statement of a material fact or omit to state
a material fact required to be stated (including any document deemed incorporated by reference therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and nonassessable and,
other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights of first
refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration
Statement and the Prospectus as of the dates referred to therein (other than (i) the grant of additional options or other awards
under the Company&rsquo;s existing stock incentive plans, (ii) changes in the number of outstanding shares of Common Stock of
the Company due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into,
Common Stock outstanding on the date hereof, (iii) as a result of the issuance of Placement Shares, or (iv) any repurchases of
capital stock of the Company) and such authorized capital stock conforms to the description thereof set forth in the Registration
Statement and the Prospectus. The description of the securities of the Company in the Registration Statement and the Prospectus
is complete and accurate in all material respects. Except as disclosed in or contemplated by the Registration Statement or the
Prospectus, as of the date referred to therein, the Company does not have outstanding any options to purchase, or any rights or
warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments
to issue or sell, any shares of capital stock or other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform the transactions
contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and
binding agreement of the Company enforceable against the Company in accordance with its terms, except to the extent that (i) enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally
and by general equitable principles and (ii) the indemnification and contribution provisions of <U>Section 11</U> hereof may be
limited by federal or state securities laws and public policy considerations in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization
of Placement Shares</U>. The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors
of the Company or a duly authorized committee thereof, or a duly authorized executive officer, against payment therefor as provided
herein, will be duly and validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance,
security interest or other claim, including any statutory or contractual preemptive rights, resale rights, rights of first refusal
or other similar rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when issued,
will conform in all material respects to the description thereof set forth in or incorporated into the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority having jurisdiction over the Company is required for the execution, delivery and performance
by the Company of this Agreement and the issuance and sale by the Company of the Placement Shares as contemplated hereby, except
for the registration of the Placement Shares under the Securities Act and such consents, approvals, authorizations, orders and
registrations or qualifications as may be required under applicable state securities laws or by the by-laws and rules of the Financial
Industry Regulatory Authority (&ldquo;<B><U>FINRA</U></B>&rdquo;) or the Exchange, including any notices that may be required
by Exchange, in connection with the sale of the Placement Shares by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Preferential Rights</U>. Except as set forth in the Registration Statement and the Prospectus, (i)&nbsp;no person, as such term
is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act (each, a &ldquo;<B><U>Person</U></B>&rdquo;), has
the right, contractual or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other
capital stock or other securities of the Company (other than upon the exercise of options or warrants to purchase Common Stock
or upon the exercise of options that may be granted, or issuances of Common Stock or other equity awards, from time to time under
or outside of the Company&rsquo;s stock incentive plans), (ii)&nbsp;no Person has any preemptive rights, resale rights, rights
of first refusal, rights of co-sale, or any other rights (whether pursuant to a &ldquo;poison pill&rdquo; provision or otherwise)
to purchase any Common Stock or shares of any other capital stock or other securities of the Company from the Company, (iii) no
Person has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of
the Common Stock as contemplated by this Agreement, and (iv)&nbsp;no Person has the right, contractual or otherwise, to require
the Company to register under the Securities Act any Common Stock or shares of any other capital stock or other securities of
the Company, or to include any such shares or other securities in the Registration Statement or the offering contemplated thereby,
whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated
thereby or otherwise, except for those shares and securities currently subject to registration statements on file with the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Public Accounting Firm</U>. GBH CPAs, PC (the &ldquo;<B><U>Accountant</U></B>&rdquo;), whose report on the consolidated financial
statements of the Company is filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form 10-K filed
with the Commission and incorporated by reference into the Registration Statement and the Prospectus, are and, during the periods
covered by their report, were an independent registered public accounting firm within the meaning of the Securities Act and the
Public Company Accounting Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not in violation
of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<B><U>Sarbanes-Oxley Act</U></B>&rdquo;)
with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability
of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus, other than such
agreements that have expired by their terms or whose termination is disclosed in documents filed by the Company on EDGAR, are
legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent
that (i)&nbsp;enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo;
rights generally and by general equitable principles and (ii)&nbsp;the indemnification provisions of certain agreements may be
limited by federal or state securities laws or public policy considerations in respect thereof, and except for any unenforceability
that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Litigation</U>. Except as set forth in the Registration Statement or the Prospectus, there are no legal, governmental or regulatory
actions, suits or proceedings pending, nor, to the Company&rsquo;s knowledge, any legal, governmental or regulatory audits or
investigations, to which the Company or a Subsidiary is a party or to which any property of the Company or any of its Subsidiaries
is the subject that, individually or in the aggregate, would have a Material Adverse Effect and, to the Company&rsquo;s knowledge,
no such actions, suits or proceedings are threatened or contemplated by any governmental or regulatory authority or threatened
by others; and (i)&nbsp;there are no current or pending legal, governmental or regulatory audits or investigations, actions, suits
or proceedings that are required under the Securities Act to be described in the Prospectus that are not so described; and (ii)&nbsp;there
are no contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement
that are not so filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consents
and Permits</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries have made
all filings, applications and submissions required by, and possess and are operating in compliance with all approvals, licenses,
certificates, certifications, clearances, consents, grants, exemptions, marks, notifications, orders, permits and other authorizations
issued by, the appropriate federal, state or foreign governmental or regulatory authorities (including, without limitation, the
United States Food and Drug Administration (the &ldquo;<B><U>FDA</U></B>&rdquo;), the United States Drug Enforcement Administration
or any other foreign, federal, state, provincial, court or local government or regulatory authorities including self-regulatory
organizations engaged in the regulation of clinical trials, pharmaceuticals, biologics or biohazardous substances or materials)
necessary for the ownership or lease of their respective properties or to conduct their businesses as described in the Registration
Statement and the Prospectus (collectively, &ldquo;<B><U>Permits</U></B>&rdquo;), except for such Permits the failure of which
to possess, obtain or make the same would not have a Material Adverse Effect; the Company and its Subsidiaries are in compliance
with the terms and conditions of all such Permits, except where the failure to be in compliance would not have a Material Adverse
Effect; all of the Permits are valid and in full force and effect, except where any invalidity, individually or in the aggregate,
would not be reasonably expected to have a Material Adverse Effect; and neither the Company nor any of its Subsidiaries has received
any written notice of proceedings relating to the limitation, revocation, cancellation, suspension, modification or non-renewal
of any such Permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have
a Material Adverse Effect, and has any reason to believe that any such license, certificate, permit or authorization will not
be renewed in the ordinary course. To the extent required by applicable laws and regulations of the FDA, the Company or the applicable
Subsidiary has submitted to the FDA an Investigational New Drug Application or amendment or supplement thereto for each clinical
trial it has conducted or sponsored or is conducting or sponsoring; all such submissions were in material compliance with applicable
laws and rules and regulations when submitted and no material deficiencies have been asserted by the FDA with respect to any such
submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Filings</U>. Except as disclosed in the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries
has failed to file with the applicable regulatory authorities (including, without limitation, the FDA, or any foreign, federal,
state, provincial or local governmental or regulatory authority performing functions similar to those performed by the FDA) any
required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the
aggregate, would not have a Material Adverse Effect; except as disclosed in the Registration Statement and the Prospectus, all
such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable laws when filed
and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations,
listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate, would not
have a Material Adverse Effect. The Company has operated and currently is, in all material respects, in compliance with the United
States Federal Food, Drug, and Cosmetic Act, all applicable rules and regulations of the FDA and other federal, state, local and
foreign governmental bodies exercising comparable authority. The Company has no knowledge of any studies, tests or trials not
described in the Prospectus the results of which reasonably call into question in any material respect the results of the studies,
tests and trials described in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries own, possess,
license or have other rights to use all foreign and domestic patents, patent applications, trade and service marks, trade and
service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, Internet domain names, know-how
and other intellectual property (collectively, the &ldquo;<B><U>Intellectual Property</U></B>&rdquo;), necessary for the conduct
of their respective businesses as now conducted except to the extent that the failure to own, possess, license or otherwise hold
adequate rights to use such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect.
Except as disclosed in the Registration Statement and the Prospectus (i) there are no rights of third parties to any such Intellectual
Property owned by the Company and its Subsidiaries; (ii) to the Company&rsquo;s knowledge, there is no infringement by third parties
of any such Intellectual Property; (iii) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding
or claim by others challenging the Company&rsquo;s and its Subsidiaries&rsquo; rights in or to any such Intellectual Property,
and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iv)
there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the
validity or scope of any such Intellectual Property; (v) there is no pending or, to the Company&rsquo;s knowledge, threatened
action, suit, proceeding or claim by others that the Company and its Subsidiaries infringe or otherwise violate any patent, trademark,
copyright, trade secret or other proprietary rights of others; (vi) to the Company&rsquo;s knowledge, there is no third-party
U.S. patent or published U.S. patent application which contains claims for which an Interference Proceeding (as defined in 35
U.S.C. &sect;135) has been commenced against any patent or patent application described in the Prospectus as being owned by or
licensed to the Company; and (vii) the Company and its Subsidiaries have complied with the terms of each agreement pursuant to
which Intellectual Property has been licensed to the Company or such Subsidiary, and all such agreements are in full force and
effect, except, in the case of any of clauses (i)-(vii) above, for any such infringement by third parties or any such pending
or threatened suit, action, proceeding or claim as would not, individually or in the aggregate, result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Clinical
Studies</U>. To the Company&rsquo;s knowledge, the preclinical studies and tests and clinical trials described in the Prospectus
were, and, if still pending, are being, to the Company&rsquo;s knowledge, conducted in all material respects in accordance with
the experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards
for products or product candidates comparable to those being developed by the Company; the descriptions of such studies, tests
and trials, and the results thereof, contained in the Prospectus are accurate and complete in all material respects; the Company
is not aware of any tests, studies or trials not described in the Prospectus, the results of which reasonably call into question
the results of the tests, studies and trials described in the Prospectus; and the Company has not received any written notice
or correspondence from the FDA or any foreign, state or local governmental body exercising comparable authority or any institutional
review board or comparable authority requiring the termination, suspension, clinical hold or material modification of any tests,
studies or trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Market
Capitalization</U>. At the time the Registration Statement was or will be originally declared effective, and at the time the Company&rsquo;s
most recent Annual Report on Form 10-K was filed with the Commission, the Company met or will meet the then applicable requirements
for the use of Form S-3 under the Securities Act, including but not limited to General Instruction I.B.1 of Form S-3. The Company
is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar
months previously and if it has been a shell company at any time previously, has filed current Form 10 information (as defined
in General Instruction I.B.6 of Form S-3) with the Commission at least 12 calendar months previously reflecting its status as
an entity that is not a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Defaults</U>. Neither the Company nor any of the Subsidiaries has defaulted on any installment on indebtedness for borrowed
money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material
Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of
its last Annual Report on Form 10-K, indicating that it (i)&nbsp;has failed to pay any dividend or sinking fund installment on
preferred stock or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more
long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Market Activities</U>. Neither the Company, nor any of the Subsidiaries, nor any of their respective directors, officers or controlling
persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably be expected to cause
or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Broker/Dealer
Relationships</U>. Neither the Company nor any of the Subsidiaries (i)&nbsp;is required to register as a &ldquo;broker&rdquo;
or &ldquo;dealer&rdquo; in accordance with the provisions of the Exchange Act or (ii)&nbsp;directly or indirectly through one
or more intermediaries, controls or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo;
(within the meaning set forth in the FINRA Manual).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Reliance</U>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice
in connection with the offering and sale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not
being contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except as
otherwise disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined
adversely to the Company or any of its Subsidiaries which has had, or would have, individually or in the aggregate, a Material
Adverse Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment
which has been asserted or threatened against it which would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Real and Personal Property</U>. Except as set forth in the Registration Statement or the Prospectus, the Company and its Subsidiaries
have good and marketable title in fee simple to all items of real property owned by them, good and valid title to all personal
property described in the Registration Statement or Prospectus as being owned by them that are material to the businesses of the
Company or such Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those matters that (i) do
not materially interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries
or (ii) would not, individually or in the aggregate, have a Material Adverse Effect. Any real or personal property described in
the Registration Statement or Prospectus as being leased by the Company and any of its Subsidiaries is held by them under valid,
existing and enforceable leases, except those that (A) do not materially interfere with the use made or proposed to be made of
such property by the Company or any of its Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate,
to have a Material Adverse Effect. Each of the properties of the Company and its Subsidiaries complies with all applicable codes,
laws and regulations (including, without limitation, building and zoning codes, laws and regulations and laws relating to access
to such properties), except if and to the extent disclosed in the Registration Statement or Prospectus or except for such failures
to comply that would not, individually or in the aggregate, reasonably be expected to interfere in any material respect with the
use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. Except as set forth in the Registration Statement or the Prospectus, the Company and its Subsidiaries (i)&nbsp;are in
compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating
to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(collectively, &ldquo;<B><U>Environmental Laws</U></B>&rdquo;); (ii)&nbsp;have received and are in compliance in all material
respects with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses as described in the Registration Statement and the Prospectus; and (iii)&nbsp;have not received notice of any actual
or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes,
pollutants or contaminants, except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply or
failure to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
Controls</U>. The Company and each of its Subsidiaries maintain systems of internal accounting controls sufficient to provide
reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. The Company&rsquo;s internal control over
financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial
reporting (other than as set forth in the Prospectus). Since the date of the latest audited financial statements of the Company
included in the Prospectus, there has been no change in the Company&rsquo;s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting
(other than as set forth in the Prospectus). The Company has established disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure controls and procedures to ensure that material information
relating to the Company and each of its Subsidiaries is made known to the certifying officers by others within those entities,
particularly during the period in which the Company&rsquo;s Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as the
case may be, is being prepared. The Company&rsquo;s certifying officers have evaluated the effectiveness of the Company&rsquo;s
controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K for the fiscal year most recently
ended (such date, the <B>&ldquo;<U>Evaluation Date</U></B>&rdquo;). The Company presented in its Form 10-K for the fiscal year
most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date and the disclosure controls and procedures are effective. Since the Evaluation
Date, there have been no significant changes in the Company&rsquo;s internal controls (as such term is defined in Item 307(b)
of Regulation S-K under the Securities Act) or, to the Company&rsquo;s knowledge, in other factors that could significantly and
adversely affect the Company&rsquo;s internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley</U>.
There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&rsquo;s directors
or officers, in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley
Act and the rules and regulations promulgated thereunder. Each of the principal executive officer and the principal financial
officer of the Company (or each former principal executive officer of the Company and each former principal financial officer
of the Company as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect
to all reports, schedules, forms, statements and other documents required to be filed by it or furnished by it to the Commission
during the past 12 months. For purposes of the preceding sentence, &ldquo;principal executive officer&rdquo; and &ldquo;principal
financial officer&rdquo; shall have the meanings given to such terms in Exchange Act Rules 13a-15 and 15d-15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Finder&rsquo;s
Fees</U>. Neither the Company nor any of the Subsidiaries has incurred any liability for any finder&rsquo;s fees, brokerage commissions
or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to Agent
pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Disputes</U>. No labor disturbance by or dispute with employees of the Company or any of its Subsidiaries exists or, to the knowledge
of the Company, is threatened which would reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company Act</U>. Neither the Company nor any of the Subsidiaries is or, after giving effect to the offering and sale of the Placement
Shares, will be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company,&rdquo;
as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<B><U>Investment Company Act</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Operations</U>.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects
with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the &ldquo;<B><U>Money Laundering Laws</U></B>&rdquo;), except as would not reasonably
be expected to result in a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator having jurisdiction involving the Company or any of its Subsidiaries with respect to the Money
Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Off-Balance
Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the Company, and/or
to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structured
finance, special purpose or limited purpose entity (each, an &ldquo;<B><U>Off-Balance Sheet Transaction</U></B>&rdquo;) that could
reasonably be expected to affect materially the Company&rsquo;s liquidity or the availability of or requirements for its capital
resources, including those Off-Balance Sheet Transactions described in the Commission&rsquo;s Statement about Management&rsquo;s
Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to
be described in the Prospectus which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriter
Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other &ldquo;at-the-market&rdquo;
or continuous equity transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>ERISA</U>.
To the knowledge of the Company, each material employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended (&ldquo;<B><U>ERISA</U></B>&rdquo;), that is maintained, administered or contributed to
by the Company or any of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been
maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations,
including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the &ldquo;<B><U>Code</U></B>&rdquo;); no
prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result
in a material liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or
administrative exemption; and for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302
of ERISA, no &ldquo;accumulated funding deficiency&rdquo; as defined in Section 412 of the Code has been incurred, whether or
not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions)
exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions other than,
in the case of the items in this paragraph, as would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) (a &ldquo;<B><U>Forward-Looking Statement</U></B>&rdquo;) contained in the Registration Statement and the Prospectus has
been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. The Forward-Looking Statements
incorporated by reference in the Registration Statement and the Prospectus from the Company&rsquo;s Annual Report on Form 10-K
for the fiscal year most recently ended (i)&nbsp;are within the coverage of the safe harbor for forward-looking statements set
forth in Section 27A of the Securities Act, Rule 175(b) under the Securities Act or Rule 3b-6 under the Exchange Act, as applicable,
(ii)&nbsp;were made by the Company with a reasonable basis and in good faith and reflect the Company&rsquo;s good faith commercially
reasonable best estimate of the matters described therein as of the respective dates on which such statements were made, and (iii)&nbsp;have
been prepared in accordance with Item 10 of Regulation S-K under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agent
Purchases</U>. The Company acknowledges and agrees that Agent has informed the Company that the Agent may, to the extent permitted
under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own account while this Agreement is in effect,
<I>provided</I>, that (i)&nbsp;no such purchase or sales shall take place while a Placement Notice is in effect (except to the
extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &ldquo;riskless principal&rdquo;
or in a similar capacity) and (ii)&nbsp;the Company shall not be deemed to have authorized or consented to any such purchases
or sales by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Margin
Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the
Company as described in the Registration Statement and the Prospectus will result in a violation by the Company or its Subsidiaries
of Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company
and each of its Subsidiaries reasonably believe are adequate for the conduct of their properties and as is customary for companies
engaged in similar businesses of similar size in similar industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Improper Practices</U>. (i)&nbsp;Neither the Company nor the Subsidiaries, nor to the Company&rsquo;s knowledge, any of their
respective executive officers has, in the past five years, made any unlawful contributions to any candidate for any political
office (or failed fully to disclose any contribution in violation of law) or made any contribution or other payment to any official
of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public
duty in violation of any law or of the character required to be disclosed in the Prospectus; (ii)&nbsp;no relationship, direct
or indirect, exists between or among the Company or any Subsidiary or any affiliate of any of them, on the one hand, and the directors,
officers and stockholders of the Company or any Subsidiary, on the other hand, that is required by the Securities Act to be described
in the Registration Statement and the Prospectus that is not so described; (iii)&nbsp;no relationship, direct or indirect, exists
between or among the Company or any Subsidiary or any affiliate of them, on the one hand, and the directors, officers, or stockholders
of the Company or any Subsidiary, on the other hand, that is required by the rules of FINRA to be described in the Registration
Statement and the Prospectus that is not so described; (iv)&nbsp;except as described in the Registration Statement and the Prospectus,
there are no material outstanding loans or advances or material guarantees of indebtedness by the Company or any Subsidiary to
or for the benefit of any of their respective officers or directors or any of the members of the families of any of them; and
(v) the Company has not offered, or caused any placement agent to offer, Common Stock to any person with the intent to influence
unlawfully (A)&nbsp;a customer or supplier of the Company or any Subsidiary to alter the customer&rsquo;s or supplier&rsquo;s
level or type of business with the Company or any Subsidiary or (B)&nbsp;a trade journalist or publication to write or publish
favorable information about the Company or any Subsidiary or any of their respective products or services, and, (vi) neither the
Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any employee or agent of the Company or any Subsidiary has made
any payment of funds of the Company or any Subsidiary or received or retained any funds in violation of any law, rule or regulation
(including, without limitation, the Foreign Corrupt Practices Act of 1977), which payment, receipt or retention of funds is of
a character required to be disclosed in the Registration Statement or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Status
Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule 405 under the Securities
Act at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Misstatement or Omission in an Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue date and
as of each Applicable Time (as defined in <U>Section 24</U> below), did not, does not and will not include any information that
conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including
any incorporated document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not
apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information
furnished to the Company by the Agent specifically for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation
of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof
and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will
constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company is a
party or to which any of the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as
may have been waived and (ii) such conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such
action result (x) in any violation of the provisions of the organizational or governing documents of the Company, or (y) in any
material violation of the provisions of any statute or any order, rule or regulation applicable to the Company or of any court
or of any federal, state or other regulatory authority or other government body having jurisdiction over the Company, except where
such violation would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sanctions</U>.
(i) The Company represents that, neither the Company nor any of its Subsidiaries (collectively, the &ldquo;<B><U>Entity</U></B>&rdquo;)
or to the Company&rsquo;s knowledge any director, officer, employee, agent, affiliate or representative of the Entity, is a government,
individual, or entity (in this paragraph (uu), &ldquo;<B><U>Person</U></B>&rdquo;) that is, or is owned or controlled by a Person
that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(A)
the subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control,
the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively,
&ldquo;<B><U>Sanctions</U></B>&rdquo;), nor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(B)
located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar,
Cuba, Iran, North Korea, Sudan and Syria).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0.5in">(ii) The
Entity represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: 24pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(A)
to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such
funding or facilitation, is the subject of Sanctions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(B)
in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering,
whether as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0.5in">(iii)
The Entity represents and covenants that, except as detailed in the Registration Statement and the Prospectus, for the past 5
years, it has not knowingly engaged in, is not now knowingly engaged in, and will not engage in, any dealings or transactions
with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: 24pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Transfer Taxes</U>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to
be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully
paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Laws</U>. Each of the Company and its Subsidiaries: (A) is and at all times has been in compliance with all statutes, rules,
or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the
Company or its Subsidiaries (&ldquo;<B><U>Applicable Laws</U></B>&rdquo;), except as could not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect; (B) has not received any FDA Form 483, notice of adverse finding,
warning letter, untitled letter or other correspondence or notice from the FDA or any other Governmental Authority alleging or
asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits
and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B><U>Authorizations</U></B>&rdquo;); (C) possesses
all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of
any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any Governmental Authority or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Authority
or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not
received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke
any Authorizations and has no knowledge that any such Governmental Authority is considering such action; (F) has filed, obtained,
maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented
by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to
be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, &ldquo;dear
healthcare provider&rdquo; letter, or other notice or action relating to the alleged lack of safety or efficacy of any product
or any alleged product defect or violation and, to the Company&rsquo;s knowledge, no third party has initiated, conducted or intends
to initiate any such notice or action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection
with this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the
matters set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Covenants of the Company</U>. The Company covenants and agrees with
Agent that:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Statement Amendments</U>. After the date of this Agreement and during any period in which a Prospectus relating to any Placement
Shares is required to be delivered by Agent under the Securities Act (including in circumstances where such requirement may be
satisfied pursuant to Rule 172 under the Securities Act), (i)&nbsp;the Company will notify the Agent promptly of the time when
any subsequent amendment to the Registration Statement, other than documents incorporated by reference, has been filed with the
Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed and of any request by the
Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information, (ii)&nbsp;the
Company will prepare and file with the Commission, promptly upon the Agent&rsquo;s request, any amendments or supplements to the
Registration Statement or Prospectus that, in such Agent&rsquo;s reasonable opinion, may be necessary or advisable in connection
with the distribution of the Placement Shares by the Agent (<I>provided</I>, <I>however</I>, that the failure of the Agent to
make such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&rsquo;s right to
rely on the representations and warranties made by the Company in this Agreement and <I>provided</I>, <I>further</I>, that the
only remedy the Agent shall have with respect to the failure to make such filing shall be to cease making sales under this Agreement
until such amendment or supplement is filed); (iii)&nbsp;the Company will not file any amendment or supplement to the Registration
Statement or Prospectus relating to the Placement Shares or a security convertible into the Placement Shares unless a copy thereof
has been submitted to Agent within a reasonable period of time before the filing and the Agent has not objected thereto (<I>provided</I>,
<I>however</I>, that the failure of the Agent to make such objection shall not relieve the Company of any obligation or liability
hereunder, or affect the Agent&rsquo;s right to rely on the representations and warranties made by the Company in this Agreement
and <I>provided</I>, <I>further</I>, that the only remedy Agent shall have with respect to the failure by the Company to obtain
such consent shall be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of filing
thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus,
except for those documents available via EDGAR; and (iv)&nbsp;the Company will cause each amendment or supplement to the Prospectus
to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the
case of any document to be incorporated therein by reference, to be filed with the Commission as required pursuant to the Exchange
Act, within the time period prescribed (the determination to file or not file any amendment or supplement with the Commission
under this <U>Section 7(a)</U>, based on the Company&rsquo;s reasonable opinion or reasonable objections, shall be made exclusively
by the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Commission Stop Orders</U>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof,
of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement,
of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation
or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent
the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the
Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment
or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering of
the Placement Shares or for additional information related to the Registration Statement, the Prospectus or any Issuer Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Prospectus; Subsequent Changes</U>. During any period in which a Prospectus relating to the Placement Shares is required to
be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances
where such requirement may be satisfied pursuant to Rule 172 under the Securities Act), the Company will comply with all requirements
imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates all
reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to
Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If the Company has omitted any information
from the Registration Statement pursuant to Rule 430B under the Securities Act, it will use commercially reasonable efforts to
comply with the provisions of and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the
Agent promptly of all such filings. If during such period any event occurs as a result of which the Prospectus as then amended
or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or
supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify Agent
to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration
Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance;
<I>provided, however</I>, that the Company may delay the filing of any amendment or supplement, if in the reasonable judgment
of the Company, it is in the best interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Placement Shares</U>. During any period in which the Prospectus relating to the Placement Shares is required to be delivered
by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares, the Company will use commercially
reasonable efforts to cause the Placement Shares to be listed on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Registration Statement and Prospectus</U>. The Company will furnish to the Agent and its counsel (at the reasonable expense
of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein)
and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period
in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all documents
filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon as
reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agent&rsquo;s
request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made;
<I>provided</I>, <I>however</I>, that the Company shall not be required to furnish any document (other than the Prospectus) to
the Agent to the extent such document is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Earnings
Statement</U>. The Company will make generally available to its security holders as soon as practicable, but in any event not
later than 15 months after the end of the Company&rsquo;s current fiscal quarter, an earnings statement covering a 12-month period
that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &ldquo;Use of Proceeds.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Other Sales</U>. Without the prior written consent of Agent, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant
to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire,
Common Stock during the period beginning on the fifth (5<SUP>th</SUP>) Trading Day immediately prior to the date on which any
Placement Notice is delivered to Agent hereunder and ending on the fifth (5<SUP>th</SUP>) Trading Day immediately following the
final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has
been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension
or termination); and will not directly or indirectly in any other &ldquo;at-the-market&rdquo; or continuous equity transaction
offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement
Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights
to purchase or acquire, Common Stock prior to the termination of this Agreement and the sixtieth (60<SUP>th</SUP>) day immediately
following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice; <I>provided</I>,
<I>however</I>, that such restrictions will not be required in connection with the Company&rsquo;s issuance or sale of (i)&nbsp;Common
Stock, options to purchase Common Stock or Common Stock issuable upon the exercise of options or other equity awards, pursuant
to any employee or director stock incentive or benefits plan, stock ownership plan or dividend reinvestment plan (but not Common
Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter
implemented, (ii)&nbsp;Common Stock issuable upon conversion of securities or the exercise of warrants, options or other rights
in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent and
(iii) Common Stock or securities convertible into or exchangeable for shares of Common Stock as consideration for mergers, acquisitions,
other business combinations or strategic alliances occurring after the date of this Agreement which are not issued for capital
raising purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
of Circumstances</U>. The Company will, at any time during the pendency of a Placement Notice advise the Agent promptly after
it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material
respect any opinion, certificate, letter or other document required to be provided to the Agent pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Due
Diligence Cooperation</U>. The Company will cooperate with any reasonable due diligence review conducted by the Agent or its representatives
in connection with the transactions contemplated hereby, including, without limitation, providing information and making available
documents and senior corporate officers, during regular business hours and at the Company&rsquo;s principal offices, as the Agent
may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Required
Filings Relating to Placement of Placement Shares</U>. The Company agrees that on such dates as the Securities Act shall require,
the Company will (i)&nbsp;file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under
the Securities Act (each and every filing date under Rule 424(b), a &ldquo;<B><U>Filing Date</U></B>&rdquo;), which prospectus
supplement will set forth, within the relevant period, the amount of Placement Shares sold through the Agent, the Net Proceeds
to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii)&nbsp;deliver
such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be
required by the rules or regulations of such exchange or market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representation
Dates; Certificate</U>. (1) Prior to the date of the first Placement Notice and (2) each time the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)
files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely
to an offering of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement
Shares by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference
into the Registration Statement or the Prospectus relating to the Placement Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information
or a material amendment to the previously filed Form 10-K);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)
files its quarterly reports on Form 10-Q under the Exchange Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iv)
files a current report on Form 8-K containing amended financial information (other than information &ldquo;furnished&rdquo; pursuant
to Items 2.02 or 7.01 of Form&nbsp;8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification
of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under
the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &ldquo;<B><U>Representation
Date</U></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information
contained in such Form 8-K is material) with a certificate dated the Representation Date, in the form and substance satisfactory
to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as
necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented. The requirement to provide a
certificate under this <U>Section 7(l)</U> shall be waived for any Representation Date occurring at a time a Suspension is in
effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Placement
Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation
Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date
when a Suspension was in effect and did not provide the Agent with a certificate under this <U>Section 7(l)</U>, then before the
Company delivers the instructions for the sale of Placement Shares or the Agent sells any Placement Shares pursuant to such instructions,
the Company shall provide the Agent with a certificate in conformity with this <U>Section 7(l)</U> dated as of the date that the
instructions for the sale of Placement Shares are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legal
Opinion</U>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading Days of each Representation Date
with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section 7(l)</U> for which no waiver is
applicable and excluding the date of this Agreement, the Company shall cause to be furnished to the Agent a written opinion of
Barclay Damon, LLP or The Matt Law Firm, PLLC (&ldquo;<B><U>Company Counsel</U></B>&rdquo;), or other counsel satisfactory to
the Agent, in form and substance satisfactory to Agent and its counsel, substantially similar to the form previously provided
to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended
or supplemented; <I>provided</I>, <I>however</I>, the Company shall be required to furnish to Agent no more than one opinion hereunder
per calendar quarter; <I>provided</I>, <I>further</I>, that in lieu of such opinions for subsequent periodic filings under the
Exchange Act, counsel may furnish the Agent with a letter (a &ldquo;<B><U>Reliance Letter</U></B>&rdquo;) to the effect that the
Agent may rely on a prior opinion delivered under this <U>Section 7(m)</U> to the same extent as if it were dated the date of
such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus
as amended or supplemented as of the date of the Reliance Letter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Comfort
Letter</U>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading Days of each Representation Date
with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section 7(l)</U> for which no waiver is
applicable and excluding the date of this Agreement, the Company shall cause its independent registered public accounting firm
to furnish the Agent letters (the &ldquo;<B><U>Comfort Letters</U></B>&rdquo;), dated the date the Comfort Letter is delivered,
which shall meet the requirements set forth in this <U>Section 7(n)</U>; <I>provided</I>, that if requested by the Agent, the
Company shall cause a Comfort Letter to be furnished to the Agent within ten (10) Trading Days of the date of occurrence of any
material transaction or event, including the restatement of the Company&rsquo;s financial statements. The Comfort Letter from
the Company&rsquo;s independent registered public accounting firm shall be in a form and substance reasonably satisfactory to
the Agent, (i) confirming that they are an independent registered public accounting firm within the meaning of the Securities
Act and the PCAOB, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the financial information
and other matters ordinarily covered by accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters in connection with registered
public offerings (the first such letter, the &ldquo;<B><U>Initial Comfort Letter</U></B>&rdquo;) and (iii) updating the Initial
Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date
and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date
of such letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Market
Activities</U>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed to cause or result in, or that
constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of Common Stock or (ii)&nbsp;sell, bid for, or purchase Common Stock in violation of
Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any of its
Subsidiaries will be or become, at any time prior to the termination of this Agreement, required to register as an &ldquo;investment
company,&rdquo; as such term is defined in the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Offer to Sell</U>. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agent in its capacity
as agent hereunder, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity
as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities
Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement
Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Blue
Sky and Other Qualifications</U><I>. </I>The Company will use its commercially reasonable efforts, in cooperation with the Agent,
to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold,
under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may designate and
to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares
(but in no event for less than one year from the date of this Agreement); <I>provided</I>, <I>however</I>, that the Company shall
not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction
in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt,
the Company will file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification
or exemption, as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event
for less than one year from the date of this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley
Act</U>. The Company and the Subsidiaries will maintain and keep accurate books and records reflecting their assets and maintain
internal accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
and including those policies and procedures that (i)&nbsp;pertain to the maintenance of records that in reasonable detail accurately
and fairly reflect the transactions and dispositions of the assets of the Company, (ii)&nbsp;provide reasonable assurance that
transactions are recorded as necessary to permit the preparation of the Company&rsquo;s consolidated financial statements in accordance
with generally accepted accounting principles, (iii)&nbsp;that receipts and expenditures of the Company are being made only in
accordance with management&rsquo;s and the Company&rsquo;s directors&rsquo; authorization, and (iv)&nbsp;provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could
have a material effect on its financial statements. The Company and the Subsidiaries will maintain such controls and other procedures,
including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations
thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files or
submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed
by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&rsquo;s
management, including its principal executive officer and principal financial officer, or persons performing similar functions,
as appropriate to allow timely decisions regarding required disclosure and to ensure that material information relating to the
Company or the Subsidiaries is made known to them by others within those entities, particularly during the period in which such
periodic reports are being prepared.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary&rsquo;s
Certificate; Further Documentation</U>. Prior to the date of the first Placement Notice, the Company shall deliver to the Agent
a certificate of the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date, certifying
as to (i) the Articles of Incorporation of the Company, (ii) the By-laws of the Company, (iii) the resolutions of the Board of
Directors of the Company authorizing the execution, delivery and performance of this Agreement and the issuance of the Placement
Shares and (iv) the incumbency of the officers duly authorized to execute this Agreement and the other documents contemplated
by this Agreement. Within five (5) Trading Days of each Representation Date, the Company shall have furnished to the Agent such
further information, certificates and documents as the Agent may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Covenants of the Agent</U>. The Agent represents and warrants that it is duly registered as a broker-dealer under FINRA, the
Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold,
except such states in which the Agent is exempt from registration or such registration is not otherwise required or would not
otherwise have a material impact on the sale of the Placement Shares as contemplated hereunder. The Agent shall continue, for
the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable statutes
and regulations of each state in which the Placement Shares will be offered and sold, except such states in which the Agent is
exempt from registration or such registration is not otherwise required or would not otherwise have a material impact on the sale
of the Placement Shares as contemplated hereunder, during the term of this Agreement. The Agent will comply, in all material respects,
with all applicable law and regulations in connection with the Placement Shares, including but not limited to Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Expenses</U>. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including
(i)&nbsp;the preparation and filing of the Registration Statement, including any fees required by the Commission, and the printing
or electronic delivery of the Prospectus as originally filed and of each amendment and supplement thereto, in such number as the
Agent shall deem necessary, (ii) the printing and delivery to the Agent of this Agreement and such other documents as may be required
in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii)&nbsp;the preparation, issuance
and delivery of the certificates, if any, for the Placement Shares to the Agent, including any stock or other transfer taxes and
any capital duties, stamp duties or other duties or taxes payable upon the sale, issuance or delivery of the Placement Shares
to the Agent, (iv)&nbsp;the fees and disbursements of the counsel, accountants and other advisors to the Company, (v)&nbsp;the
fees and expenses of Agent including but not limited to the fees and expenses of the counsel to the Agent, payable upon the execution
of this Agreement, in an amount not to exceed $50,000, (vi)&nbsp;the qualification or exemption of the Placement Shares under
state securities laws in accordance with the provisions of <U>Section&nbsp;7(r)</U> hereof, including filing fees, but excluding
fees of the Agent&rsquo;s counsel, (vii)&nbsp;the printing and delivery to the Agent of copies of any Permitted Issuer Free Writing
Prospectus and the Prospectus and any amendments or supplements thereto in such number as the Agent shall deem necessary, (viii)&nbsp;the
preparation, printing and delivery to the Agent of copies of the blue sky survey, (ix)&nbsp;the fees and expenses of the transfer
agent and registrar for the Common Stock, (x)&nbsp;the filing and other fees incident to any review by FINRA of the terms of the
sale of the Placement Shares including the fees of the Agent&rsquo;s counsel (subject to the cap, set forth in clause (v) above),
and (xi)&nbsp;the fees and expenses charged by the Exchange incurred in connection with the listing of the Placement Shares on
the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
to Agent&rsquo;s Obligations</U>. The obligations of the Agent hereunder with respect to a Placement will be subject to the continuing
accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company
of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to it in its reasonable judgment,
and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Statement Effective</U>. The Registration Statement shall have become effective and shall be available for the (i)&nbsp;resale
of all Placement Shares issued to the Agent and not yet sold by the Agent and (ii) sale of all Placement Shares contemplated to
be issued by any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Notices</U>. None of the following events shall have occurred and be continuing: (i)&nbsp;receipt by the Company of any
request for additional information from the Commission or any other federal or state Governmental Authority during the period
of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements
to the Registration Statement or the Prospectus which have not, as of the time of such Placement, been so made; (ii)&nbsp;the
issuance by the Commission or any other federal or state Governmental Authority of any stop order suspending the effectiveness
of the Registration Statement or the initiation of any proceedings for that purpose; (iii)&nbsp;receipt by the Company of any
notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv)&nbsp;the occurrence
of any event that makes any material statement made in the Registration Statement or the Prospectus or any material document incorporated
or deemed to be incorporated therein by reference untrue in any material respect, or that requires the making of any changes (which
have not been made) in the Registration Statement, the Prospectus or documents so that, in the case of the Registration Statement,
it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will not contain
any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Misstatement or Material Omission</U>. Agent shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&rsquo;s reasonable opinion is material,
or omits to state a fact that in the Agent&rsquo;s reasonable opinion is material and is required to be stated therein or is necessary
to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&rsquo;s reports filed with the Commission,
there shall not have been any material adverse change in the authorized capital stock of the Company or any Material Adverse Effect
or any development that could cause a Material Adverse Effect, or a downgrading in or withdrawal of the rating assigned to any
of the Company&rsquo;s securities (other than asset backed securities) by any rating organization or a public announcement by
any rating organization that it has under surveillance or review its rating of any of the Company&rsquo;s securities (other than
asset backed securities), the effect of which, in the case of any such action by a rating organization described above, in the
reasonable judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material
as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner
contemplated in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legal
Opinion</U>. The Agent shall have received the opinions of Company Counsel required to be delivered pursuant to <U>Section 7(m)
</U>on or before the date on which such delivery of such opinion is required pursuant to <U>Section 7(m)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Comfort
Letter</U>. The Agent shall have received the Comfort Letter required to be delivered pursuant to <U>Section 7(n)</U> on or before
the date on which such delivery of such Comfort Letter is required pursuant to <U>Section 7(n)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representation
Certificate</U>. The Agent shall have received the certificate required to be delivered pursuant to <U>Section 7(l)</U> on or
before the date on which delivery of such certificate is required pursuant to <U>Section 7(l)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Suspension</U>. Trading in the Common Stock shall not have been suspended on the Exchange and the Common Stock shall not have
been delisted from the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to <U>Section 7(l)</U>, the Company
shall have furnished to the Agent such appropriate further information, opinions, certificates, letters and other documents as
the Agent may reasonably request. All such opinions, certificates, letters and other documents will be in compliance with the
provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Act Filings Made</U>. All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to
the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing
by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Approval
for Listing</U>. The Placement Shares shall either have been approved for listing on the Exchange, subject only to notice of issuance,
or the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to, the issuance
of any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA</U>.
If applicable, FINRA shall have raised no objection to the terms of this offering and the amount of compensation allowable or
payable to the Agent as described in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Termination Event</U>. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant
to <U>Section 13(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Indemnification and Contribution</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Indemnification</U>. The Company agrees to indemnify and hold harmless the Agent, its affiliates and respective partners, members,
directors, officers, employees and agents and each person, if any, who controls the Agent or any affiliate within the meaning
of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment
thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make
the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included
in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement
or omission; <I>provided</I> that (subject to <U>Section&nbsp;11(d)</U> below) any such settlement is effected with the written
consent of the Company, which consent shall not unreasonably be delayed or withheld; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all expense whatsoever, as incurred (including the reasonable documented fees and disbursements of counsel), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission (whether or not a party), to the extent that any such expense is not paid under (i)&nbsp;or
(ii)&nbsp;above,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 108pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>provided</I>,
<I>however</I>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity
with written information furnished to the Company by the Agent expressly for use in the Registration Statement (or any amendment
thereto), or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agent
Indemnification</U>. Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company
who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the
indemnity contained in <U>Section 11(a)</U>, as incurred, but only with respect to untrue statements or omissions, or alleged
untrue statements or omissions, made in the Registration Statement (or any amendments thereto) in any related Issuer Free Writing
Prospectus or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating
to the Agent and furnished to the Company in writing by the Agent expressly for use therein. The Company hereby acknowledges that
the only information that the Agent has furnished to the Company expressly for use in the Registration Statement, the Prospectus
or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) are the statements set forth in the eighth and
ninth paragraphs under the caption &ldquo;Plan of Distribution&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>.
Any party that proposes to assert the right to be indemnified under this <U>Section 11</U> will, promptly after receipt of notice
of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties
under this <U>Section 11</U>, notify each such indemnifying party of the commencement of such action, enclosing a copy of all
papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any
liability that it might have to any indemnified party otherwise than under this <U>Section 11</U> and (ii)&nbsp;any liability
that it may have to any indemnified party under the foregoing provision of this <U>Section 11</U> unless, and only to the extent
that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action
is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will
be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly
after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party
similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after
notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will
not be liable to the indemnified party for any legal or other expenses except as provided below and except for the reasonable
costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will
have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be
at the expense of such indemnified party unless (1)&nbsp;the employment of counsel by the indemnified party has been authorized
in writing by the indemnifying party, (2)&nbsp;the indemnified party has reasonably concluded (based on advice of counsel) that
there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available
to the indemnifying party, (3)&nbsp;a conflict or potential conflict exists (based on advice of counsel to the indemnified party)
between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct
the defense of such action on behalf of the indemnified party) or (4)&nbsp;the indemnifying party has not in fact employed counsel
to assume the defense of such action or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable
time after receiving notice of the commencement of the action; in each of which cases the reasonable fees, disbursements and other
charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or
parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable
fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction (plus local counsel)
at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by
the indemnifying party promptly after the indemnifying party receives a written invoice relating to fees, disbursements and other
charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim
effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party,
settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating
to the matters contemplated by this <U>Section 11</U> (whether or not any indemnified party is a party thereto), unless such settlement,
compromise or consent (1)&nbsp;includes an unconditional release of each indemnified party, in form and substance reasonably satisfactory
to such indemnified party, from all liability arising out of such litigation, investigation, proceeding or claim and (2)&nbsp;does
not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement
Without Consent if Failure to Reimburse</U><I>. </I>If an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for
any settlement of the nature contemplated by <U>Section&nbsp;11(a)(ii)</U> effected without its written consent if (1)&nbsp;such
settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (2)&nbsp;such
indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being
entered into and (3)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request
prior to the date of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing
paragraphs of this <U>Section 11</U> is applicable in accordance with its terms but for any reason is held to be unavailable from
the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages
(including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement
of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons
other than the Agent, such as persons who control the Company within the meaning of the Securities Act, officers of the Company
who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company
and the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company
on the one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on
the other hand shall be deemed to be in the same proportion as the total net proceeds from the sale of the Placement Shares (before
deducting expenses) received by the Company bear to the total compensation received by the Agent (before deducting expenses) from
the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not
permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not
only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand,
and the Agent, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense
or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering.
Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of
a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the
Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such
statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions pursuant to this
<U>Section 11(e)</U> were to be determined by pro rata allocation or by any other method of allocation that does not take into
account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the
loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this <U>Section 11(e)</U> shall
be deemed to include, for the purpose of this <U>Section 11(e)</U>, any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim to the extent consistent with <U>Section 11(c)</U>
hereof. Notwithstanding the foregoing provisions of this <U>Section 11(e)</U>, the Agent shall not be required to contribute any
amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation
(within the meaning of <U>Section 11(f)</U> of the Securities Act) will be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. For purposes of this <U>Section 11(e)</U>, any person who controls a party to this
Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or agents of the Agent, will
have the same rights to contribution as that party, and each director of the Company and each officer of the Company who signed
the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof.
Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect
of which a claim for contribution may be made under this <U>Section 11(e)</U>, will notify any such party or parties from whom
contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be
sought from any other obligation it or they may have under this <U>Section 11(e)</U> except to the extent that the failure to
so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought.
Except for a settlement entered into pursuant to the last sentence of <U>Section 11(c)</U> hereof, no party will be liable for
contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to <U>Section
11(c)</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in <U>Section 11</U> of this Agreement
and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of
their respective dates, regardless of (i)&nbsp;any investigation made by or on behalf of the Agent, any controlling persons, or
the Company (or any of their respective officers, directors or controlling persons), (ii)&nbsp;delivery and acceptance of the
Placement Shares and payment therefor or (iii)&nbsp;any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Termination</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Agent may terminate this Agreement, by notice to the Company, as hereinafter specified at any time (1)&nbsp;if there has been,
since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any change,
or any development or event involving a prospective change, in the condition, financial or otherwise, or in the business, properties,
earnings, results of operations or prospects of the Company and its Subsidiaries considered as one enterprise, whether or not
arising in the ordinary course of business, which individually or in the aggregate, in the sole judgment of the Agent is material
and adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the
Placement Shares, (2)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or
the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change
or development involving a prospective change in national or international political, financial or economic conditions, in each
case the effect of which is such as to make it, in the judgment of the Agent, impracticable or inadvisable to market the Placement
Shares or to enforce contracts for the sale of the Placement Shares, (3)&nbsp;if trading in the Common Stock has been suspended
or limited by the Commission or the Exchange, or if trading generally on the Exchange has been suspended or limited, or minimum
prices for trading have been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company on any exchange
or in the over-the-counter market shall have occurred and be continuing, (5) if a major disruption of securities settlements or
clearance services in the United States shall have occurred and be continuing, or (6)&nbsp;if a banking moratorium has been declared
by either U.S. Federal or New York authorities. Any such termination shall be without liability of any party to any other party
except that the provisions of <U>Section 9</U> (Payment of Expenses), <U>Section 11</U> (Indemnification and Contribution), <U>Section
12</U> (Representations and Agreements to Survive Delivery), <U>Section 18</U> (Governing Law and Time; Waiver of Jury Trial)
and <U>Section 19</U> (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination.
If the Agent elects to terminate this Agreement as provided in this <U>Section 13(a)</U>, the Agent shall provide the required
notice as specified in <U>Section 14</U> (Notices).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole
discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other
party except that the provisions of <U>Section 9</U>, <U>Section 11</U>, <U>Section 12</U>, <U>Section 18</U> and <U>Section 19
</U>hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Agent shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion
at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party
except that the provisions of <U>Section 9</U>, <U>Section 11</U>, <U>Section 12</U>, <U>Section 18</U> and <U>Section 19</U>
hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall remain in full force and effect unless terminated pursuant to <U>Sections 13(a)</U>, <U>(b)</U>, or <U>(c)</U>
above or otherwise by mutual agreement of the parties; <I>provided</I>, <I>however</I>, that any such termination by mutual agreement
shall in all cases be deemed to provide that <U>Section 9</U>, <U>Section 11</U>, <U>Section 12</U>, <U>Section 18</U> and <U>Section
19</U> shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided</I>, <I>however</I>,
that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or
the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares,
such Placement Shares shall settle in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of
this Agreement shall be in writing, unless otherwise specified, and if sent to the Agent, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cantor
Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">499
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">New
York, NY 10022</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.8in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attention:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Capital Markets/Jeffrey Lumby</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Facsimile:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(212) 307-3730</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">with
copies to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cantor
Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">499
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">New
York, NY 10022</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.8in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attention:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">General Counsel</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Facsimile:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(212) 829-4708</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">and
with a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0pt">  <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cooley LLP</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1114
Avenue of the Americas</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">New
York, NY 10036</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.8in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attention:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Daniel I. Goldberg, Esq.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Facsimile:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(212) 479-6275</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">and
if to the Company, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">757
Third Avenue, Suite 2018</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">New York, NY 10017</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.8in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attention:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sergio Traversa</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Facsimile:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">888-228-5672</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Barclay
Damon, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">One
Park Place</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Syracuse,
NY 13202</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.8in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attention:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Thomas Slusarczyk, Esq.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Facsimile:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">315-624-7359</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new
address for such purpose. Each such notice or other communication shall be deemed given (i)&nbsp;when delivered personally or
by verifiable facsimile transmission (with an original to follow) on or before 4:30&nbsp;p.m., New York City time, on a Business
Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii)&nbsp;on the next Business Day after timely
delivery to a nationally-recognized overnight courier and (iii)&nbsp;on the Business Day actually received if deposited in the
U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &ldquo;<B><U>Business
Day</U></B>&rdquo; shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An
electronic communication (&ldquo;<B><U>Electronic Notice</U></B>&rdquo;) shall be deemed written notice for purposes of this Section
14 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed
received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving
Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<B><U>Nonelectronic
Notic</U>e</B>&rdquo;) which shall be sent to the requesting party within ten (10) days of receipt of the written request for
Nonelectronic Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective
successors and the parties referred to in Section 10 hereof. References to any of the parties contained in this Agreement shall
be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party
may assign its rights or obligations under this Agreement without the prior written consent of the other party; <I>provided</I>,
<I>however</I>, that the Agent may assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments
for Stock Splits</U>. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted
to take into account any stock split, stock dividend or similar event effected with respect to the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement; Amendment; Severability; Waiver</U>. This Agreement (including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements
and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement
nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event
that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal
or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to
the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall
be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that
giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of
the parties as reflected in this Agreement. No implied waiver by a party shall arise in the absence of a waiver in writing signed
by such party. No failure or delay in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power,
or privilege hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>GOVERNING
LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY
HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>CONSENT
TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION
CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT
IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT
FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE
OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR
REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES
THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE
DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile
or electronic transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The section and exhibit&nbsp;headings herein are for convenience only and shall not affect the construction hereof. References
herein to any law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority shall be deemed
to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority as amended,
reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations
promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted
Free Writing Prospectuses</U>. The Company represents, warrants and agrees that, unless it obtains the prior written consent of
the Agent, which consent shall not be unreasonably withheld, conditioned or delayed, and the Agent represents, warrants and agrees
that, unless it obtains the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned
or delayed, it has not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free
Writing Prospectus, or that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule&nbsp;405, required
to be filed with the Commission. Any such free writing prospectus consented to by the Agent or by the Company, as the case may
be, is hereinafter referred to as a &ldquo;Permitted Free Writing Prospectus.&rdquo; The Company represents and warrants that
it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo;
as defined in Rule&nbsp;433, and has complied and will comply with the requirements of Rule&nbsp;433 applicable to any Permitted
Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping. For the purposes
of clarity, the parties hereto agree that all free writing prospectuses, if any, listed in <U>Exhibit&nbsp;22</U> hereto are Permitted
Free Writing Prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence
of Fiduciary Relationship</U>. The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between
the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party,
on the one hand, and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated
by this Agreement, irrespective of whether or not the Agent has advised or is advising the Company on other matters, and the Agent
has no obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly
set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neither
the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated
by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and the Agent and its affiliates have no obligation to disclose such interests and transactions to the
Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of fiduciary
duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that
the Agent and its affiliates shall not have any liability (whether direct or indirect, in contract, tort or otherwise) to it in
respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the
Company, employees or creditors of Company, other than in respect of the Agent&rsquo;s obligations under this Agreement and to
keep information provided by the Company to the Agent and the Agent's counsel confidential to the extent not otherwise publicly-available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
As used in this Agreement, the following terms have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B><U>Applicable
Time</U></B>&rdquo; means (i) each Representation Date and (ii) the time of each sale of any Placement Shares pursuant to this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B><U>Governmental
Authority</U></B>&rdquo; means (i) any federal, provincial, state, local, municipal, national or international government or governmental
authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality,
court, tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political
subdivision of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B><U>Issuer
Free Writing Prospectus</U></B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433, relating
to the Placement Shares that (1)&nbsp;is required to be filed with the Commission by the Company, (2)&nbsp;is a &ldquo;road show&rdquo;
that is a &ldquo;written communication&rdquo; within the meaning of Rule&nbsp;433(d)(8)(i) whether or not required to be filed
with the Commission, or (3)&nbsp;is exempt from filing pursuant to Rule&nbsp;433(d)(5)(i) because it contains a description of
the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be
filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule
433(g) under the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B><U>Rule
164</U></B>,&rdquo; &ldquo;<B><U>Rule 172</U></B>,&rdquo; &ldquo;<B><U>Rule 405</U></B>,&rdquo; &ldquo;<B><U>Rule 415</U></B>,&rdquo;
&ldquo;<B><U>Rule 424</U></B>,&rdquo; &ldquo;<B><U>Rule&nbsp;424(b)</U></B>,&rdquo; &ldquo;<B><U>Rule&nbsp;430B</U></B>,&rdquo;
and &ldquo;<B><U>Rule&nbsp;433</U></B>&rdquo; refer to such rules under the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
references in this Agreement to financial statements and schedules and other information that is &ldquo;contained,&rdquo; &ldquo;included&rdquo;
or &ldquo;stated&rdquo; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information that is incorporated by reference in the
Registration Statement or the Prospectus, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing
shall be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer
Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule&nbsp;433, are not required to
be filed with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all
references in this Agreement to &ldquo;supplements&rdquo; to the Prospectus shall include, without limitation, any supplements,
&ldquo;wrappers&rdquo; or similar materials prepared in connection with any offering, sale or private placement of any Placement
Shares by the Agent outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[<B><I>Signature
Page Follows</I></B>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 225pt; text-align: left; text-indent: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very
    truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RELMADA
                                         THERAPEUTICS, INC.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Sergio Traversa</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:&nbsp;Sergio
    Traversa</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:&nbsp;Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ACCEPTED
    as of the date first-above written:</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CANTOR
    FITZGERALD &amp; CO.</FONT></TD></TR>

<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Jeffrey Lumby</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:&nbsp;Jeffrey
    Lumby</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:&nbsp;Senior
    Managing Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SCHEDULE
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;__________________________</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Form
of Placement Notice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">__________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.8in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada Therapeutics, Inc.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.8in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To:</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cantor
                                         Fitzgerald &amp; Co.<BR>
                                         Attention: [&#9679;]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subject:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Placement Notice</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[&#9679;], 2015</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms and subject to the conditions contained in the Sales Agreement between Relmada Therapeutics, Inc., a Nevada corporation
(the &ldquo;<B><U>Company</U></B>&rdquo;), and Cantor Fitzgerald &amp; Co. (&ldquo;<B><U>Agent</U></B>&rdquo;), dated October
2, 2015, the Company hereby requests that the Agent sell up to [&#9679;] of the Company&rsquo;s common stock, par value $0.001
per share, at a minimum market price of $[&#9679;] per share, during the time period beginning [month, day, time] and ending [month,
day, time].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SCHEDULE
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;__________________________</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">__________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to 3.0%
of the aggregate gross proceeds from each sale of Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SCHEDULE
3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;__________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Notice
Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">__________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>The
Company</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sergio
Traversa (straversa@relmada.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Douglas
Beck (dbeck@relmada.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>The
Agent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeff
Lumby (jlumby@cantor.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Josh
Feldman (jfeldman@cantor.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sameer
Vasudev (svasudev@cantor.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With
copies to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CFControlledEquityOffering@cantor.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SCHEDULE
4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;__________________________</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">__________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated
by reference to Exhibit 21.1 of the Company&rsquo;s most recently filed Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Exhibit
22</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Permitted
Free Writing Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None.</FONT></P>



<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>fs32015ex4i_relmadatherape.htm
<DESCRIPTION>FORM OF COMMON STOCK CERTIFICATE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="ex4i_1.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="ex4i_2.jpg" ALT=""></P>

<P STYLE="margin: 0; border-bottom: Black 1.5pt solid"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>fs32015ex5i_relmadathera.htm
<DESCRIPTION>OPINION OF FENNEMORE CRAIG, P.C.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: small-caps 18pt Times New Roman, Times, Serif"><B>Fennemore
Craig, P.C.</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">300 E. Second Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Suite 1510</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Reno, Nevada 89501</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(775) 788-2200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; text-align: center; font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 20%; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: left"><B>Law Offices</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Denver&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;(303)&nbsp;291-3200</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Las&nbsp;Vegas&#9;&nbsp;(702)&nbsp;692-8000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Nogales&#9;&nbsp;&nbsp;&nbsp;&nbsp;(520) 281-3480</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Phoenix&#9;&nbsp;&nbsp;&nbsp;&nbsp;(602) 916-5000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Reno&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(775) 788-2200</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Tucson&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(520) 879-6800</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">October 2, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Relmada Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">757 Third Avenue, Suite
2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">New York, New York 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have acted as special
counsel to Relmada Therapeutics, Inc., a Nevada corporation (the &ldquo;Company&rdquo;) in connection with the preparation of
a registration statement on Form S-3 (the &ldquo;Registration Statement&rdquo;), filed with the Securities and Exchange Commission
(the &ldquo;Commission&rdquo;) relating to the offering from time to time, pursuant to Rule 415 of the General Rules and Regulations
of the Commission promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), by the Company
of the following securities of the Company with an aggregate offering price of up to $200,000,000: (i) shares of the Company&rsquo;s
common stock, par value $0.001 per share, in one or more series (the &ldquo;Common Stock&rdquo;); (ii) shares of the Company&rsquo;s
preferred stock, par value $0.001 per share, in one or more series (the &ldquo;Preferred Stock&rdquo;); (iii) senior and subordinated
debt securities, in one or more series (the &ldquo;Debt Securities&rdquo;); (iv) warrants for the purchase of Common Stock, Preferred
Stock, or Debt Securities (the &ldquo;Warrants&rdquo;); (v) rights to purchase shares of Common Stock or Preferred Stock (the
&ldquo;Rights&rdquo;); (vi) purchase contracts relating to the sale of securities by the Company under the prospectus included
in the Registration Statement (the &ldquo;Purchase Contracts&rdquo;); and (vii) units comprised of one or more of the securities
offered under the prospectus included in the Registration Statement (the &ldquo;Units&rdquo;), which Registration Statement includes
a sales agreement prospectus (the &ldquo;Sales Agreement Prospectus&rdquo;) covering the issuance of up to $75,000,000 worth of
shares (the &ldquo;Placement Shares&rdquo;) of Common Stock. The Common Stock, the Preferred Stock, the Debt Securities, the Warrants,
the Rights, the Purchase Contracts, and the Units are collectively referred to as the &ldquo;Securities.&rdquo; The offering of
the Securities will be as set forth in the base prospectus contained in the Registration Statement (the &ldquo;Prospectus&rdquo;),
as supplemented by one or more supplements to the Prospectus (each supplement, a &ldquo;Prospectus Supplement&rdquo;), including
the Sales Agreement Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: red"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 16pt; font-variant: small-caps"><B>Fennemore
Craig</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 16pt; font-variant: small-caps"><B></B></FONT>Relmada, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">October 2, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the purpose of rendering
this opinion, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true copies,
of such records, documents, instruments and certificates as, in our judgment, are necessary or appropriate to enable us to render
the opinions set forth below, including, but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">A.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">Registration
                                         Statement, including the Prospectus contained therein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">B.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">The
                                         Articles of Incorporation and Bylaws of the Company, each as amended to date (collectively,
                                         the &ldquo;Governing Documents&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">C.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">Such
                                         corporate records and proceedings, minutes, consents, actions and resolutions of the
                                         board of directors as we have deemed necessary as a basis for the opinions expressed
                                         below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In our capacity as such
counsel, we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the issuance and
sale of the Securities, all as referenced in the Registration Statement. We have made such legal and factual examinations and
inquiries as we have deemed necessary or appropriate for the purposes of this opinion. We have also obtained from officers and
agents of the Company and from public officials, and have relied upon, such certificates, representations and assurances as we
have deemed necessary and appropriate for the purpose of rendering this opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Without limiting the generality
of the foregoing, in our examination, we have, with your permission, assumed without independent verification, that (i) all documents
submitted to us as originals are authentic, the signatures on all documents that we examined are genuine, and all documents submitted
to us as certified, conformed, photostatic, electronic or facsimile copies conform to the original document; (ii) all corporate
records made available to us by the Company and all public records we have reviewed are accurate and complete; and (iii) at the
time the shares of Common Stock and Preferred Stock being registered under the Registration Statement are issued, there will be
sufficient authorized but unissued Common Stock and Preferred Stock, as the case may be, available to allow for such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nothing herein shall be
deemed an opinion as to the laws of any jurisdiction other than the state of Nevada. We express no opinion concerning any securities
law or rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on the foregoing,
and in reliance thereon, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">1.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">When
                                         and to the extent (a) the board of directors of the Company or an authorized and duly
                                         formed committee thereof (collectively, the &ldquo;Board of Directors&rdquo;) has taken
                                         all necessary corporate action to authorize and approve the issuance and sale of any
                                         shares of Common Stock and Preferred Stock, as applicable, including, without limitation,
                                         shares of Common Stock and Preferred Stock issuable upon the due and proper conversion
                                         of any validly issued Preferred Stock or Debt Securities that constitute binding obligations
                                         of the Company, or in connection with the exercise of validly issued Warrants, Rights,
                                         or Purchase Contracts that constitute binding obligations of the Company, including without
                                         limitation any such securities that are included as part of a Unit (collectively, the
                                         &ldquo;Offered Stock&rdquo;), (b) those certain stock certificates of the Company representing
                                         the shares of Offered Stock are in a form approved by the Board of Directors and otherwise
                                         compliant with law and have been manually signed by an authorized officer of the Company
                                         or authorized transfer agent and registrar for the Offered Common Stock, and have been
                                         duly registered by such authorized transfer agent and registrar, and thereafter have
                                         been delivered to the subscribers for or purchasers of such Offered Stock, and (c) the
                                         Company has received payment in full, including, without limitation, by exchange or by
                                         payment of all conversion or exercise prices or pursuant to any deferred payment arrangements,
                                         of such consideration per share of Offered Stock as has been prescribed by the Board
                                         of Directors, such shares of Offered Stock will be duly authorized, validly issued, fully
                                         paid and non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 16pt; font-variant: small-caps"><B>Fennemore
Craig</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 16pt; font-variant: small-caps"><B></B></FONT>Relmada, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">October 2, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Page 3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">2.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">Assuming
                                         (i) any Indentures (including any Debt Securities issued thereunder), Warrants, Rights,
                                         Purchase Contracts, and Units to be entered into by and between the Company and any purchasers
                                         or subscribers has been duly authorized by the Company&rsquo;s board of directors (the
                                         &ldquo;Board of Directors&rdquo;); (ii) any Indenture (including any Debt Security issued
                                         thereunder), Warrant, Right, Purchase Contract, or Unit has been duly executed and delivered
                                         by the parties thereto to the extent due execution and delivery are prerequisites to
                                         the effectiveness thereof; (iii) the obligations of each party set forth in any Indenture
                                         (including any Debt Security issued thereunder), Warrant, Right, Purchase Contract, or
                                         Unit is such party&rsquo;s valid and binding obligations, enforceable in accordance with
                                         their respective terms; (iv) the Debt Securities are issued in accordance with the terms
                                         of the relevant Indenture:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">a.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">The
                                         Debt Securities will be validly issued and will constitute binding obligations of the
                                         Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">b.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">The
                                         Warrants will be validly issued and will constitute binding obligations of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">c.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">The
                                         Units (including Securities underlying the Units) will be validly issued and will constitute
                                         binding obligations of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">d.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">The
                                         Rights will be validly issued and will constitute binding obligations of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">e.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">The
                                         Purchase Contracts will be validly issued and will constitute binding obligations of
                                         the Company; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">3.</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">With
                                         respect to the Placement Shares, when issued and delivered by the Company against payment
                                         therefor in accordance with the Sales Agreement attached as an exhibit to the Registration
                                         Statement, and with due authorization of the Board of Directors or a duly authorized
                                         officer of the Company, and as contemplated in the Registration Statement (including
                                         the Sales Agreement Prospectus), the Placement Shares will be duly authorized, validly
                                         issued, fully paid and nonassessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 16pt; font-variant: small-caps"><B>Fennemore
Craig</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 16pt; font-variant: small-caps"><B></B></FONT>Relmada, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">October 2, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This opinion is issued
in the State of Nevada. By issuing this opinion, Fennemore Craig, P.C. (i) shall not be deemed to be transacting business in any
other state or jurisdiction other than the State of Nevada and (ii) does not consent to the jurisdiction of any state other than
the State of Nevada. Any claim or cause of action arising out of the opinions expressed herein must be brought in the State of
Nevada. Your acceptance of this opinion shall constitute your agreement to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consent to your filing
this opinion as an exhibit to the Registration Statement and to the reference to our firm contained under the heading &ldquo;Legal
Matters.&rdquo; We further consent to the incorporation by reference of this opinion and consent in any registration statement
filed pursuant to Rule 462(b) under the Act with respect to the Securities. In giving these consents, we do not thereby admit
that we are within the category of persons whose consent is required under Section 7 of the Act, the rules and regulations of
the Commission promulgated thereunder, or Item 509 of Regulation S-K. This opinion letter is rendered as of the date first written
above and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought
to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters
set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company
or the Securities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 40%; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">Very truly yours,</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">/s/ FENNEMORE CRAIG, P.C.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0">FENNEMORE CRAIG, P.C.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.25in; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.25in; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.25in; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.25in; text-align: justify"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.25in; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>fs32015ex12i_relmadatherape.htm
<DESCRIPTION>STATEMENT REGARDING THE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
12.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RATIO
OF EARNINGS TO FIXED CHARGES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth our ratio of fixed charges and preference dividends to earnings for each of the periods indicated.
You should read this table in conjunction with the financial statements and notes incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Year Ended June 30,</B><BR> <B>2015</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Six Months Ended June 30,</B><BR> <B>2014</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Year Ended December&nbsp;31,</B><BR> <B>2013</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Ratios of fixed charges and preference dividends to earnings</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 24.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have computed the ratio of fixed charges and preference dividends to earnings set forth above by dividing pre-tax loss before
fixed charges and preference dividends by fixed charges and preference dividends. Fixed charges are the sum of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.3in; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">interest
    expensed and capitalized; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.3in; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">amortized
    premiums related to indebtedness; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.3in; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
    estimate of the interest within rental expense. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
Therapeutics, Inc. (&ldquo;Relmada or the Company&rdquo;) has not pay any cash dividends on any shares of our capital stock during
the periods set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada
has not recorded earnings for the fiscal years ended June 30, 2015, for the six months ended June 30, and for the year ended December&nbsp;31,
2014. Accordingly, the Company was insufficient to cover fixed charges for such periods and we are unable to disclose a ratio
of fixed charges and preference dividends to earnings for such periods. The Company had a deficiency in earnings available for fixed charges and preference dividends for the for the fiscal year ended June 30, 2015, for the six months ended June 30, December 31, 2014 and for the fiscal year ended December 31, 2013 was approximately $20.8 million and $19.9 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>fs32015ex23i_relmadatherape.htm
<DESCRIPTION>CONSENT OF GBH CPAS, PC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B>&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">We hereby consent to the incorporation by reference in this Registration
Statement of Relmada Therapeutics, Inc. on Form S-3 of our report dated September 11, 2015 relating to the consolidated financial
statements of Relmada Therapeutics, Inc. as of June 30, 2015 and 2014 and for the year ended June 30, 2015, for the six months
ended June 30, 2014, and for the year ended December 31, 2013. We also consent to the reference to our firm under the headings
"Experts" appearing therein.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">/s/ GBH CPAs, PC</P>

<P STYLE="margin: 0">GBH CPAs, PC</P>

<P STYLE="margin: 0">www.gbhcpas.com</P>

<P STYLE="margin: 0">Houston, Texas</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">October 2, 2015</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #/ 58# 2(  A$! Q$!_\0
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M%%% !2$X!(!) ) &,G'89(&3T&2!ZD#FD=MB.X4L55FVKC<VT$[1D@9.,#)
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M3F?TK$@=>]%>(_ _]H#X8_M'_#WP_P#%;X-^*-(\:^ O$8B&FZYI=Z&\NZ7
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M+]8DYSJ1DH."C"JU.,59Q6IZQ152WOK6[ACGM;B"XBF56BDBE61'WCY<%-Q
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M-A[052>'K8''8ZMAVX<ZA%Y?0Q$I12^-PIS]Y7C%H_BK%_3VX,I9_P#V9E7
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M&#,I7C",41AWWQ ^268G)=8U;/0@<4 ?)#?L-_LXPZ(MA:^"S:ZW%;7$3?$
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M^M[QMUNMG9Z!1115%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:)OT"M"8U6"*!8(;=K.UMXH1''%;0D)&%MXUC"QQPQHJ+$H$)50-@7*UNJC
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M\<_!2IG'$D^-\I5+&4L=!4,]R^4J=*=5J:]GB8NM.G&;AAKTI02D]%ROH_Q
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MU.Z0P(&VJ[RNJ+G)/'/ O\9?A-"Q67XE_#U"-O#^,_#2,=W3B35%(ZC&>3G
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M/!*ZP^)K4J>'Q;TPU6M)-%USA6/HI/Y U2E;8WG$D*$+R<%L*H);"J"QXS@
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M)GK.YFC;;][=L)]FX^GKS^=(^Y8V5<,R(6PS,BLP'RJSA7*@D@%@CD9R%8@
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M7ZZ1H?C/PKK.JE))18:5XAT74;ORX>)IA;6=[/.883_K9!'^[P01D '\8?\
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M?#WXA^!_&_BW6?%'CG_A,[6]\*W7A_[!!93Z!INCP0WDFHZE:JLF;2*4F26
M#[3Y6#Y?F/\ T3_\%(D\[]A+]IR,,5W?";6QY@"G:=EH,CS&1"!U)9@HYW<
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MPM6G0Q^&QU6M9XG$4\7*"6(IN5*K3;<)R3]WYCZ,%+$4<R\;Z&?8J.9\;?\
M$2W/B7.\/%TL#GE6KA8XS+,5@<+RWP%&&74ZL)8:<N>,^6,_>C'F^2OV\N?V
M-/VH#N*?\6,^(QWJ,E0/#^J?,!E<D=0"1D]QUK^9K_@FG_P4A^'/[$G@3XD>
M%OB)X&\<^+M3^(?BS0_%>D7GAF3P\MI;P6GA>'2KNQOI+_5;58)(XK'[:LCO
M")"XAV*%,[?TS_M[QB+]BW]J1I'(4_ KXD)D  X;PYJ; J22H.& &>,\GTK\
M6/\ @AOI/P9U7X4_&_\ X6?H7PUO[R;XEZ++I,_CVS\&7=_;6/\ PC"R^78'
M5H6N(X#<"9&,;1DMA@,!@OI^'E7):'@QQ[5SK+<]SG#OBGA>+RO)\WCEZQ$*
M."5>K.K0^HXRI6G2C>:J1<$J:=.SDDSQ/&3#9[B/I!>&,>&,\RGA7/O^(<<6
MX7#\29SD6#SK#8&I5Q4L''#-8O,<&H.MB:BBG&G5A%R]MSV<HGL"_P#!P3^S
MA"9(3\&_C"SM(PRVH_#Y@DAP,HX\2X"Y')+$8XW#&:>W_!P7^SF@4-\&?BWO
M(PK_ &WX?2$9QR?+\3.2,\_=)] 3C/ZUGP?^R?M8GPU^SRN-Y1/[%^';DY&5
M&]+?<,8QEL@D],9ILG@[]E!E5(_"O[/#[X]K[M)^'1^9L@@1R6KHQZ#:T;*P
MX*D$@_(5\?X78FG7J8/PHXQHUJU?%U,+B,SSO$XI4J+=-4O9<N487DH^ZW*,
M^:4YKFER[2^Z64>.T,9AE7\??#?$0P]3#RS&A_J-D-+ZW",**FW5GQ)&%.:4
M:D%&4Z<I<RJ0BHZ+V#PQXAB\5Z-H'B*WA>&VUK3=*U>&WN[5$N;>'4K>&[AB
M>:U>>TDEC64*S0W$D6X;D=U(W=V_1O\ >;_T,UQ^A:KX;U6-(O#.L:-J5GI\
ML-FT/A[4K*ZL],"0K]GLI[>QN)(;8.@Q;Q)#$%C" *%&\]7+(0&"KN)#M]['
M(;..A.<<].E?D-:=#ZU6='#3PE)5J<%2GK--U:SC%Q48R3C"<(MN$>:SG9*]
MOZ$PJJU,'1=3%X+,*U6DHSQF P-# 8;$590ITN>/U?%XRC5C.I&?+-5VJ<&H
M/3WG_*#\4$Q_P7Q\)C/7XR_#.3I_U3/1CCK[]?TK^LVOY*/B]J-CIW_!>?PS
M?W]W:V=G:_%KX:7%U=W=U;65M9P#X9Z.C27<VH36BQ*) $ 7S&<'**3\M?U-
M?\+1^'7_ $/7@S_PJ=$_^3*_=_&&AB,5EOA)6P^&Q5:E#PQRK!2G3PN*FEB<
M%C:]/$T[PP]3^'.O22G=0J*?-3<XJ4E_,_T=L?E^'S;QZ6(S# 8:4_&;.IPC
MB,=@\/*<8X"%-SA'$8JA*4>>G./-&,HMQTEJK][17 /\4OAX$8KXY\&.P5BJ
M?\)5HHW, 2%RMVQY.!PK'GA2>#HZ+XV\.^(FFCT+6=#UJXMFA%W;Z1K-EJ,E
MFMQ'(T#7:P,7@\YHI$A5D)EV,R9"N%_$*N#QE"C+$5<'C*=&#493E@\7%1;5
MU?FPT-+;N]EU/Z8AFV4U*D:-+-LJK5Y*\,/1S++ZV)J*]FZ>'HXRM7J13=G*
M%*23T;3.JE4/%(C<*\;J3[,I!_0U_);_ ,%GD3_AX5\!#L$BP_#_ .$),3#>
M) OQ=\3!D*Y&_>K$;,C=G;D'D?UF/)*\9"H S J2'W"/=P&.%^;;]['!('49
MX_DU_P""SD,;?\%!/@3(TYWQ^"_@_'Y0:&*25_\ A;7B/"HTDX9-S$!76*0Y
M&521AM/[3]'B:7B!B*UKJAP7QCB,/VGB_P"QL12HP:>D6N?G3GRI.*;L['\X
M?2XYO^(59;*%6-"J_$3@%8:M*$I2PN)JY_AJ=+$RIQC*HX*[ISBH-\K;:Y;L
M^S_^"Q/["C_$_P (M^U5\*=%FD^(_@#0HX?B%I&B1M!?>,? .CF75$UV%[7R
MW?Q?X/A>^O+#4A;S7<T=OIUBFQ-.21_9/^"37[>D'[2WPNM_A=\1=3LW^.WP
MQTG3K6\NIG^RS>/O!\4)BTOQ9IT$AR][IZ1?8?$&G1O<R6J_8-6ENG.J-;0_
MK?=VL]U97%NC1_Z3;LDMM)#BVFMC+);M:F*21E6*:)V%P6+K+%\K*.M?R7_M
MZ_L[>//^";7[4?@_]J[]GN"?2?AUXA\13:SI42.[Z-X5\97B/)XN^'6KR>>L
M"^&?&5G)/!HXG-O;-(MII2J)-,-W<=G 57*_$?AO%^%'$DZ4.(,JPV(SG@CB
M+%S]D\974<177#E3$5)1IJ+K15*A"56G)TK2I0_<1YO'\2,LQO@WQ_2\:^%,
M%B*W#^;5,'DGB[D670=>CG/+'"4:.?83!8>$Y8!93-_7,?C9T*5&NJ3C*K*5
M50?]5WQ#^(W@[X4> ?%7Q#\>:NFA^$?!VB:QK?B#5KH@0VEEIHVS1JA93+<W
M<C+%IL$>Y[Z5TCCQ(Z*?Y./#UA\4?^"Q?[<.H:GK:WVA?!'PI &OHK8W4MOX
M&^%4>J/#8>'K.XDEMHH_&7C]+6[>_NH41K:^@ENELY+73+.*_P!/]N#]O3QG
M_P %&->^#'[,W[/'AC6;'2?%\OA^X\2^&KB:07WBWXCK);-+8W%U:6@0^!/
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MX@\:0CD/#669-.G5QM%9C[65?,X48N53FAA*M2C1K)*$*U2$'4IU8.WZG?\
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M_P#4>U&OYJ_^#>O_ )'C]IC_ +$GX5_^GGQU7])_Q3D/_"L?B0 A)'@/Q>%
M#,S.?#^H!55$1G8DG "JS$X 4D@'^8W_ ((!^*] \.^-?VE'\0:OI.AI<>%_
MA?86K:SJ=II"W4T&J>.)+C[/_:KV33?9S+;K*L2O@S*,[]D<G3P,G+P>\7\-
M!.>(Q=7AS#X:A3C.K5K5HSABI1A3I4ZLK*A2J5')J,4HVYG)I'+XK5Z-'Z0O
MT=L36J0I8;#QXWC7KU90I4:3Q>%C@L.I5*M6E%>UQ*=)--I?%)Q@U)_U//\
M?'^Y'_Z4K3Y,E, X;,9#8W8S(1D@]<''4\YKAF^)7P\)1AX[\&[AY8=3XHT7
M"@2K(6#"\(; &-JC.?P!<WQ+^'RDE/'7@J08.-_BO18E!#;QN+79*KG@G:<
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MO#^DV.BW-AIITO2[#1K62TDOXGD:)K>TS+;NICE29H),H"S^$_\ $/+\$?\
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ML*$W]8A*2E&+@^56*_DHZK(ZLQ/EOAAB:,A@5<LG)"X!'RD8XVXI^>!M<?\
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M&*X,S=Y9AZ.,P6.AC)8>ID.6YO&<L"Z-/&+]YBII4_9QG4M[D9/0Z^7]O_\
M8MB+JW[3?P6BEB$;.C?$#PVI+/AHQ@7IRC @AE)&T_,0N37T1X"^)W@#XJ^%
M;/QW\-O%WA[QYX5O&EBM/$'A#5K;Q!I-Y/ 0CQ6][I;74+M&Y"W'S#R2<L""
M0/R^^'WBW]H#3? /@VYM?^";OP^U2RB\)^'[B'7A\=?A()KVU30[=K?4,2>#
M9IX;BX55N7B'VF6V+@+-<?*[?II\/&-OX'\."]\&Z5X#O+C0],U"_P#!&E3:
M5=:?X<U+4+1;C6M-L[G28+.QO$TB]NI;.XUBW2&*\V27RVEKY_V>N;/N'\LR
MJ,J>&P<H*IB/95YQS/+,;S58OD=U@:DG2DHWBX5&YQ::DERRMGP)Q3GO$<8U
MLPFL/4EE<L='"UN&L^X>4:-7,'E]&5)9Y1H?7H_76J/M<'SP@FG-*$U,\]^(
M_P"UO^S9\)O$=QX/^)_QM^%O@3Q5;V-OJIT#Q5XVT70M573[G?\ 9+J:SO[B
M*XB2Z:&86ZB-C.(\Q[MV!@>'/VV_V2O&&NZ=X9\-?M'?!O5=>UB6*'1](MO'
M_AJ2]U.>XGCM+>VMH&OE>6ZN;R6.TM;2'SKFZFDCC@CDD<1U^;_BW4?B#IO_
M  4L_:5?X??L\:'^T'=S_ K]GT:GI.L^,?"W@Q/#EK!>>.)AJ%M/XJT75;:_
M.MEI;1K2![;;_9".US,+C9!YW^W+JGQ9U[X%)I'C_P#8D\'_ +/'A?6/B5\)
M[?6OC5HOQ&\&>/;SX:+>_%;PO;V^MV7A;PGX?\/^)+V^^TO;VHOK?4+:RMWN
M?[0D%Q$HLY/=I\$9+6P^7QJ46JN)P5'$QQ#S?)J<L.Z\)U(QA@*M:.8U%^[Y
MWR1;G=\B;4K?&XGQ5SJB\\JX>KA94L@SK&Y-BL-C>&^)*JK5L#BJ6'Q+HX_#
M8&6#]G2JUJ=%U%4G3E*2J4Y3IKG7] :3*^QU$,HSD-$'9L*N]B$5 Q*D84!6
M9V*A5RP X#XA_&7X:_"BTT:^^)_C7POX$L/$&MV/AG1KSQ/K5OI$6H^(=3.=
M/T>T:]6!9KNYC!*KD!92L))9@PZ*V>"PTZ!9[A+>*"T\VZD=Y!_H]LEFT\\\
MZ!39+ "PE:0H=CF9I(T&1_.GXV_:%_9%_;&_: ^+7B;]I'XBV=I\$_ VB>(_
M@S^SSX/F\,>,]?M/$+:M:3Z/\4?CQ!J?A_PYX@TB.\NM3>*Q^%>IQW[ZG;6&
MFW6MVCPWT=O!7B9#PZ\]Q&:T:T<8LHRB-)XC&4,-7JU81JVA1A",5^]G4FT^
M:FY1A2C*56VCE]IQ9QO'AK \.VED]#B/B9RC@,MK8NCE^%KRAA7CJLZ^,QKH
MX?#*.'C.-*>*J48UJ[CA*,YXF7L3^DLZ@IMV:.-I<[A&5.1C='$KR-L*Q@/*
MDCD[E6U$DX+>68SY?\2?C?\ "SX-Z59:U\6?'/A7X?Z/J&HC2K+4_%6LVVF6
M5W?_ &2>]:W@G=2I9;6VN)V\WRPL<+LY48-?GI_P3*_:HM?BUX$\4? K6?%U
MOXZ^('[/>J6F@:=XPDM]2T2;XG?"1G:Q^'GQ(M]+\06MKKT%Y>Z48M'\1R7F
MF 2:G:RS17=\;KSFH_\ !36XU>+Q+^Q#/H'@+3?B1KD'[5=A-IG@K4;_ $W2
M+/Q3/!X)\;-;Z-/J^JP7UCIR2_)>#4+BQNH$^P^7+%'%*9X=,-PC.CQ>^'\R
MGF-&AAZ<JE)4*U#"QQ>$EA:N,I8I5L;RTX.<(4TG7J4_8PG4]I!RI21A_P 1
M'HXOP]PO'>15,JQRQ%6M@ZK<,PQT*&883'/ 8S"^RRRO1JSEA\1&<7&-.3J-
M0G2DZ=2FY_6(_;X_8KE9(H?VG_@J7E98U1?'6@MN9R%50S7:$$G"@@=\Y-?4
M&A>*="\5:5I7B+PWJ%CKNAZQIEIK.F:SI-W!J6FZK87*.UO<:;>6+3Q7D<C<
M*T3;9"P9"Q(4_F3J&N?M%ZUH6J:/_P .Q_A2R:KIM]ITD^K_ !K^$]SIH2^M
M9;9CJ-O#\/KRZFL LI:[AMK:XN)+?S$A@ED98V^E?V'O@UXO_9Y_97^#_P (
MO'-[I]_XQ\$^'9AXBBTQXY;"PO-2UF]U:/1],>WAAC_LW2H+W[)#(L0!BMDD
M6(0NN#B#)<DR[!2JX&KC,+BIYMA<+3H8O-\JSB6,HU:4W4K4ZF4U*JPM.E4A
M&C..(]G[5U8SA!JG.H'"'%^>YOFG+F6#I9AA)Y'C,RJX[!91G>38?*L10Q6&
MHT,%5HY])U\;5Q-"OC,3"M@E*C2IT'2JR5:I3C+H?&O[9_[+'PZ\3ZYX+\<_
M'GX2^#_%.@ZC;Z=K>A>(O'.@Z/J>FZA<0PW-I;W5MJ%W;/%-);S0SK&X!*..
MO6M?X<_M7?LY_%[Q!)X2^%?QK^''Q!\31VDE\VA^%?%>AZWJ/V*'F>Y^SV=Y
M(S0PCEVCWD("V-H+#\GOACK_ ,1M,_:D_;U_X5]^R?X1^/UGJ7[0GA^34-8U
M[XB> _!5WHUQ#\*_"MN?#\5CXFT;6[F_L;BXC>[EO5DLE*7DD*V,IC,K?IG^
MS^_CG6+[Q'>?$#]E?PS^SU=Z9#86V@7FA>,_"7C6X\06U\MV]Z@N_!^@Z&=,
MAL);>U!M[E)H9C<I(SAX0LG?G/#.7Y;1J2Q.%E7Q$<NPV)PM6.9Y1>-7$87#
M5U">#E.6+LYUXM1AR2C%*4I6LSBX9XUXAS_,(TL'7P=?"O.*V"KTZN09U5IT
MJ5'$XVDHRS.E3C@,-4>$PV'J*%>3;<G):1DH_0'B[X@>$?AYIEKK?CS7]#\+
MZ;>:OH^A6E[JMXEI%/KVO7\&FZ-I,#;=LM]J-_<06MK #YDL\J(JD'([LW($
M1DP90J%V1"I<_*64+N(!9^ @+*/F!) YK\N/^"J+PO\ L\>!6N8XLK^TI^S=
M<!YA&D$:R?%OPO%93N78;6^V36X5MRF/=YS#:FUOTJ%XOE3$R0+ (I56831?
MO2/LX@=$CDD)4IO&YBC J,QKG%?,8K+I4LFX>QKJ2EBLPQ6(I8NC&,G&C##8
MBC2@HU(0G"2K0JN=U4=_9W]W2_VF&S^-;/\ BW+93RC#PX>H8-J%#%4*=6=;
M%8&MC$Z]&K5IU'*/LU3C*G"<%[T)24_=>)X<^)'@OQI?>,M(\*^(M%U[5/ 6
ML-X;\8Z?IM^ES<>'=>%I'?/I.KQJF;.Y6SG@G="7D59"/+#)AO)?'W[6_P"S
M#\*O$LG@SXD_'+X6>!O%L4$%R?#GB7QCHVD:N\5T ;9H;'4KFUEF\\LOEB,%
MGW *I)Q7R1^P8B_\+O\ ^"C@A4(T_P"U>TK%842"X,OPR\"Q22Q'!2YDC<7#
MW!:8N9"RM;AB0WWQXJ^'7@;5[?6=7UCP9X7UC6&L+F.XU74/#FC7FJWD%O -
MEJU[+9_:#"4'EJAD) 8E&5L,.ZM@<IP/$,,#C9YE7P?L\%%SRS&82E&%?&4,
M/6]G659-2J7K32?LFH1IRA*49QDSSJ>?<19CPM+-,IJ91A<7'^T)M9CA\?BU
M5HX!UI5*M-Y=C:,8>SHT6W"I)SG-VIJ5^4\5L_V[?V-=2NK&PTK]I?X+ZEJ.
MJ2VUOI5MI_CK0+V34+J^N%L["VLC9W4ZW%W<WLD-K';1%I?.<( 7PI^BO&7Q
M!\+_  ]\-:IXQ\;ZYI?AGPMHR6+:EKNM7:66F60OKFWL86GN)%*QM-?7-O:P
M(X4S2W$:I\Q"U^=/_!,7X>^"=1_8E^#6JZCX,\(ZGJ4T'CR6;4[KP[I-S<3S
M0?$?Q1;VLWVB2&9T>-+2W1(P[F$1* _[OY^D_P""I6!^PO\ 'I#'$\<MOX3=
MQ=)YD!5?B)X5(,Y8A2B-*LEO'P0L>%<<$;XW*LKEQ \JP+QZI4JWU>NLQK8:
MM-U76Y%.F\-^[A3Y(RO%RD^=\W,XGF4.)N(L+P)GG%V:3RW'U:'#T,VRF&68
M7,<+&K2J5^7FK4\QQ.(K>UD_ABE2<:=U.FI.,G^AUQJNVW>5<&-E@>.2*16C
M*3133$K(ZJIC$:(RRA2I# [< Y^6_&O[;?[(/P^UJ]\,^/?VB/@WX>\2:9++
M;7VB:GXY\/-J5E/"KM,M];64\LMDL!BG%VUVD36GDR^?&OEFO=[MYH_"EU(B
M!IE\.++;(\9+BXBL)"%3Y75%$0*(!&X8,<;@65OS@_X)<_#GP!<_L3_##Q/?
M>$/"%_XJ\4ZC\2-:\6:_?:!ID&I:SJ=W\4/&Z37>MW,UE'<3SQ64OV:6&[NG
M*6UJ8E5O,6,Q@\KRJAA\QS3'O.:L,!B\-@*%#*>7E<L32Q%:3KJ2G#F_V:U*
M$:<JDU*?))1IM/ISKB+B6>9Y)E/#D^',#C,[X;H9]+$Y]4S>3PT:.&P<L52P
M^$RG%X6K52>+4ZM2HI1A/EA%M\T8_:OPR_:@_9]^,NH3Z3\'?C!\._B'J&GP
M0WFHZ5X1\3Z5J>IV=G->)8PW-Q860N;I;9[EU6:63RUMHW668QHQ(]J\3^+_
M  SX.T'4/$?BO7M$\-^'=(M)+_5M=U_5+?2-%TVQB3S)KR^U.\VV=I:P1JTD
MUQ<RQPQJ,NX&2/D'Q5\/OV7= _:;^ ?B74+30_"'[0$NG_$VU^&.G:'93:%%
MXWL[S1HI_&<&MKI.AK:ZW!H^DQ+>:;/JUW&EE<R&XAADN'4UYG_P5#\-Q>+/
MV4=4T";Q9X6\(W5QX[^%(T./QMJ%[I/A3Q;KMGX^T,V'P\\1ZS;1+;Z3IGC^
MX$?AN6]OIXM.CBU%YKZ>WM8IIH\89=E>8YMEN#4\QP&!SBC&M5><6AB8?[1/
M#\U"*A&+PR4$I5(I1564HSLZ<C:IGO$&7Y)GF+Q,<@S+B#(\3' RAD];,\3A
M*U66%IXJ3Q>!Q>.J9I3KQ=:GRT*%6GSTFG%2G[T?0I?^"D'[#L,S1C]ISX,L
M4N7MO-3QG;21&Y@E$=Q")4L'5FC? 0HY64D!9%+ U]?^"_'WA;Q]H6D>*?!_
MB'1/$_AG7X$N='U[0]5L]3TW4HI8Q-&UG<6LDB2%8@YN(V9)K>1#$\3$.8_S
M-@\9?M56VBVT'_#LSX3_ &6WTR6V<6W[0OPEFT];<PV\K1VHD\!/FRFMHG\@
M%2UPTT:,\!5M_HW_  39U?X87_P5\4Z1\+OAQXI^$$/A'XW?%GPWXZ^&_B3Q
M=;>,SX6^(R^)EU3Q99:/K.D7ESIE]X9:\ND.@2V;6MK:VTTML+)5699/6S;A
MK!9?E>)Q>68>-.CA:M.A5G'-LHS'GJ58U73G*&7U?:T%:DXIUJ;4IRY>:,E9
M^#POQKGN9YO@L!Q&L+0Q>/P]7%X+#8/A7C3AZ"PM&I&E6=6IQ3B,;2S"HJ\X
MI5\LJT,-3IWA.E.K*,X_I!@,=P/0\^^*?4(;;CC.Y@OTZ<_J/2IJ^)HN<J<9
M35F[O=.ZOY'Z^U;TUM\@HHHK004444 %%%% !1110 4444 %%%% $<R>9#*G
M'SQNG(R/F4CD9&1SR,C/J*\9\)_!#P-X)^(WQ7^*7A[3I;;Q=\9[GPK=^.KZ
M6XDGCU.?P;I+Z'H!AMV*I:BSTZ1XODWAR22.@7VAUW(R@XW*RYQG&01G&1G'
M7&1]148B(_CZ(%'R^G?KSGTK2E5JTG44*CA"I3Y)0L[2?.I)NV]K+1]KK4Y<
M1A,/BJV"JUZ,:D\MQ+Q^#G))NGBE2GAUR7UC*5*I)<VBLVF]2A/ PAN"BAG,
M(1%ZAV5?E4CT+ #OD?KY)\)?@;X#^!'A?4_#'PQTBZTG2-:\8^*_'M_876J:
MCJKR>)_'.M3:]XFU 75_<S7:QWM_,Y6SBGCM(8\JD(WOO]J:'<NPN<'(/'7/
M7O\ YQ2F($8)X!XZ\ =!U_/U]!4TZLX894&YVE/FJ1A-QYG'G46VI13MS-JV
MJYGKN*I@L/5JTL1[&E2QE&GC8T,QC3A+&X59C[*.+HT)RC)1IUE0I2J).TI1
MCHVKGB/C7X"_#[QWXR^$_P 0/$^EW>H^)O@OXEUCQ3\/;B._N+&+1M7\0:1<
M:!?W4\=FT!OT&CWMW9BWNFDMV6:3S8Y5+)70_%GX7>$?C/\ #GQ=\+/'UO<7
MWA#QOHM_H7B"SL[Z[TZYN=,U%#'<16^H6,L-[92B-B(KJTFANK=PLMO-%,BN
M/3#&Q!!<'.[^#L<;0/FXVXX]?:E,>1][!Q@$*,CZ<_Y^M7/$XESPE:-6K[7"
MU+TY.;<H0E-3GRN3DE[R4]%=M7M=G/5R?+<1#-O:X'"*>?U/:YU+V3B\SJK#
M4L'&MCW1E2J5:D,+0IX>#C6CRT?<BU:Y^<4?_!.#]GVT2ULX/$G[0:6EFJV]
MC:)^TW\:+:SLH!$((H+>VM_%L;K%$@'DQQRQR+@!)$8 CZ_^$?PC\-_![P7H
M_@+PE?>*M1T#1K_4KJTN/&OBKQ!XWU[_ (FU]/J-U$_B'Q/J&I:K);)=39MH
M9+AA J ;F<EQZPMK@'?(93D']XH('TR<@^ASQZ&I5B9=V9 0>%4)M"#T'S'.
M>_3-=N89KCLQC[/$XFM74:E*?-5GS<SBK.27*G%QBE!+1.[:3>IY.2<'<-\.
M>WADV29=EKQ$:5&=;+88VE&5&CB5CHJNL=F6/G*7UM<Z]A[&%K\U-R?.O%=&
M^!W@+PY\6/''QLT^RN8?B1\1/"W@OPCXMUI]2U.>TOM&\"SZI/HUO9:1>WEY
M8:;Y$FLWQ86T8:0.JL[MYCRN^-'P4\ _'7P!J7PX^)^F7.O>$=7U30=4N]/M
M=3U+1Y9+SP[KEEXDTF<WVDW5I?XMM9L+2[-LURUG+Y/E3VTL9=6]F: O@,X(
M#JP&S&%4Y*?>Z-W/:D^SD[P\@968,HV8V$9Z$-TQQVZ"N3ZQ7EB(UIUJKG0A
M3I4)*<E:G&+M&R:TA)VBFE:-XQNF[^Q5R^G+ YC@(4L+[#&5*V*J1]A#]_B<
M7B*=?$3G[GQ-TXWE)W<K-2L>9_$CX>:%\3O GB_X<^)KG68?#OB_0;GPMK4F
M@:QJ'A_6/[*U2#['?K8ZUIT\6I6-U/:EXENHK@R1GY_G.0T7@/X=>"/AAX0\
M-> ? N@:?X;\(>%-(LO#7A?2-/MGMX])TO3+1;6VM%FD>2601Q%2D\Q>4S;I
MI'DE+/7I4]@)TF1I/EG<,XV'[@R&3B0?>!QN&"#R!3/[/D# +=%85B\M8?+)
M&0"$9V,V7VYZ8&1P"!65;$XV5"G@OKF,CA\1C(UJWU&I'#0H1I8>252MSMRJ
M2J3?LE*E3G4C!S^&$Y,=7+\!+,HYE++,'B<31PN$P%&O6P>#J8BGAXI5$\-C
M,1"M/"4\+BDJU6C"A?$-*493DE!^%ZS\ ?ACJ/Q@\"_'Z[T>\MOBIX$T37/"
MND^(-(U35+!;W0O&+6YU?1O$6G65[%9^(='6YM8K_2+37([^#0-0:6\TU(I)
M7SK_ !+^!OP_^+/B#X6^)?&NDOJ6J?"'QQ;?$3P--%<36PTOQ-:6%]IMO=2)
M&Q2XC2SU"6-XI<K)@9PK,A]>-A(\D;27"E8_**JD)C;?&RLQ,@E.Z.3:0T;*
M0,\-ZWO+.6.[DC ^7[O;IGGCKT_05K#'8U5HUWB<9.='#U<'!XBLJE25).4:
M2HS3:IT71G4@H2Y&N=\T8ZLY'D.5QP]7"4<OP6'P^)S!YCB*.&P.&PM.>/E*
M,L7CJWL.6.*JXZM"G7]I.C2J04.24'S7*$L"QLHW*L8P%C"C##NIP.=W((_+
MM31:JTIE1RJL"64 JQ9D*.7(/S K@ _*5 &#PNVX('VD-(&/5&,8!1N<'[QS
M@X.,C)'7IB18R,%F#$#!(7;D>A )ZUPTX1DKRI5*3E45>ISU%.4JT)/EU4ZB
MY;:Z./1-:'M)U:;E&#H.BJ:H1I0I*#=&2?/=\J5TVTEM9MVOJ?!7C#_@GK\
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MHP^8Y%FW[3_Q8^P!7A^R00_83XC.ZWLX-L5G;A\1HH0EC7UC\#_@/\-?V=O
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,B@HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !B 1@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBN7\;>
M-?"7PW\(>)?'WCSQ#I7A/P9X.T74/$7B?Q+K=U'9:3HFB:5;27>H:C?7,A"Q
MP6]O$[D -)(P6.)))71&_AG_ ."BG_!QG\=_C+XDU[X=_L2:GJ'P.^#%E=7.
MG1?%$6-LOQ=^(=O$S0-JFG37\-U%\.M O@&FTZ+38?\ A,7MVM[N76=$N#)I
MZ?7<)<$YYQEBJE#*J-.&'P[A]<S'%2E3P6%Y[N$)3C"<ZU><5*5/#4(SJRBG
M.7LJ:]H_#SOB'+L@HQJ8VI*56KS>PPM%1GB*W+I*48N48PIQ;2E5J.,$VHKG
MG[B_O HK_(6\<_&'XI_$?59-:^)'Q3^('CK6[F66:75?&GCCQ'XDU2>6<_OI
M'O=:U2\NI'E('F,9"7P V<#'N?P&_;M_;#_9EUS3]>^"7[17Q2\&/ITT<HT$
M^*=2UWP5J*QD'[+K?@77Y]2\*:S:,!L,5]I4CQ*S-:S6TVV5?U>M]'_'QP[E
M0XFP53%*+:I5LMQ5'#2FE\*Q$<36JQ3>G/+#RY='*+5T?%4_$["NK:IE&(A1
MYK.<,71J55&^[I.C3@VEKRJJK[)[,_U=J*_(3_@CQ_P4\L_^"D?P*US4/%ND
M:5X4^/WPBOM*\/\ Q<\-Z*TB:'JBZO:37'ASQ]X7M;F>XO;/P]XH2RU&W:PN
MI[A]*US2=7TU;JYA@@F?WG_@IQ^VKHG[!O[('Q+^-LTUK+XZN+)O!7P@T2X*
ML=;^*/B:VNK;PWO@/,VFZ ([KQ3KB_('TC1+RVCD6YN;97_%Z_#><8?B#_5B
MMA)1SEXZEE\<,I*<9UJ\H*E4A4BG&>'J4JD<3&NER/#*55\O).,?OZ>;8"KE
M?]L0KIX#ZM/%.JTXN-.FI.<90;O&K&<72=-^][6T%?FBW^@5%?Y4$W_!17_@
MH#/--/+^W#^UOYL\LD\GE?M%?%NVB\R9VD?RK:V\6PVUM%N8^7;VT,-O FV*
M"*.)$1?Z2O\ @VL_;4^/GQE^/7[1OPC^/7QT^*WQ@6Y^&'A?QUX)_P"%J_$G
MQE\0+K2KS1?$=QHWB&VT(>+-8U8:9!/9ZKIUS>BR,'VEXHS,',<9'Z-Q'X-9
MMP[D>89W4SK+<;3RZC"O5PV'PF84ZLZ<JU"C-PG6DZ:]G[=5)<RUA&5K/;Y7
M*>/L#FN8X7+H9?B\//%5)4X5:M?#3A&2IU*D5*--*;Y_9N*L])-7NC^Q6BOR
MU_X+0?'KQ)^SG_P3?_:,\?\ @CQ=KG@3Q]>:+H/@[P+XL\-:O?:#X@T7Q+XL
M\3:3IEO>:-K&F3VNH:?J,=B]^;:XLKB&XC< QRH<L/\ /E'_  40_;]  _X;
MA_:\X&.?VD/C$3^)/C')/O7E<%>%^9<:Y9B,TPV:8++J-#&SP,88K#8RM.M.
MG0I5JE2$L-*,%"#K0IM2O+GN]%:_9Q!QCA.'\92P=;!XC%5*F'CB'*C5H4U3
MC*I.G&,E53DY2]G*::TY;=3_ %9**_GX_P"#>W]OSQ!^UK^S%X@^$GQ?\=:U
MXV^/7[/VM-::KXA\7ZS>:YXN\;?#7Q3<W5_X0\3:KK&JWEUJNO:CHU\-6\(:
MMJ%U)-<);Z;X>N-1N);O5EEF^;O^#F/]K3XS_ 'PY^R9X%^!GQC^)GP@U_QG
MKOQ3\7>*-2^%OCOQ+X!UB_T;PIIWA#1=%L-5U+PMJ>E:A>:9<WWBK5;F&QFN
M)+)KO2_M$L!GM[62/Q\/P+FE;C1\$U*U'#XZ.)Q%'ZY4I5Y85T*.%J8R&,C3
MA:O*A7P\83II/F3J\DGS4YG?5XCP=/A]<0QIU*N&=*E4]A&=-5E4J5HT)8=R
M=Z:J4ZKE&;:M:%TK2B?U,45_FC_L,_MC_MU?%[]L3]FWX>Z_^VC^U7JGAC7?
MBYX1D\86&K_M$_&"[TBX\&Z-?KKGBQ=6M'\7NEWIBZ!INH-?6KJR7%L)87!1
MV%?/_CW_ (*9?MT^+_'WC[Q=H/[9_P"U3H^@>*_'7C+Q-X?T;1?V@/BQI&C:
M/H&O^)=3U;0](T?2;+Q7;6>EZ5IFE7=G8Z=IUK;P06=G;PV\4,:QA!]\O G-
MY8VI@EQ#E3E2P='%SJ?4<SY$J^*K8:E2MS\W/)8>K6O?E]G&UFW=?,OQ(P*P
M\<0\KQMIUYT(P^L83F;IT:=6<[\MN5.K"G;?F>]M#_4XHK_*<_X>(?M_?]'P
M?M=_^)(?&'_YL:/^'B'[?W_1\'[7?_B2'QA_^;&NK_B &<_]%)E'_A!FO_RP
MQ_XB=@/^A3CO_"G!_P#R)_JQT5_ER_!G]O[]M'6/C#\)M+\?_M[?M4Z#X OO
MB9X$M_'NN:S^TE\9UTG1_ S>*=*/C'5-1%OXMFN9+2Q\-KJ=S-!;12W5RL?V
M:VCDN)8T/[,_MP?\'-?QC\3Z_K'@S]AGPWI'PS^'NFRW-C;_ !D^(NAV_B7X
MB>*(H&:--9T#PEJK3>&?"%A,L:W%J?$UEXGU2YAE;[;IVE3*%/C8_P $>*,/
MC\'@<#BL#F2Q-&M7Q&,C#%8'!9?"G5A1A'$5L5[656M7E*<J6'PM*K6<*4YR
MC"#C-]^&\0\GJX;$8G$T<3A/95(4Z6'<J.(Q&*E.$IR=*G1Y%"G32BIU:TX4
MU*:BG*2<3^X&BOY*_P!@C]C+_@L-^V%X=T;X_?M6_P#!0?\ :4_9U^'OC"TM
M]:\*^!?"NMS:/\2O%&AW92>TU;4/#=@N@>&?ASIFJVTLEQI<-QI%WKKVIL[B
MXT>TMYX4C_I1^ ?P'U3X%Z-)HEY\?_C]\<+=K=(H[GXZ^*?"?C#5+283&5[N
MVUK2/ _AC6Y)'0BV\K4=2U"U2W12L NFENI?@>(.'\!D5:KA(\2Y9F^.P\W3
MKT,LPF95*%*K%\M2E_:%:,,'4J4I*49JDJD5*,H^TYHM+Z;+,SQ.94X5Y93B
M\#AJL>>E5QE?"1JS@U>$_JM-RKQC---.;B[-/DY6F?0=%1R^;Y4GD>7YWEOY
M/FEA%YNT^7YA0%Q'OQO*@MMSM&<5_GK_ /!1/PG_ ,%KOV&/'OBSQ-\4?VG?
MVK;WX/>)_&?B#4?"?Q6^&7[1'QEOOA=:VNOZ_J-[H_AN\@A\46]WX!N;*VGA
MTW3=%URPT^Q:&*UM=(NK@-# O5P;PC'C#&5\!#/<KR?%PA2EA:&8JO*IF,IR
MJ*I3P<:,J:G4H1A&<Z;FZDXS7LJ51QGRXY]GCR+#T\3++<9CJ$I35:IA734,
M*HJ+C.NZBERPJ.3C&7*HQ<7SSC>-_P#0LHK_ "G/^'B'[?W_ $?!^UW_ .)(
M?&'_ .;&M71O^"E/_!0K0=0AU.P_;=_:HDNH-I1-7^.OQ'\16)VRQ3#S=*\0
M^(=4TJX^>% 1<64H:,R0L##--')^F/P SI)\O$>3MVT3P6:13?1.7/*R??E=
MNS/D5XG9?=7RK')7U:Q&#;2[VY5?TNO4_P!4ZBOXW_\ @B__ ,%S/VDOC!^T
M?X!_9'_:WU?2OBC8?%1=5T3X=_%A=#TSP]XVT7QAI6BZEX@L]'\7+X>M=/\
M#_B#1=<T_2;S3K/4H]%T[6;+6/L!O[S5H[^:6V_L@K\GXJX4S7@_,_[+S94'
M4G0CB</7PM1U</B</.<Z:JTI2A3J1<:E.=.I2JTX5*<U:7,I1G+[;)<ZP6>X
M/ZY@G44(U)4:M*M!0JT:L8QDX32E.+3C*,HSA*49Q=U9IQ11117S1ZP4444
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M$?Q'KVEOJ'A'1Y](CT#1_$?A'3]<,GBGQ%%KWA#^HGP?^S/^S)_P6'_X)?\
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MF_TKPM8W6J0RF1],M(H991_&E_P<#?\ !<2W_P""CFB> O\ @F]^PSX5^/\
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M:SO?&\6D:)#:>((_!MC=FWCT[7?$%S9:CXLOKJ#2?#O@V_N);.2^^+OVS?\
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M:PTCX?Z3JWA:#Q+K4^J^(-2^PVD7A_2K8W%[%K=[]E@ET98=1F\I)#C^8/\
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M?@U+I]I=>%;OQ]_PEFK:QJ4?COQ1$YU6'PQ8M_:-O%K/AWPR=+_X2UK_ $U
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MV]?^"47Q.^'/_!'_ /;<^"W[&]YXL_: _;D_:<TWP=K'[0'QZ\=ZAIJ_'O\
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MT0IXO\6^)4LI=3U+QLOA#6M?NOM\ME;6WS#_ ,'!_P#P5<^/W_!3O]K#P?\
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M?A+XW_8*_8#^&WBRQ^-7A;]A/0?VH_$OQN_X*/\ _!0?P]\-]?U+X1Z9X_\
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MOPB_9M^!'B/2EC30_A38>.IM!D^+?Q-LM<2%OB1\5O$FMZ-/K@6Q@T30-/\
M"NF?Z, ?CA_P10_8TM/^"@7[4?[0G_!8[_@IMXHTK1_V0O@#\0/$GQS^,'C_
M .(C/I_@WXI?'"?4H_&%IX.C^T(\6I>$O!TE_IFHZSX8TI+U[Q9O!7P[T[2[
MM?$26*[W_!QA_P %/?VF_P#@H)X[^!O[/_@OP[XO^%'[.'CVYT/QK\ OV99M
M-NK'XO\ QET;7M0?P[\*_CA\9?#EJ6ET.;XEWS7TWP-^$=SYFH:1X2%EXVU>
MT>[\7>';T_U)_L'?\$9OB'\0O#'P$C_;Q\$Z#\(/V1OV8+;1;S]E+_@F!X3\
M1V?C'PK8^*K(+J<WQX_;5\>:2PTGXZ?'77==NM0\0:IX9L%E^'6AZU>7$=M!
M<6!N]-O?A_4?^">7[<GAC_@NA^V;^VB_[&.K_M$_%;Q#XO\ "@_8'^+WC_Q-
MX/\ #?[&'P=\(3^!;?PQ:_%GXLZK#K=Q\1-1\3_!3PIHF@>#O"WPI\(^#?[;
MUK7VUC4K34M+MH](\11@'A_@G7_AC_P:M_\ !-B]L;7PUH'Q9_X*[_M5^!M,
M^(7CS18+-M<T_P"!O@V^O6T'PQ>>.]0L(7_L+X2_#KQ#?)H=E!=WFGCXO_&B
M[O['3+BZT;28V\/?D?\ \$%_^"4OQ4_X+5?MB>.?VT?VT]4\3>/_ -G3P!\0
M/^$F^,?BKQC?7][J7[0WQ;NC;ZS9_"6SU&2>.X7P[86,]CJ/CJ73Y8X-"\*R
M:#X1TF&R/B"SN='_ *I/^"BW_!#GXG^.?^"67[7/@SX:^+=4_:C_ ."CW[1?
MB+X8?%_XX?''QO<Z3X;\1?'35?A?XNT?Q.GP@\"VEZ_]A_#?X6>'-*L+BP^$
M7POT_4=*T"PU'3]"_M;57FW7$5K]BS]EO]N7Q1^QS\$?^">GP)^#7Q(_X)=_
MLB^!/ .GZ'^T9^T)\4+[P2?VS/C7XLURT74_BQI?P*\$>"]7\6:#\,(/&OBK
M4M<AU'XR^,]9;Q%IVCLB^!_#<4RV6H0@'\_?_!R5_P % -9_X*)_M7_ W_@C
MS^P):P^,OAQ\(_B)HG@:]T+X??9(?#7Q'_:*"-X+T+PEHLECLTP>"?@GH]QJ
M.A+<0/%H-MK=[XFO)]]EX8TB^A_I%^!7[-\?_!)_]G;]AS_@D_\ L<>)-.B_
M;+_:;^)7ACXG?M!?%;2-%TK6=6\._"OP3JN@>*OVKOCUKEIJ=E/!;^'7T'1[
M7]GKX,?\)+:QP3ZWXL\+V-F[:MIU_7XB?\$F/^"6'[=/_!,K]L/]JGQGHG_!
M./Q=\<_VDH]>U_X=?L>?'CXF_%'X?^&OV2/AI\./$-YKRZ]\7/&/C==6U+XF
M^(/$OB/P]_8VCKI_@[P++XI31Y_$>@7*Z;-XIU"33_[ /V%OV$]3_9MU;XF?
M'WX_?$^;]HW]MS]H:33;GXX_'>]TH:+HNEZ%I!>7PU\%/@CX4:6X'P[^!O@.
M2XN?^$?\.0SR:CKNIS77BCQ5=WNL7:+9 'Z,#.!DY..3TR?7%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%<3\2_'FC?"OX<?$#XG^(H
M[R;P_P##CP3XK\>:[%IUNUWJ$NC>#]"O_$.IQV%JGSW-X]EITZVMNGS33E(U
MY84 ?.'[;G[=_P"S9_P3Z^#\WQC_ &D?&R^'M,O;X:#X'\':-:MKOQ&^*?C&
M= ;#P3\-?!MH_P#:?BCQ'?R/#&(;9([*P6>*XU:]L+5Q,?X(/^"]/[7O_!0K
M]M77/@7^R5XCM_&OPL^*'[4OB;1]6^$?_!,'X3WZ7WB[P5\+-3U&2S^'OB_]
MLCQ5IK1MXI^,WQ2O(9==T+X21G3_  )\(_!6E3>*_%*?VO/8ZH_TA\,OVEO$
M7Q)^(GA[_@JO^U-X4M?VR_\ @IG^TU!J%K_P2!_X)A^"KD^-=%_9N^&5_J5_
M;>"?C'\1-"TZ==/\(:3'$L?B*?QCXD.EZEJEEYOB:&[L=:UJ.X\$?T'_ /!(
M3_@C;J_[*/C/QY^WE^W)XJT[]H+_ (*<?M$W>I>)/B1\2)Y!J_A[X+67B:%?
MMWPW^%DT\:P1SV]@8O#^N^)].@M;1=&L;7P7X.AL?!MC+)X@ /5?^"'O_!'K
MX<_\$E/V8K?PO.NC^+OVF_BG;Z9X@_:%^*EK;AS=ZO';B6Q^'/A*ZF'GP?#_
M ,#R37%MIY"V\WB35I+_ ,3:E#$]W8:=I/[8444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%13P0W,,UM<PQ7%O<1207%O/&DL,\,J&.6&:*0-'+%*C,DD;JR.C%6!!(HHH
M _+?_@G'^S7^SG\'-9_:&\2?"+X _!3X5^(M3^*.KZ1J6O\ PX^%?@7P/K6H
M:39W5\UII=]JGAC0=+OKO3K5G<VUE//);0%W,42ECG]3:** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex4i_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4i_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (R U(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.TUZTD4-?:NYD_=@XF'R]_XOQZX _63R=<3:HU76MJQJ1)F;[I&3@9Z\X_\
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M*/XA1YBD]:^!YOBMXYAVE?&>M>9D8W:A-M(P3T'^!R.E$GQ9\?H4\SQEKC#
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M7^MU#_GW+\/\S]$C(H[TNX&OSFD^+GCY9&/_  FWB(,#E(_[1N&_]FZ\]/\
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MT9Z>A[U/^I^)_P"?D?Q_R*_ULP__ #[E^'^9^B&]<]:7>*_.I?CU\2F2,_\
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M;,/_ "2_#_,^_P#<*3S%]:^ (/VAOBE)N\OQE.W1OO(WR\Y(_=^GZ_A4MO\
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MUKN)(_,+% N\L%8D@@ '.Y&&.N/F6\\*?LIV$D>W6M,N(]H=GBUF\D&3C<N
M=Y R6/ = 6QD8-6_VVXO!_A7]AVQT_P;<6MSX;CU73Y;"4:F\T4J23M,SERQ
M8D;L;L XVA@N,5M'.\4Z<ZLE&T8N7NRN].ZMIZ_@>/#@G+:F-PV"ISK1=6I&
M#=2DH1L^J?,[M=NQ]16BVOB'2[74;.;[?:W Q#-;8E5\ ]2N0PRN 1G(W#J
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MMZMMGT)]C!O=%2WTJ%+DK'&9%RR[T@WQRAAN+ GC<%()7&1SD=A!!I_EW,C
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M[M%.5HK2\G:R5U=GT1I=[X?\6W2VVGZEHM]-&I!2QN()Y!@$#(4_CNSCGJ2
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MR,ZY(&0_"]<FE?LW^%]0\/7FB_\ ",Z?;^&9W:62Q2 ):N6=6;:BX!8E02P
M(VJH&!BO)>7S=*-&55>[&:VZR=U;T?XGU[XZP3QM3%0PSY:E:G.UU_#C3]G-
M/I=INW0_,?5O@C=2_L*^-O'VHJSZCXL\96CQLRL&G"W!R <A7S)-+DJK;=I&
M<9 TOVS?A1_8'[+_ ,![J-E>2_LKB3*A_P!XWV6!R,,<$)D#<  2#R<#/Z-R
M_LJ>%_$?P]E\*W'A^'_A&[? %O.KI&CHY8,JC:.'R^1U8 Y.<U4UW]D_PK\4
M/#>FZ+JGAZWNM.\,GRM-:=7"V:81&5 ,*?DC5=H!"A.NXG,RP-?V4J?M5=PY
M6]=W/G;^]^OD;4>.LO\ KE+$U,/.T*]2HDK? Z7LX15VM597V79O8^6Y/@[^
MS5I\L,*W_P .S)<PX$[W<F2!@&1T8EBV<[4P.QQ@$#&_;=\!>%O^&+EN/"-Q
M8WF@KJVGPP?V<S-#&BNT8C&6+&0$!6'\&[W#'ZMM_P!@CX5ZA'^Y\#V>VSD?
M#DR@8.1@,3C.<,2H)&P<D\UTUQ^RKX/\2^"(_!K>'+7_ (0_3[AKN#3<,EL+
MC=O#\DD88Y &>6;KT'9[;%.E.A)0BI1<6XIIZJROH>+1S')J&/PV.ISQ-5TJ
ML9VJ2BU9;\MI.SZ)[6;N?#?Q>_8\NM2_9=\"_$3PS-##XB\(Z/:7-T+1B)[J
MVV)(Q!#'Y[<J\F_<!M5QU7957_@EG\.(?''CGXC:A(J_Z9;Q7!V*R"1I9I7<
MX#J @W$!&8YW="#D?HMI'@&UMAI^GVUG)'I&DVR6UM!Y6((8T& H!ZYX7820
M0H)S@5C_  J_9J\(?"?6[I_"OAZUT6.X*"86ZE8P$RRJ!GG[QQG."YQCH.7Z
MO4AB:.)A.SBES+NTN5/U[G1+BNC7R/%Y17HN4JDOW<M+Q@YJ;C+K9/X;72O;
M1)'!3_!BV31)KNZ=43RXBXQ)^Z4$E2Y#@,Q*_*H#%!V!'*3?!6"SM5N)A'_Q
M\)Y8!+&)R 5CY;RS)\P)<*4&.N.GM%OX9EGUF4LK2!I?,._)1?4#H!QT'S'U
M.,"G6WA?9YEJC3R.HVO,ZC<-W)?@!0QSG@'GDU]+_;-;;F/RO^Q:;UY3QF;X
M$PJUHP95D8NBMF15=F'S!0[<1C:"S;<DDX8DT7'P4MK18%-QM-Q ?WL[RG?$
MO5L$EE7+_*H526[$9->R)X46:V;38_.5?+42R;3D '[H8\8XZ8(Q@;0*=J/A
M-KRSAL-T_P LPE=X\\GW<C@#CD'.5 &.,*.=5KI.7_##_L6FU=1_X?L>,ZC\
M K?[?Y:M'%&\L32JXD:7[^T#Y2S;FQ@#@8SD)@4VW^!%NE[)\JB,LY(1W$C2
MXW$ JQ/'!8EAC'!SD#VJ?PFL[6]JK3K'&#N2/Y$P1M)8CDGCJ"#UZY),6I>&
M6EU2&'YGA\@P_9UCQ&4#< XQP,*#DXP,8/-$<ZQ&W-T&\EHK[)XM8? NU>-B
MOEF"-##&Z,P"  B1R ^/*7+C)8;B3U%36_P*AN=%F\X+) R !E#A40?,"Z[@
M"Q8#"_,>,XSU]H/AA;;53E9)FN"&*$#RDVE0. !P.O)ZDXY)IQT5=)O\KNF8
MEG+2 X0' )! "CC"Y/09ZT/.Z^RD$<EHVUB>+WGP+BBC:65MTL<X=L(_D[N5
M50-X5G 8EFPP7?C<!G:Z?X#1P&&2$Q-)YC1Y<R-"^?O,,L $4<,=HW%2,D@;
MO8K?0X?L?V>WDN9/,0QNV<.4/W2. JCOD #GIDTLGAQ8(6L(9I7DN(L/,5#2
M2,@!"LQ&T+C(QC&'. !4_P!N8B_Q!_8=#^7\>IXY'\"(8)(UAD\L21X9IBZL
M4&3YH&3C/.U=@R2#MQG#K?X*V3W]PL<B^3O#36X9VG3@X3;N8F4J1P-NT$@X
M&#7M4_A4V5NNUF6-6$Q4L6,LAW!MQY)&"",YY ] *++PJNLZ-=6=];PS:9=1
M"%;8QA<+@ALX/ ((QC!&"1UXG^VZ_P#,S2.1TKVY3YWN=&TO^W[C2]+AN/$U
MXLA?[-I3/)Y$C9;:\VXJH!^\0_4=N171^#_V2-:UPB3Q#J%OHUBR"+[#II,D
MS)S\KR-E5ZGA0PYS7O/A+PAIW@K2(['3+&UT^U0#]W!&%!/<GNQ]SDFM3%%;
M/Z]N6CIYO5_Y+[F_,UP_#]!>]7U\EHO\W\_N.2\"? _PQ\.QNTW2K=;KG-W,
M/.N&Z?\ +1LD#@<# &!Q75^4*=17BU*TZDN>HVWW;N>[3HPIQY::27D%%%%9
MF@V0X0U\S_'C]H7PA>?M$I\+_B1X1TMM!D@2ZM-8U!MT8,B?*Z97,7SAXRZL
M""!D@&OIH]*XWXJ_ KPK\:[*WM_$VBV^J+:LQ@D8M'-!GKMD0A@#@9 .#CFN
M3&TJU2ERT&E+3=7375/R9[G#^.P>%Q7M,=&3C9I.$G&<)/:<=4FT^CT:;\CX
M(_;;^'?P[^"FL^']8^$^M2-XDO+S,EKIFH"\CMHQ&=DXD7<\;APBJNX[@QP
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M>(]*I@,QP-:FVJSJ.D]+PC4FIRC+7:Z325];][G=4445],?DH$9IODCWIU%
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M:VMU/F#PC^Q?\&=3\+Z6;K4M#CN6M5$H_P"$H"R2S;!NVJ2<*A)W/@8*X!X
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M/C]')# T$7B4R,VZ16L+D*$R3TQC/OG@X(VY*U]0[?K^=&/\YI1S;#I_P?\
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M .!?_:A_9.)_Y_\ _DO_ -L?.I_:D\/M92LFH7_G=%1;6=AD]SE2#@$$G.&
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M^TMI!#&:;4H<?.VVSN%+?=Z?*>O'0 @]"<D5[IC_ #FDV_7\ZE8O"]:3_P#
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M_M9>&6EDVZTTD?1)S!/DXP<_ZO(^]P<-@YZ@XKV/1;*YBOIA-&ODL!D$$%I
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M;L?O'[^OK[UZW$>F5T5YK_TE_P"9S<,_\C&H_P"Z_P T>E4445\&??A1110
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MC.0>@Z>9[U8@%C,RJK:C\W0&\E_^+I.F'MEY&_N&>HI-_/\ ]>L-X;-MR_\
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M-&6VEL##;N@/51TK2K'67SI=+9OO?:6&<=_*EK8K.6AO3DVKA1114EA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/5]5_LUK=5MYK
MF2X<HJ1;01A2Q)W,!C ]:I7%M>>(8?)DC^QVC?ZP%PTT@[I\N0H/<AB<<#!Y
M$^KC_B;:;_UV?_T4U7X3\E5L1:[=_P"MC(U?1+C4I"=D.U!B-=V!VZ^G?IZU
M5C\,W2#=MB+G@_/C(/;I_G)KI**J-625D92P\).[.6'AF^%JP:.%FV@!5;:O
M';^1_ 5*_ABXF@17CC;;@\OGIS72457MI$_5(')R^%K^2?=MCZ%1^\XYQ[>O
M/3M[U#_PB-^TKM)'%)YG!#2C&,_[M>&?\%"OVF/$'[//B/P_)IOB:WT'36TR
M]OI[:**TDU#4IHGM]BPPW@2.]4(90UK;W$-TS21E"0>$^.W[4'Q \#?'/Q5H
M>BV-K<>']-U'P7:"]D\M6TT:EJ9@NAL8;IO,CVH"#^[)W8XJO;S,Y86DGU/>
M[GPU?,%VK&W4X\S'/&.?3K26WAN\0<J.G/S# ]NO^>*\5MOVPM6F_;X;P689
M5\!;F\,)=_V7*(&UP6@OSB]QY/\ J=\'D[O,\U#\O<\U^SE^U+\0O&?Q1U2U
M\02JVB7>E>)]2TYKBPMX5<Z9JR6<7V5H)7>1%C?]\+E(VWM&8]ZER#ZQ,GZO
M24K:_P##'T=_PBUYY*J$4R9/SLPQWV]\]#2-X8O2BJ43U/S@'/3U_P _C7R_
M\"_VQ/&7CO\ 8S\7^-+CQAX3NO$UEI6G7$+7,^FBSTN:X0;S)]EGE\H%F8+]
MK\L*T>7P@D(]P_8P^,MY\:_A%<ZC?7\FJ76GZQ=Z7)<26UM$S^4XP"UK++;3
M$!@IE@8(Q!&U&#*#ZQ,TCA:;[G:+X6NLL=JY8<YD]?3TQS^0J&7PG?$L/+CD
M5E/63DGMU_S_ "KL N.U&.:GZQ)#>"ION<6-,O=%GCF\M5;<,,6RJ]N?J,CJ
M.M:5C)-#-)<:>L=S#<'S+BV+[9(Y#C+(3QSCE3@$\Y!)SL:O&HTJYS_SS8]/
M:N+BOI(9<P,V"03CC:.>?R'N.16D;U5KN83MAW9:IG66?B2.>YAMY+>\MYIL
MA5EA.W(&3\PRO3G@UI5@V\SRSZ$9&W.Q?<?4^4:WJYY*SL=].5U?^M@HHHJ2
MPKR7XXRLGQ?^'85D4N^HKEB03_HXX!'\7ID'/O7K5>/_ !]B=_B[\.T0[>=3
M.[&[ %L,_+GYO<>F?K7=EO\ O'RE_P"DL\W-FUAG;O'_ -*B=3J-PD6@7'EK
M^^4@2!SY8^;ONR=AW$_,,@$$<@&O"?BF([KQ)"H$=DLTADN4(,$I)52S,%/R
MG:)5WJ"JB1L,3A1[OJL]U;>$YV2&0ML4;D7S6P54,=G&Y>N0.2!P.F/ OBE+
M)?>,M/FN/.BDBX MQYX*DP$!6QEUWK!A206+J<*K9KV,DB_;/YGS^>R7LX_+
MI^IW?@FZ:?P_>2>3(MM#.I$5N?+B=2%VD'((CVA=HXP4+GT$MS#'';,K-\KQ
M[1(CARV&)()! VCD>YZ+BF>'[>:73KAKQ8Y+J:=FC67[R@J#(VP94$9(9AG
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M&J6HO;6TD222:6 OY?F81&PN_P"7)P,U\5_M'?\ !.'XR>-_^"</@GP+I/\
M8>I:OX3T[6TE\)WT27G]K7=^TT5C>7-Y]HMX6O;."YDFDF*R(]VS3K&[)%CT
M7]J_X"?$SXG7>E^(M!\&_$#3OBU-X$MM)T_Q-X9\<Q:'I&D:IN>8IJ5G]I)F
MMX)VW;<7R2*SIM/#,N5;BYY/H?4/Q6_:5\ _ _7]%TGQ5XHT?1=4\12"/3K*
M:3=<W7S*A=8U!;RPS*ID("*64%@2*P]._;<^$^I_%S_A!;?QMI$GBW^U)-%_
ML]1)O:^C5V>W#;=AD54<E0V0$/H:^>OCQ^R_\8M/_;=U?X@^";GQ!-<^*+#P
MW:6.H66JVUKHND_8;B?[?%J=I*?/GMI+>:1HHX/-_>2R?ZE]LX]Z\8?!O5O&
MO[7/@/6VL;>U\$> ]/U/5HV255:]UV\VVL;F(<GRK1KW+MU:\7!)4X-"N:39
M[&#D4444BQLOW#]#7-AE;#'S,\DCH1UX/?@5TDGW:Y8SJ+D':S;?EP#W&1Q^
M9YK6F<N(Z&DCKYVE\*,W3C&.A$4O^%;-8HC"SZ5V_P!*8CW_ '4M;51+<VI[
M?UV04445)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M$X% &9K!_P")OIO_ %UD_P#135H0?=_&L[5CNU;33_TUD_\ 135HP?<_&JZ$
MQW?]=A]!.T45E^./"\?C;P9JVCS?ZK5+26U8EY$P'0K]Z-TD'7JCJWHRG!$E
M$VB>*--\3:<UYINH66H6:RS0&>VF66(20R-%*A921NCD1T89RK(P.""*JR?$
M3P_%X&_X2AM<TA?#/V'^T_[7-Y&+#[)L\S[1Y^?+\K9\V_=MV\YQ7S=\%_\
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M5)8A8XVE).%8?+D!<@+@$ <J#6FU5KS.?_ETO0^>?VA+EF\5:QYD'EW#&$<
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ME/EP0^6NPHI7C((4*0$0;0=A8Y&*L:IY07:L;+&JE4W/EL[OG(QP.<Y;A3R
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M#M4E44@':%5@3SR3X(:LMGIOES6,-U%N+EXX%D6",F5PKJQRRX$J[E(88SC
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MI^FMHL\=DBRR+-,J@,X7:'/<XR<?3-?#5O\ \%,_'FC?\%:-%^!>H:?X9NO
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M=_+9"QX 8D8XR?SB_P""MG@C6/BW\>O@'\#M2NHY_'7Q<\1Q>)_&$EN \%A
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MW]O&LT[006]M:K/$?F:-V9GE.U0, DT>T?F'LX]CZU/A/36/_'C:_7RQ3?\
MA$=-/_+E;_\ ?L5\;Z[_ ,%)/&'@N3P-_:_A[1R]CX@\1:+X^CLEDE6*'1UC
M:>]LLL&VK$YN#&P=BJL@R0"?<O@G\?\ 6OB3X ^)VL+IUGJ]SX2\1ZMI>CVM
M@VS^TX;95:W7<2P+R9 W#@[@0*7M/-ARQO:W]:?YH]6_X1+3?^?.W/U0&E_X
M1+32?^/&VY_Z9BODC]F']LOQU\?O$<NAP^-/A3<>)-0T2:YET2?1+_2-6\'Z
M@ I6*:SN)O,OK=22CRIY)!4, 5-9^A?MG?%[P[X#^(7B77)? 6N1^$?&$GP\
MT_2K#2;FRDU+5GNK6VM[AIFN9!'!ON<M'M+8'WQUI^TNKW#DCV/L8^$=,)_X
M\;7_ +]BF_\ "%:3G_D'6>?7R5_PKYG^('[6_CK]C[Q%JUG\4)/"_BZS;P5J
MWB[3+S0;&;2Y!/IR1O-82122SAE=9 4GW+@@AD'!KI/!?B/X[>&](M_$'BN;
MP)KFAZKH%UJ=Y;:=8RV,_A:Z6W\Z"(.T\@OHB<QLV(F!^<<':#G?F'LX]D>[
M_P#"):8&S]AM?^_8JY9V46GVZPPQK'%&-JHHPJCV%?*7[#'[;/B+]MV[T632
MI/#]II7AG0[&?QC,UL_VK4-5N8-QMK2$R P6\3!\SOO$C*40$*9#]8H,(/I0
MI70**6R%HHHH*"BBB@ KR'XZ[4^,G@+<P$:PZF2#'O!_=1CGVY/OC/7%>O5X
M_P#':Y^Q?&'P"S)YFV/4F0;]AW[(@N#V))XSD9Z@BN_+/]X_[=E_Z2SS<V_W
M9^L?_2D=9?6<EQX8;]Y)M;RWB9F RP"X^?((+# #GH3R!T/S[\1R^F^-["'Y
M+B96Q'),=CLQVX+C#;"%.XRKQB)NA (]VU*+3[SP9=EW>*-@&D0KN**0OWXS
M]Y0"%=.X']XUX3\3YICXKM8K*1H;6:4#=%M<(X*J[#))<!6E&SYCO5 0=WS>
MSD=_:R7K^1X&=V]G%^G4[CPI#]C\-WJ6\YO)%G4EVMQLW*H"@C)).Y=RJH8_
M-G@G%.UUY[:%FD4O(Z%9 \F["[EPHS@;LX)Z]>!VJEX0GAE\.W4-JSQP^<!]
MIFN"2Z^4@RN<!590C,QX&=H3)*U//&8HF^QS+<-'&"[%/+R#C:&8XPH7H/E'
M4\X-;1C:JV^_]7['')ITHV[?U;N?//[0LGVOQ)JSHK*<Q8"+T^5.1S_=[CTZ
M5]D?LJY'[/'A'(P?[.3(QCN:^-_C\;C^V=7CG98PKQ!C]W+!4(4D>F2W'K]!
M7V-^RG+Y_P"SKX1DQCS-.1OS)-=W%&F!HKS_ $%PK_OM7_#^IZ%1117P9]\%
M%%% !1110 5\M_\ !2I=T'@_]WYC%[M5]F(BQ]?Z=?8_4E?+?_!296:'PAM^
M]ONP,-S]V+I[]/PS7M<._P#(QI_/\F>/G_\ N%3Y?FCSWX6Q^5/J+,KR2?((
MPN< G=VR>N. <CKQZ>EV%OL7Y2(?G"R2(&8H <LS-U5SQSE0HSTX-<%\+TDA
M-]"(0I9(R[GCRQ\V2&! X& 3QU'J0?0K2RBN;57D.+9)-Q#?N]R X554 _*6
MYX!)/KG(^TS*7[QW/A\'&\#G_BE<!]S+M7;;P&*U;YIYY<MLQM! .&' !VA5
MY!(Q8^"SR)HK3"2%!+N$X6/Y98PQ0%UZE&VQ#S 6(WJ"3MJ/XI6TEQ,X5DCO
M);%8XHXUS A8MC>6+9"G>.<EB0NT ?-8^"D/V:RCEF:Z:X\U@V3B1\EL %<*
MLA7:2C9&%/ 5B3PU+/ _U_7S.BE_O?\ 7<]8^(T-M<>&K^3S&$-Q:[V@E;<N
M\1MC<<ENP^;D<#!/-:?[+H4?L_\ A$1IY:#3(P%Y^4?C5#XE)9W^C:H?LWE3
M?96*D(8_FV2<C(^8D!@5QDYQT)-:7[,(9?@#X1#+M8:;&-OH.U?*UO\ <?\
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M* "BBB@ KQOX^7,D/QH\ LD;29M]4 & P!\N+'&"3]!S@D]0*]DKQKX]1_\
M%[?AZV%E40ZHOE-D;LQQ<AARK>A[=\#)'H97_O'_ &[/_P!)D>9G'^[/UC_Z
M4CI]0U!%\+2+-;!9E>((K2[5&0-N' .-N3S@A2#V%> _$U&@\7V\EQL A8QR
MHK"*1@G#EL8520DB!P2-LA^7[@/OVI-(WAEXYE\F60AX&1-S+\@+[AT?C>2@
MY900 >H\#^)EE);^+-/CW-<&U*"/ $D)C4QXVJ<EAE8?E(&=W&%SM]G)-*K^
M9\_GB;IQ?H=;X6N%U'PG<O+&UAIRD*P\GRUV&)"H;.&^5&4! 5!VDGH2);C[
M--:XA8+@DPL'&7F_C("Y&[LQ&0N!SV67PVD\>BR374:S2+,[PQ)(99-P0%PA
MY&=S.ID[%0 W& MSJ:W=JVZ.-5FCP57EASR222-I)..22,MCL>B,G[1M;7_K
MU.3E_=I/>WS/G7X\*MEX@U(1^7)LDC&['EY)"\#/'!_FQK[,_9601_LZ^#5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCBOA9#;SQZ@T@\HM(D?W N2"_H<[<CN1WYXKTRUMV>X$";5W-C[08R_E#<
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MY;+ON;8(&),T*_-)&!N0<L *N6/Q-\-ZGJT=A;>(-$N+Z:YGLX[:*^B>9YX
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MKNPQ<F_BVJ2R@2>/I?#?Q8_X)_\ P,^&/P0\-ZEX/^.EKJ\EOX6M9YOL^J^
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M#(7_ ./F6ZA<9X(?\6TT#XW?L2?L]_#_ /9W\-ZMX7^-FEO<2>&[<78LM2\
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M0O[*'[/OA3]EOP]K6A_%#3]'U&[\,I93?V?>>"],@M9+75K34)&4E))YO]$
M<9>[*RY_=$FO^U;-X7_:&_9U^ GA_P#98\-ZW9>/--\,:E>:5#I#G3;SPSX;
MCMVM=5TZ\=E;;<7,ZBV17!9KN,RAAY;/18'6/U$T'XAZ!XJEACTO7-(U.2X@
M-U$MI>1SM)")#&9 %)R@D!0L. P(SD8IVB^/M#\2311Z=K6E:A)/;F[C6VNX
MY6DA#E#*H4G*;P5W#C((SFOS!_;);PK^TI\'/@=HW[+6A:LGBJQ\'7^HV::#
M)_9UQH_A 0&VOM*N6(8BXN)T6VCC<,ZW4+OP49C)^V^/#'[2OPH^".C?LNZ'
MK2^+M/\ !U[?V:Z!*=-N-(\'_9S;WFE7$A#;9[B5$@AB8EEN8&?(*%B6%[8_
M3C0_B%H/BB>*+3=;TG49)[?[7&EK>1S-)#O,9E 4G*;P5W#C<",YXHT;XAZ!
MXCN(X=/US2+^6:V^VHEM>1RL\&\Q^: I.8]ZE=W3<",Y%?F!^VW'X5_:4^#7
MP3TG]EO0=6_X2;2_!-YJ$47AV7^S;G3/!?V<V]WI$S;6VW%S,BV\,3 LES"[
M_*49B[]N5?#/[1WPL^#.D_LOZ#K \1Z7X'NM1DB\.R?V7=:?X&,'D7>CS,5)
M6YN)E6"&!LNEQ!))P8V).47MMS]/-&^(OA_Q%-''I^N:/?R26OVU%MKR.5FM
M]Y3S@%)S'O5EW_=R",Y%&D?$7P_X@GCCT_7-'OI)K47R);WD<K/;EB@F 4G,
M>Y67?]W((SD5^87[=L?A?]I/X9?"'2_V9?#^K3:SH_@&?4KN#P](=+NK;P T
M'D7&A.VUBMU<2QK#! <O'-;RM\I5B9?V\5\,_M.>"?A)IW[-.@:K-KND^ )]
M4O8_#LW]E7%MX">$0SZ%(VT[;FYEC6*"!OGCFMI6^3:Q)RC=:U_ZOZ'Z<Z-\
M1/#_ (BGCBT_7-'OY)+7[<B6UY'*S6^XIYP"D_N]RLN_[N5(SD4NC?$#0?$=
MRD.GZUI-_-):K?(EM=QRLUN6*B8!23Y996&_[N01G(K\Q/V\?^$7_::\"_"6
MQ_9KT'5KK6M&\!3ZG?IX<G_LN>U\"-!Y4VA2-M.VYN7C$,$#?/'+!*WRX8F3
M]O74?#G[0?A+X56W[,^@ZW/JVD_#^XU#4QX5E72YK3P'+$(YM%8E3MNIY(MM
MO"?GCEMI3\IR2<H>V/T]TWQAI.M.JV>J:?=LT N@(;E)"8B2HDX)^0D$;NF0
M1VHTWQ?I.M.JV>I:?>,\(N%$%PLA:(DJ)!M)^7((W=,@U^7O[?EWX5^/_@OX
M4V?[,NF:S?:II?@&YU'4H_!UVFGRP> GAV2Z4Y(.+JXD3R[:,_O(YH9C\IW$
MN_;OO?"G[0OA'X4V?[,>FZOJ&K:9X NK_4HO!UY'I\]OX#E18Y=+?*L3<W$D
M1CMHSETF@G/RG))R@ZV]O^'/U TWQ?I.LE19ZGI]V6A%R/)N$DS$20).#]PD
M$;NF156?XE^'+6.%I/$&B1K<QB:%FOHE$L9) =?FY4D'D<<&OS#_ &_M1\'_
M +0O@_X50_LUZ;JVL7&G> ;J_P!9C\%7J:>\?P^D15FTJ0X.+FX>)H[6(_.D
MT$Y^7YB<SX_>*_@WXL_;0TG4M)\4_LNZ'\/[[X0Z"WA>3XHZ%'JFDRVHO+X(
MEA&UU;>5(JX60'<P"A2%(:CE&ZUC]7K#Q'I^J.%M;ZSN6,*W $4RN3&V=KX!
M^Z<'!Z'%5)?B!H,"6[/K6DHMU&)H"UY&!,AZ,O/S+[CBOR\\<7NJ_#/]MNZ^
M+OPLFT/7M-^$_P )/"M[?:+X.BC@T7Q3X<N)KY+Y+&-6946*.)+FV4.P'D!<
MMG-<7^QW?_ W1/$'P+7XZWGPY_X1UOV;=*&GGQ>UKY$UPVJ7);R!,3F8QAN(
M\MCIFCE)]MTL?L3)?0PSQQO+&LDN?+1CAI,#)P.^!SQ4?]L6GE>9]JM_+\WR
M-WF#;YF[9LS_ 'MWRXZYXZU\0?\ !/K]CX?%/X+?"GQOK6L_$+1X?!-YJR>%
MM)N-1N8([O0GU&Z.G"[B<AV46;1>6&VD1^6#N50H] 7_ ()4>'U^&$/AK_A8
M7Q-S#XE'BG^T3KLWVR2Y"[S$S;L>0;HFY*@!M_\ 'WHLC3FD]4CZH5MPXHJ.
MVMUM+=(U^[&-J@G. .G-25)H%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>+_ ![M&N_CCX&",WF+8:IM1'VNW$'W3^F#P0<&O:*\6^/U
MNUS\<? L:YYLM2)Z8X\C@_W0?[W8<]J]#*_]X_[=E_Z2SS,W_P!V?K'\T;^H
MM)9^!;AEE7[-E?/82&(KA!NPR$%,@* V3RP&-I%>'_$41Q^.;+[,R_:I)!%&
MQ7RY4D.TKNV\ J&7<06&$RJ@XS[I>R+%X8N9XU9U0J+BU0&X8X3 ^0'+J?E!
M!YVC/!KP/XEF"_\ %5HL4S0VTBF/(E$OE[VX8LS98#,@7.06"Y7FO:R6[JOY
M_D?.YUI3C;R.P\+6+6WA&1A+;ZA))=?=239;NZHH4'=EAEMYV DX^;Y2Q#3:
MH_D32"_6%&"JTBQGY%(QAMW)SD'"@<#@GTC\.P^5X<9;)I&D6[\J)IX@9B^Q
M,$KD#E07).0=X 7Y2:CU5F@A8EDG&S+L6!+#/ ZX],M@DD+@ 5UTXWJ-/O\
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M_ ,#_A2WA,KNVG1[4C/7_5+7R];_ ')?XOT/K,+;ZY+_  _J=?03@445Y1[
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M_1;?Q1:>(M)\22^$_)\;>&K>"Y2X73+6]AD2-HU*,B32JS*LK;DE*@G2L_\
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M#PS-(MYXHU:+=%IURBM&@MHTR+N1%)S.%C'[M=S,^-?[$/Q:_;A^'G@7P?\
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M2"/;R6WM)?/U/G,ZNH1^7H=UX9GCU;PG-MMUT^SD?:SI(8XX8C&KDDD@[0H
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MIHXVFC+$)D$8/'J.<\<?7'->@VEQ:K<)O5UU*.8F!5<_ZS@!F.0%89Y.1M!
M)&0*^PS#XV?%X/X+,ROBU</%<7BW6!/+:+%/-,V_R@R_O"5Z)P5QC:(U&,9R
M3)\$9K6Y\/KYD</V%4&[$#LCQ^8Y(8 GY2/D\Q>0$!(X8BM\51-$MUQYMK':
M)(T\*[1*@+;MI;#$%L'J"Y!.X@&KWP'FFAL;-IK=FCDD#QMN7?P96RAR<L7$
MN8V/(W* !\M<-7_<;+RZ^1TTO][/3_C7;WDO@C6H_P#5^7IDXC(P?.4PR# (
M/;)Z]<G  R:ZWX$\?!GPB-I7_B2V@P1@C$*UR7QJ5H?AYKRFYBDC_L^784)
M91&X:/&3M/#'(QC'.!D5UOP*3R_@YX55<!5T>UP >!^Z6OEZW^Y+_%^A]7A[
M_79/^[^IUM!&X44CDJO"[CZ5Y9[ RX4X!&..Q'6A!L3-$PRW^?>@$^5\W'':
M@0Y3O-."XJ. ,!R,?CFI*!H",TFP4M% !T% Y%%% #0G'-+MI:* "C&:**
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M!I6F74IDN+:))F88<;8BS9?R8TCSL4*'S(3IR>S/G7_@H'^U!\4?^">/PO\
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M3?ZY'I?@YO %C%K>HS:C'9Z&[$R6:"5B,.-J,[9D9(XT+%44 YQ^SEJ?./\
MP4-_:9^*G_!/[PC\,M2T_P")^E>+IO%^D-X)O5U^QL[14U5XPZ^+?]&M\BWM
MSDW$ Q!Y;Q!0C98K_P %&/VG_BG_ ,$^=%^&>H6/Q,TGQ4/&&DR>"KR+Q#96
MEFL&JE Z^+3]GM\^1 <BXMQB#9)#M"MEC]$^#_\ @GC\+_!RP*VCW^NQ6G@Q
MOA[;1:WJ,VH1VNA,3YED@D8C:X(5W.9&1$4L54 .\%_\$]?A=X2EC:32=0\0
M?9_!A^'L"ZYJ4^HK;Z$2?,LE$C'Y9 55W.9'6.-68A% %(.26JO_ , ^=?\
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M8JH<JS8Y*C )]0.WTJ6BBI- HHHH **** "BBB@ HHHH **** "@G%%!&:
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M0^#_  K&T&O2^*8RNE0 QZO('6345^7BZ<22!IOOD2-EN3E:$*$NY\*^&?\
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MUK7+OX::M.? S)!-.\G@S5I/#%E/IU_#M/[J&:>Y:"0IMV2-"Y+' 'Z@^'_
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M?B-H;+3[EKJTN$9$#+=I,0_F9VY1?DQD'Z(HSBJYF+V<>QY]^SY^SY:?L_\
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M$_!W_DD_AG@J?[)M,@]1^X2L>+-:%'Y_DCT>$_XU7T7YLZ2BBBOAS[<****
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MKA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?M/^'_$WAO3-4@AU:.#5M5FTB**:V5)DDCMIKI9'7=Q'+;PB5#U*S19"DD*
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M_"7PJ_L+QS+XEO\ 4FU37+G2(-(GN#:QP"2.&>>92 HR.9R",X^4'&<UU]%
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MG^#_ !II/A2?6_[&MSJAO-5TZ!K2.6_6=7DL6:[A@8- 9!(4!8QCS%Z?X&>
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M,X(WYDR=IX3@'G'I%8>N_#3PYXGUK^TM2T/2;_4/LK6/VBYM4DD^SLX=H=S
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M$C%U?6D !.\L'W'))KV"W^)_V?PAI.H:AI.I:;?ZU="RMM-FVFX>4L^T'!P
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M3FM$MPFJ17LMQ'%-$7F7]V!;2R$OMS'AEW G#?CK\8KSP9XG\,Z7#:ZM]CU
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MW0N4&Z1P0J[B%]X\)74EWX<L9)(;^WD:W3=%?%?M2';TEV$KO]=I(SFM*B@
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M&1=(_M+^ DOFM6\6:&MPNI6ND%#<@$7=U:K=V\)_VY+=EE4=T.:\S\??M^_
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MDY'#':UR+X8^*K3]CC4=!M].OK/Q3K,=R9[5-32XN;8WEV[S*+F9V$K1Q2L
M[OE]@^92<CW"B@#YW\1>!/B-X.\5ZIX@T2VU2ZFU!;^=X8[JV,4;K]@LK,M%
ME?-(M8KBYV8*B0E0 7*GJOBIX7OKW]GJS\)SZGK4FH>*KJ'1I9IUADNVBN)L
MW*G(D3$=KYYP2QVQ %R<D^O$9_E6;)X2L9?$JZNT*MJ"0_9UE9F;8F2<!<[0
M?F(+ 9(.,XXH \*^T?%>^\77UU=:+XHM+"ZN(K-C;W]D^VV.H7I9XH?.PKBV
MAL4\S",!>R2'YH]J6_$6B_$;5=$\4K:V^O&%K;3]*TD275NNH!&N5AOGD1G:
MUF/DQ_:5G^1RMR\6%9!CWKRU_NTNP8Z4 > >/?!WQ4N-=U2[TC5_%%GI=Q?-
M'!I=FVF 6ULUW86J>4SID*+>&]NCEPRBY50=X"K5\=:-\1'?4M4M?#>I:EJ5
MKK6L:MI:2M8E(3!;?8]-# 2)YD+B22X56'F!@%;&-Y^BB,BDV#TH \VO8_$_
MA?X+W$6GS:YJ7B&\EF%K<WEM%-+;-/,[1M)$L@_<1[U7 9G5 "02&QY[X[\4
M^,?A]JFI7]U8ZFMC9:3IMLH-[:3R6EO%'-<ZM=1W+;9F7_CV@=Y!PT:O&"[;
M!]%[!Z=*Y[7?A1H/B;Q/'K%]I\=QJ$=O]DWL[A9(=Q<1R(&"2*&)(#@X)..M
M 'AMMI7Q@\,Z3H]];R>(]8DLK"!IM,-U:-%J$T.DW<\CM)+^^43ZA/;6X0N2
M!:EB0AJ]H.@_$>\\0Z7<:E!XR@M[35M3U1D-]I\AD\NSAMK:%QO=5AG>2YF"
MIGRY !L"A&3Z$\M?[HHV+Z4 >!^ _#WQ6UKPOHMKX@NO%&GS6]]:17TOVG3D
MGO+2'2 9G=HMX5Y]09U;RRK*-I3:J@F[X,L_B)K5EX;DU2/7(;S5+RWU+78;
MJ2.VM[-! D<MK;R0S-(FR8"4!E9)MKH=H?</<=N:0( >E 'EOQ0_X2Z_\?0P
MVLEUHOAW2QIVIMJR3QK!MCN9)+^*9<EWW6T:1*I78/M+29+1KLS/#7AKQ5I/
M[(%Y_8\NL2^,->L;K5;<#[-'=VEY?.\^!O5(MT;S$_. ,J1D#&/5O$/A:Q\5
M6\4.H6ZW,,,JSB-R=I=<X) .&'/0Y'M5]5PN* /"-3\(^.+?Q/XKATRSUZWL
M=2U6QL]-1[NWAL8M+AM+8R+')!(+BW8R/>*),,0T:?*5*YW/VDO#?BOQIJNC
M:'I.E:A?>';QH7U6:VNX+=5QJ%CE7+2H[(+7[8Q158/\H/96]<*Y-&* /GFW
M\/\ Q*\5:3K&G^(=$\07&G7M[;(D$U_I[>;;SZU/)= [)!\D-@MM&H."4+?*
M[LX'2?LYZOXSUKQ/XHC\327JKHA6V6TN)87;[5-+/>/EHLJ52WGLHH^>%C8D
M98@>MZGIT.KZ=<6EPN^WNHVBD7)&Y6&",CGD$]*K^&_#-CX1TJ.QT^WCM;6/
M[L:#]23DD^Y.: /G[3X/C''H<FK2:'XE769+JVGET[^V+ Q7 BTB>5T4&9HX
MHY-0:.W*H5^5(W.Y=[MH7/PG\:^(_$-X-4D\0S6SS:#;%YI[%[>6VL8Q?2S!
M!EA-)>!X'!&U@Z'YD4>7] 44 ?/7A?1?BY/X=TQM1&OPZQX?L89W+7EF%U=S
MI<OG(VQV1IGOY54!U$4:6R,K#<0\^K>$OB!X*9K>.'QCXNCMO#%E9-?1ZC8Q
MSRWDT\@OIHR[QR"1(X8&VJ8T82 1LCAF'OU(5!H \$?3/B5;R7D=C;^*H8]!
ML(X]&,U]:73ZI+*LB23W3R2@/(HD63R2H17ME"R;&(?:\*:'XH^'/[/M]]BT
MG5(?$5[K=Q=RPS3QZA>6\%QJA+RJY=EE>*T?>@9CGRU4K_!7L6.:1UWKCI0!
M\Q?$7PMXH>TOH[SQ!KD&I:/HUQ96&'@FDCN=:U%[>R1I&B;]Y!"D<;.&)^<X
M;JS=)>>%?&6A^--2TZSLO$R^&Y+JRT.VO+#^S8KB'38M+D?S;=E*-&#>2"-M
MZ_+Y>4 1MR^M:3\+]%T75+>]@M#]JM7EDCDDGED8/)@.YW,=S%1M#')"_*"%
MXK?" =J /#++PW\1?&ES=?VA=^*-#.J:^+:X^RS6D<.G:9;7%Y*CPG<[,US$
MMM#(ZA7'GJ1@HQ7KO@Y/XH@2XN->TO53)K&H2RQ--<INT^U\I7B2>$S.L<B$
MFW)MRXE:(3-M\QL>C 8H Q0 "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O"_C&7?]IK0T63R]WAJ[W%4\QBOVF(D
M;>K9P.!SQGM@^Z5X5\9P\G[3?A^.%-\S>'K@A=^W=BZBP,Y^4D\ G@DX/&:]
M+*?X[_PR_)GE9S_N_P#V]'\T=-XJ"6/@IO,D-QI[N59I91L+*./FP=@;;D.,
M!2?0 U\^>-K:UM_B7!% 99%:5H7N'M\/;$R$G=EL9  "@[0W PW!KZ$UZZCT
MWP>TEE!)(S2*KB$!9"VT;2. '!_=@@D;@PZ$8KYU\6FUU;Q[;W"[H]/7S2T,
M;%5"+,Q95SAD5CM4D$%>,-R"WO9$FY2>MM3YS.Y*T5Z'<:%Y<O@R..W3_0XY
MB_S2Y;&-H&WJV2$+?=4D<;AFGW-HUW)\OR2(1G^%6F_C('))'<_,<G\DT?S'
M\*>;''+#%'=%X8(D.UI"&V[G/\(4@*0!Q&27R%(348U=?)E<0918R\A+,Z#C
M+'^Z< @'D[B0 *[*?QM^;.&;]Q>B/G/XUO)%J&JMN7<MZ06BDW9!W,3QGO\
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M4FTL>$_%6G>)U,<(D^U-9R%Q"<D;5?."PR1CH:\JM_V2?BAX'^*'Q0\>Z/\
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MWN)+/1[.&Q@:>0R2M'$BHI=CRS$*,GN<UJ4 YH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44A;%)YJT .HIJR;C3J "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 44
M44 %%%% !1110 4$XHK(\5^,;/PGIGVB[9QYCB**.-=\L\AZ(B]SW]  22 "
M0TFW9$RDHJ\M@\:>,M/\">'Y]4U*Y6VL[<#<V"S,S$*B(JY9W9B%55!9F8
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M ;XK6'5-+U0HJR*\9Q<P:CL#(5"SP JVQRW8:I_P3?L9/$6GPV>K&W\-V/\
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M0TA5N456=:?P8\3:UJ/B'QEI.JWQU:/P[JT-E;WS6RV[3![&VG=6" *=LDK
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M@=1\/2^.O&DFBW,ANV:))O$-U&[>3;0MRFG0#^#SL!I?XFB'S8\V,IUGCSQ
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MY6-3_><%B,_(O#5>B\')?:Q%J6IXNKJW*M;Q$[K>R8 @M&I_C^9AYA&[!(&
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M9&#L0@(Q8  #+?=YKYW\>30GXAV<*;HXB=AFFAR4#29<]0)&5A@,0<EF5MV
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MU."FNJ"BBBI+,_Q)J%IHVDW%[J$\-K86<+SW,TK;4AC52SLQ[ *"2?2OFO\
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M2S2,"-F4),X7YF4@_*Z%) #M"E"H(W8+-RWQGG8)=2M)&8\KM@<JC.Q&!^[
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MBB@ HH)Q1F@ HHS30^>S?E0 ZBDW<]_RI0<B@ HH)P* <B@ HHSS10 4444
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MD>C:I_PL?]H&[N+>3?I?@N)K%B).#?2X,BF-X@05CQB1'P0Q'/(KT'7M8M]
MTFXO+J:.WMK6-I99)&VHB@9))["J'@'P/8_#SPC8Z1IZO':V2;45G9^22S'+
M$GEB3C)QTKFOCCK=_<6VGZ%H\EU;ZEJTP7[1%:W3BVB!^9C)  (\],LZ9&<>
MVSM5JJ$?A6GR6[^>K^9SQYJ5)S?Q/7Y]%^2^1#^SG8RW/A>[UB>3SI-<NFN
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M QAE'U>1T5&E)M:,^-SNMSUDNQZEHQ^PZ):-<JTDRY>)?M!D,4.XA6RO2,D
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MOG+X!^(UTWXC>$8)HVM[JXOX44L2S,CRC*@G&W)VY4@Y..@Z^\_M%_'CQIX
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M)CY6)*@<O^V,0FU[25UYR_ID1X1DX4ZGLX*-1V3<J:U2O9WE[NG\UNG=#_\
MAC/X= [O['O">F3JUV<?^1*=%^R#X0MY,V;>(;&,?\L;?6;E8PV>6P6/)KK/
MA#\2H?B_\+?#OBB&SFT^+Q#80W\<$I#/")$#;<CAL9X8<$8(X-=)&[;=PX6M
M8YEBFKJI+[V>56RFA2J2I5*:4HMIZ+1K1H\O'[(WAM2NW4O%X*>FNW'/_CU9
M^O\ [*^GK-;BQUCQ9'N<M*'UN<A^1COGCTZ=J]D+*F[^]7*_$K7FTR&",-,B
MS!P3 -TK< 851]<[CA5QD^E;4<PQ;FDIO[SEQ& PL:;DXI>AYI;_ +,4*7(A
MA\2>*FVYRIUJ9U_/@^A^HVDYYJ5/V;<7#1IXF\6^8N<Q#7I3_"".3R!DY]>Q
M)R"-2P\4+IVBF*&3,D3$'R)E9G;DE03A$1 V"Y.W@8))^5L'C 6.@2?9[@PJ
MWS-<K)N:0+UD9RN% R,;LLVW@E=I/?\ 6,6_M?@>6J.%71_>S-/[-OVB3:OB
M;QBMPIR8AX@E*G@GDXR/R]CUR)E_9MW2['\1>,'DW@F,:[*%VY/&<9&1^1'7
M'-7X?%<>F::+J&5K&U=E)*R [!G ^;:/F<XPN"V,EO[E31^+6TR.*Z9F1GPP
MC$JA6;:"(]^,,26!)4,HP?F YJ)8C%/9_@5&EA>J?WE!OV;(DDP-=\7?:&P2
MO]N2E%.>QQQG]/<5%<_LU6PG\C_A(/& W<G&O3\=!C/4 _7(SGVK<B\1?V=J
M4;23;I)"41F8Q^:=W+[2 6V@#+$9;>0I P#%IOBI8+J;$QEDDB9P)&VE!G?O
M:-<N,X"\_O#QVR5E8C%])%^QPM[6_$RG_9HM4G6+_A(?%BOCA!K<K9&>^>?4
M'\Q4$O[+>G7#M')JWBA;AN1LUJ=MO7KSG)) Z\CITK>TCQ9MOKJ8.TTDG,S,
MWF/"V0!'Y:#AFZ[22%W<[>-T&E^+-MO=2Q2-)(N[SG2X\PASRV6^55QR"Y)
MP0IR#MKZSC%]MD^QPCWC^)C-^REH[_NVU+Q LS#"HNMW$@ [Y);/'7\>QYIU
MS^REH)"K->:^DS99%37+EE/3.<MDXXZXSG'7FM>R\2K)I;2+=3K&P>)KL7!8
M.N<>>93@*N<X'+L0NT;3DLO/%L1L1=+<-;N%#RR&8Y/H?, ^8G VHHXYW8/
M(XC&)_&Q^RP=K\B^\R[O]E30(613=ZRLT@(4#6KEMI]<%_0?3D\=ZM7/[*WA
MV$K#-=:M'YN[8%UFY#,>3]TN<X_ 8ZYZU>D\8-'=1W&]X958#RC-M,C, ,9S
M^\91G+$[!M !)^:I$\>*VIPR?:(YI65@D?G.D>!_&4QDQKQ\[#+$':.1A/$8
M[^=A&C@KWY%_P"G-^RSX;C=8_/UA&Y8*FM7.X@#K@L?KV_&BX_93\.R']]<Z
MXN2H4+K-Q_+<?K@#KZUHV'BY;G6II%N?,N/+7>KR9\D#(5WA3H2<;4+9P,G!
M)-/L?&7F37G[Z2ZEWKRDZRR1'[H0#_5JYY+9;:ISUQ@0\3C;?&S14<%MR(S)
M_P!E?P[E9))]<6:0@#;K-SEO7JW3J>.],?\ 96\/VR+NO->#DYYUJXR>PZMW
M![=#ZUK6GBZ*ZA;_ $A9&W;EG2XWJR@[CM=N$C&0"S'GMDD4G_"81WUEY9N7
MC6.-<7 F8&1!UD9R 5S@[4!+,<\<&CZSC?YW^(>RP=O@1D3_ +*/AFS7=]JU
MY=W"EM;N<DG&/X_S_P BI%_97\/0J5DN->97&!G6+D,W3MOZ]CC]*T+OQZEY
M:I<R%K5;=TD"><R[E!R%SP7D;@E , '+'I3KWQQ]HN;>XFD_>9(6VBG*"9L#
M]V!]Z098EF("C '7.3ZQCOYV'L\"M5%&</V4_#L2QDW.O>6A'WM:N<MSW&_'
M?I@?A3O^&5/#-O:_/+K:[0%!_MJZR0.Q._W^I]JU[[QI$FMQLT_F,<B)&E*+
M]X@OY?4QK_>8?,3\N,#*#QG')J6Z2:2?SA@J[L/)4\EO+3.#D[0IP^ <\<B?
MK&->O/+\2O8X&^D$:/PR^"^E?#75[B\L)-2:2XB\D_:;^6X&W<#]UR0#P.1S
MU]37;9KC? GB1K_Q-?6K3-,53S6!GW&#YL!"H&T,1R0I..A[9Z0W:M<.&;A3
M@;7& /<?7/6O/Q#J2G>H[ON>IA5"-.U-60R]F5@9F2-C"V$+C=M/3CGJ<_K4
MXE,<&Z2.,,P^8@X4U5U<C^SF7[SK\X;'\0Y'ZCMZ4RXU:"TL;5IV7;OVDD\<
M9&3_ #K'E-.;74LO>>1;>4S?OAA03_$2.O\ /\156T5=0FF9?WD,+>3LQM\P
MK]X^^#QZ?*?6JEUX@-[=;;=5\S^ G)VXX!([\GGTRO<\:=B/[)MH;=1YDBJ6
M;)P6ZDXXY.:;C9"YDWH7+:+RH54]NW7%>>>-?!VJ>$/%G_"1>&8A)-?31IJ5
MF?NW>6AA1N/NK$C32''<D]S7;I<7$TV[:=O 4#H#SD'Z<<_7TYO%-\?H<4Z=
M1P=U]W?^O^#N%2FIJWW/L9/@KQII_CSP]:ZCI\WFP7,22A6&V1 PR R_PD@@
MX-5?B#\,='^).E^3JEOO>%)!;W,1\NXLRZ[6:*0<HQ'&17.^,_A%>::]UJ?@
M^[72M5:,L+? 6UF,=G/#;H5' 4/)&Q[?)TS4-K\>#X6>6#QAILVAR(+R07"J
MTEJT4!A);=UR4FW< C$4AR-N*VC3;ES8=Z]NJ_S^1A[16Y,0O\G_ )?,S)/^
M$A\+:_=:3H?CK1]2ND%P\.G:W"#) =L1BA$L>&*QH&8EMSD."<CFK]UKWQ#N
M[&[DM?\ A (T62X$%P]W.\83,?V?=C'S,#+N&<#Y,9Y!QM:\'Q^)]:\07%CX
MKT%A=Q:C'Y3#8WGF'R091N*@P"1%\Y$$AC9%8L""S=0^"]YJWPSC\.W3^'["
MU%\DU^[3"Y26VAAP<JD4&2)!'D,?E')<\+79[CLYVOUNOO?2YQOVFO)>VMK/
M[M[V-U_ &K>/K^\M-<\8R-;V\SB73M&46AA5FCE@$D@)D5U Z@@,&''7/=>&
M?"^F^$-+%CI=C:Z?9J[2"&",(@9B69L#N223]:\OTQ#X(\0V]Q>>,]-34Y[:
MVTG4(+>!9I]3G@\UX2"S?NYYH7Y0J2V $/ -:B?%O5/B$3;^%])OD@Y$E[=(
M;<HNX*3&'1E\Z-L[H)Q&Q'()'-<]:%25DG[OI9?DO.SWL=%&<(:R7O?>_P!?
MFM#J/B+\1[7P/I<F,W%_(A^SVR03SEF_A+K!'(ZH3QNV$=NM87PH^%/]DZK<
M^)=8AAN/$FI<O,QCN&MTZ!8Y?(AEVE<#:P.W&/7,_@'X(V_A[5FU;6+H^(-<
M9RZ7EU#N^S\MCR?,+O%PQ!"N%YX4#BNZ"[!6,JD81Y*3WW?Z+K8VC3E4?/57
MHM_F^EP ^0CIZ5E:@@TR-;J3,<<3!70?,K!B%+?7H<^@/K4]_)<1S;E!VAAN
M)^ZJX(X]><9]!G\7S-_:=HT,L>P3(00?FV_7M6,=#H>NPVTNB(6A9MTRO@ '
MYB.H/^?3UI8Y)%CC"Q+(4XW%A@8_7/X5@VVL3:5=*D\;-*@4!F8_O "1U/4X
M_4<]0:U;/6[>Z-S);LC!4##!^\>3TQ[CGV/I3E%[HSC43W&VEZSR2S,L+21L
M$=XE(#\9QUR>O!]?K6NK[HL^U8WAQ/W-PK?>N&+].@/08]0-HSWQVZ5:0_85
MBC$C2>7M0DD 'IV]ASQZTI)7L5!Z)LY;XO?"33_BH+%+RYU*!K/S#$+2\>WW
M;PH.XJ>1P.>HSD<UPTG[)FCQ+)$-8\51RMC[NO7#<9QR"3@<COR.PQ7IOQ U
MLZ)8+)'YC3,&6(1#YRV,_>/RH, C<W3-<?:^)H9].F:.\D\MBZM<QS>8H&!O
MF9\ (N?4[C@!>#N/I87$8F-.U.32/+QE/#2J_O(W?J<_/^R=I9DVG6/%4<T@
MSY<>O7#J%Z=SGOCKSU !'#KK]E6QM RIKWBRUFF1@737YV"CY2.OT/<9 Z Y
MK6/CM;O3FN?M4EJBIF282-]TDKO\P@?,0IVQJ"Q.-RY!%377B[#&^9FA=75]
MHGV[W8#:F>DC<@X&40 9/)8=GUC&=9,X_8X/=1_X8P=0_96MHI51O$7C*+SB
M6^7Q#,Q4C.  >O;OSSP*KWO[*&FVTB0W&M>*E#JRHH\0SEG'7.WKD$9!X]#V
M-=5/XQ UR":65FVRF*-5F\OS>,?[SA=N6<X7/ RPP:+^)X[C69+JZF\XJK,L
M3R%$6,<AC&!O$?0+N^9L,VW!RKCBL9UDQ2HX1+;KW.=G_8_T19/]+U'Q$K..
M FOW!,@P1DC.1D<\#&>#N'-2WG[(>BP)#YUYKGF.0J[=<N=TA]\O^/'0\<YK
M7LO&Z_VQ<3&::23:K&.60--$%#!5,*_*';(PK'"9!8!@-RZ=XYAFOIVCO/.$
M<BCSA=^;O !Q&K'Y44;AO<G9PY4'!VKZQC5]MD^QP;^ROO,B[_9)T*S,(FU#
M7"9F"*@URZ4RX).6!D/7C..A]13;O]DC0=+C5Y-4UJ/S" &;7;E&=CG:2"V.
M?08P>F1Q6K;^,H=4LS-]LA7R58BZ^TL/.16(+%W^Y&ISM&26)!X!!:5/&BZD
MEM))</:I'$FQ?M#!IE!XRV<M(^.$&0-Q+$XP*^L8U;S8O98/I'TU,:\_9*TB
MS^S>9JGB"'# (1KMRLDIZ?=W')Z?=[\YQQ2#]DZRL;15;6->C7( F.N7"N_?
M&TD^N,*1P,[N2*V]0\9PZEJ%I,TS+-;L&^S+<;/M##<3$ISE]S9+,/W> <Y%
M/F\;QZAK$3R7#3.)?+6/[08U8L_.Q?O-$O4L<;B%"_W2?6,;LYL;HX.]U'\3
M!;]EV&UM/.FUSQ9'"GW6_P"$@N Y.>-R]@1P0.>,Y'0+_P ,NP1Z;+-)KWBQ
ML*PC8>(+AF+$\''?C QC)&?NGBM>;QLNH:XOF733+-" L9E*QV^,L\@C0%N,
M !20[ ?+QE@DWBV.]U:2V,S2,WSQ$RF3[( ^T;43)WL3RH((5/FQG)KZQC-G
M+S%[/";I>6YF2?LSSZ=ITDFG^*?&UK&Q+.\6ORM@XSDJ5^;'08QD'KGK%/\
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M*[D][+\CZ;+:?)AE%+2[U^82WL_V2X/&YU)'4(QQW;)P/<C'N.M<["VM7UQ
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M2D[R=S2-.,5:*L &T4445)0CJ'7# $>AK'UF*6UBVV[R/)@81"2S#L#@$CN
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MV>517S'N)!..-Q *MD\0V?A7Q%<Q7)6YBFMU0;[5[<;F"$@;%=<F,95BJ,K
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M2K5%LD'LX6W9Q#^$_$0\V.>2W5KF(JLD<6X?P@JVV,..2N4=2VPKNW8VDN_
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M!_S[?W/_ ##ZGGG\Z^__ (!PL'_!0_6XI8]VE^'3O49VRR8 YYSN]OUIZ?\
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M3M\!1X(G\29YQ_IR\ ]ON4UO^"<W@!BO^D>)/E.1_IB>_P#TS]_T%']LY/\
MRR^[_@C_ +&S/O'[_P#@#?V2_C0?B3XPU&T\B")8[+SPR3^9N(=5Z8'KU]3S
M7N5];[V^5=V]"I!QM/(QG]?UK@?@W^RYX;^!WB.ZU317U1KB[MS:N+JX$BA-
MP?@!1SE1WZ5Z37R>:5Z%7$.>&34=-_0^HRO#UJ6'5.O\6NQDG1OMNY9-P\L
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M0CXJ8X*Y:\A)[_\ 3'WJM<_\$P? [9,.L>*HFZ\W,#@'U_U5/_6'*_[WW?\
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex4i_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4i_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" /U Q$# 2(  A$! Q$!_\0
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M+I((G. Y6OHWPW\/M%\&7&FKI6EV.GQZ;IO]G6:6T"Q):VR-&5A15  3(&
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M]N\LAEU*[U&$-<L'!G6%,,J@J7D:0DCS?EZ3Q=\?_B!X*\:GP']N\/:AKO\
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M:E936M[?:A%=:9K-]IMW')>RF:Z N+>9)0DLA#M'N\O*J=HVKC4\%?!'PO\
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MK=5"J < "MZP\/VNE7MY<6UK:PW&I2"6[ECC"R7;JBQAY"!\[!$103R%51T
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MBUX"N==TN;POX;_X1WX?:5XNO;:[TV6YBU:[O+>YE>(,9XS#:I]FVAOF<LS
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M]?7FG44 -5<'I3N@HHH 0#F@CBEHH :JX;I3J** #&**** #K1THHH ****
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M% #Z,TSSU)Q_*D\P9Q\W]: ),T5&LBYZM^-.:55'^ H =133*H%"S*Q_Q&*
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MAI/Q^DNM3DM_[%U2XDADFN& L(?[#L9 RDG]VF[S&XP,[CWS7MK#<*X[Q?\
M #P9X_\ $":IK?A?1=4U#"*\\]LK-,$.460=)%4DE5?(4YQB@#PWP+XV\0>
M/%VG^*[_ %/5+KP[8^%_#]EXEL;J5V6QCFBF8ZD W22*7:)R=N8&D=LF%0?.
M]7^(/B _LUW5TFO:T]T?@5::AYL5_()&NV=P9E=6R)6Z>8/F/'-?:TOA33[F
MXOI)+&UD;5(EAO"T2G[5&H8*C]F4!V&#D?,:Q8?@;X1AT#^R5\,Z(-+72TT0
M6OV1/*%BGW+;;C'E+DX7H,GB@#G?@7X'F\*76IS3>'-4\/M)Y<2F\\4SZU]H
M7+$E1+(XCP<#C!;('10*\IO[QO%'PC\9>/=:E\=W6LZ7K6MVK/H&N169\*V]
MC<7,43+#+=0VS!(X$D;>',C2992C87Z@$'R;>FX8-<=XF_9Y\%^,?$,VJ:IX
M=T^\O+LHUWO!\J^* !#/'GRYBH4 &16P ,8P* / /C+\0M6\5IXKFT^;6Y[?
M4'\!/:6,&I-IL\J7>ID31*R/^Y,R-Y;E6&1D;B!7J&@_!NRU3X?:Q'JVC^+/
M#C+(9T0^-K^[F?RX6"R+*EQN1?F8; 0"5!()"D=\_P '?#+AMVAZ>0QL21Y?
M4V,@DM/^_+@,GH:W[JR6]ADCF421RJ492?E93P1CZ<4 >4?L4Z48_P!EWP#K
M$UYJVH:MXC\,:5J.H7-_J=Q>-/</9QN[@RNVP%F)(0*O/2OFWPK\8?&,W[#$
M?A&3Q1KS>--7TF#5[/76N&;45TN?3#JDMUO+;ALFBN[%6+<,D6<9 K[@\.^&
M+'PGX<L=)TVUBLM-TRVCM+2VB&$MXD4(B*.RA0 ![5S5G^SOX*T^.U6'PUI<
M?V#03X8MB(_FATPA0;0-U\O"KQGM0!\Z>,?%WBSQ9#XKTW3_ !9K.@W4VO\
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MNKG+G0O$DHC":]9QE4 8G3-V]NY_UO';BF3:'XF:0,NO6:)@#;_9@/.T#/\
MK>,MD_CCMF@#IMZ@=>/6EW5RTO\ :MOK4,+>(M/62X+-#:M8J)IE7!;'[S)P
MK#.!QE3QWP_!'Q)LOB+>NN@?$+PKXB$*"=X=.6&Z98F.$;]W,WRD@@-C!((Z
MTNH'HNZDWCUKG(+#Q!$9&DUVQD4(ZC_B6XVL0=K9$O13@D<9'IU%.)M9AG:W
MF\5:0]Q,WV6*,:<$<3[!+MP9CEO*!;9UV_-T%.X'7[Q1O%<TVC>)?(D7^W=/
M\PD;6_LG@#/((\[G/U%']D>*%LRO]N:3YWF ASI+;0H!XV^?U)(.<CIC ZT
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M_P ?ZI_:'BWXIQ_9_&6I:=#;Z?X8MVT9;:WOY88HVN?L;G9L0!Y#+GK\PY-
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M%4EB=JL07*E5#,0I?,!W"\'^E.KR_P )_M:>!_$'A_7-8N/$GAG2=#T76Y]
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MMWN;!;JW2-;J;!\OS':++K;LV/,4Y<[V/NC D4!3GFG8:T #YJ=110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**"<"C=0 449I-PH 6BD# T!LT +12;LT;AC^M "T4;J0,#0 M%)N%!8+UH
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MB?P7JTBKM\6:]&5C5#M@LCO(&"YS;]3U(&!GH *Z:B@#FI_!^K3/O7Q3K</
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M*** "C%%% !WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*P3'(*\5]9^(/#T/B3P_>:=<&X2&^@>V=H)W@E164J2DB,KHP!R&0A@<$$$
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MHT3Q+8>(FNUL;ZRO6L;AK2Y%O.LOV>9<;HGVD[7&1E3@C/2@"]1110 4444
M%%%&<4 %%&[FB@ HHHH **** "BBB@ HHHH **"<5'-.L6-S*NX[1DXR?3ZT
M 244T2 CJ*=F@ HHHH **** "BBB@ HJ&\OH[&%I))(XXXP69W;:J@#))/;
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MZY92&+>6BAL$;@SY(Z'Z.UB[DN9$TC32MK)L!EGCQ_H,70%!C'F'&$!XP"S
MA=K>0^%M#N/B7^U3KOCH1K+;^';!_"GAD2(6ABQ+OU"_(R/O3*MLH&"_V20
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M#5A:QL)?%TT6[[5J+1CYGC'ER1PH>"%:1@A7@B!]/3'_ $N/TV-_-:F+Y_\
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M/]G3X&Z-^S?\(M'\(Z'ODM=+B_?W,O,]_<-\TUQ*>29))"S-D\$X'  KQ_\
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M8K)X)&NS81(SSW@((V*&\M$C*LTCS1*N&<*'>#/VE9/%O[2NM>";>WMIM/\
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M-XKU#7/BMX?L[+4(K+19K2^O&3RU>76/),$8V%CE(0UQOW+EG*+R$^^[W ]
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MK'Q1XWTGQ$TMU9:SH=O=6=K<VS)N^SW/E&6,AT88)@B/ !!3@@$@]9FDW9H
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M4!<N)IXOF;D_*".O2L]_BEK(M6D'P[\9[U8 1^?I6]LY)(/VS&!@9!/5EQD
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M.<^*>@ZMXE^%OB+3M#NX]/UR^TRXM]/NI<[;:Y>-A'(=O/RN5.1R,5X;X_\
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MC[7.L%N8Q+$I=7D(7<N5&X$D @G2?XY>%(I_$$+:Q#YGA6]MM/U11'(3:SW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!'&X8IGE?G[&I**  #%%%% !1110 4444 %%%% !1110 4444 (PR*:
MT>[M^M/HH C2/8W\_?\ SZU)110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !FN?\7_%#0_ 4EK'K&H0V,E\':W1E9FE";0Y 4$X7>N3VW#UK?;[M<IJ
M0Q\:M!'?^Q-2./\ MO8?Y]Z *D7[1'@J0G/B"PB]Y0\8_-E%/'[0G@=T)_X2
MG0\#J3<J*[+;BE*YH XZ+X_^"9!\GBK03_V^(/ZT^/X\^")MV/%WAMMIP?\
MB8Q<?^/5UI2@)BEJ&IR__"\/!:C_ )&[PO\ CJL'_P 73?\ A>?@P_\ ,W>%
M?_!M!_\ %UU>.>WY4M*S Y(?'CP3NY\8>%1V_P"0O;__ !=#_'?P2A;=XP\*
MC8/F!U:W^7Z_/76;>: *=@.23X]>!V&1XP\*8ZY_M>W_ /BZC/[0O@3/_(Z^
M$?\ P<VW_P 778;?\YIV*8'%S?M'?#ZU3=+XZ\&QJ.I;6[8 ?^/U"O[3_P -
M2V/^%A>!O_!]:_\ Q==UCFB@#A9/VGOAM&N?^%A>!_QUZU_^+IJ_M/\ PV=?
M^2A>!O\ P?6O_P 77>8I#P* .";]I7X<RW4;)X_\$L-K#C7;7U7_ &ZLC]I#
MX>$C;X\\%MGL-;MO_BZZV1MMTB_[#?GE:GQQ0!QJ_M$^ 6_YGCP;_P"#JV_^
M+J6W^/?@>[CW0^,O"<JCJ4U>W('_ (_76D<4;<T <M_PN_P:1_R-GA?_ ,&L
M'_Q5._X75X/*Y_X2SPS_ .#2#_XJNG(S2>6/2@#FD^,_A!V 'BSPTV>PU.#G
M_P >I7^,OA%%^;Q5X;'UU.#_ .*KHVA5A@JI'TIALH\<QQ'_ ( * .?'QF\(
MG_F:O#?_ (,X/_BJ4?&3PD>GBGPV?IJ</_Q5;,VCVUR?GM[5_9H@:C/AJP&?
M]!LN>N8%Y_2EJ!GI\4_#;C(\0Z$P]1J$7_Q521?$SP]/(JQZ[HLC,P4!;Z)B
M2> ,!NI/&*D/@/16?=_9&E[O7[)'S^E<C\>O 6AP? WQI(FCZ7&RZ%>MO2S0
M.I$#X(( .1UXQ3 ]%#AJ6FK][TIU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 !KC;Z8M\?=%CP>/#^H-N^MS9
M#^E=E7%W@Q^T#I;,WW?#UZ,?6YM?\!0!VE%-,J^OY4"04 .HIOF+G%'F+ZT
M.HHW<49Q0 44@;-+NS0 44FZE!S0 449Q1GB@ H/2BDSD4 0S#-W'_NM_-:G
MJO,<7B?[K?S6K"GB@ HHS10 4449XH ** <T9H ,4444 %<C\?SCX#^-O^P#
M??\ I/)779KC_P!H9]GP$\;_ /8 O^@_Z=Y* .PSS135;WY__73MU !1110
M449HH **** "BC-&: "BC-&: "BC-&: "BC/- .: "BC-&<T %%&:* "BC-&
M: "BC-% !103B@'- !111G% !11G-!.* "BBDW9H 6BC-&: "BBC- !1110
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MG[C/_I;7644 <C+I/CL'Y-?\)'_>T&X'_MY36TKQZR'_ (GWA$'_ + 5Q_\
M)E=A10!R*:7X\'WM<\)'W&B7 _\ ;NHQI7C[(_XG?A#'?_B2W.>G_7W7944
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!^W'4>)K@_\ MA0+F.TS1FN)_MOXA&1?^*9\'[<<G_A)[G/Y?V?3CK'CX_\
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M2Y0/,?B1\+-2^)/C30+BVF72;.#1=0M+IYK.VO"AG>S*Q>7(&7)6*7D;E!4
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M-?#.M-9Z;_HWCG6]5O/)M8H;P6ER^IF&1[D,6D0^?;DQ@9Y4'[A%?013<?F
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MB?JGO_IMI_\ ':ZBB@#ESXSUS;_R)^J?^!MI_P#':3_A-==_Z$W5O_ VS_\
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MIVJ3CH":ZE PVYX]0.:?13&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M/4[F36/$6I,Y9M3U.<AKB;) .W.$4$#"1H.U5<6IZ912;QZ]\4GF"@8ZBD#
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M,UP-]X(U+28RUU\3O%L$?7S)H=(10,@=39 =P/QI8/AWK&H1J\'Q.\921O\
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MP!/_ /)E(VC^-"?^0_X7_P#!!/\ _)E '4YHS7(OHGC@GY?$7A,?7PY<$_\
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MPQMQP!KL_P#\ATO]J^,#_P P'PSQ_P!1Z?\ ^0Z .JHS7*G5/&6?^0#X9_\
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M \S\)>/--_:'_:FO->MK^'Q%X7^%\DMIIDUG&K)J6N3QX:.W^9@XM+60*[Y
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M34-4\'F:72%EG8V]I-( K3B+[C2@ !78$KU7!YKKOLJ@=^NX#/>@#Y=^$'Q
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M<2!(W;  &_U?P7\$M)\#W>I26JSM#J>K7&MS1,PQ)=S2;VE<XS(1P$#$A%1
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M\X(/=>&OV?8O"_\ PEEE'?L-&\7:M<ZS>100>3=22W 42(\X8[E^7 VHAV!
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MO[.,:UXRU.[C,D&@:6OW8U 90+J=L!-Y(1<NRL",>WP'>BMUXSGZUX9^RO\
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M>ZU/26FL1I^E^'E,FEZ=D-LF92K7$I!*EPK.JC)_UCNQ9F&SN ,44 ,CC\L
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MV7HV^*]]K?[1WQ(L[;2UUNTEM/"6G7<2[=#T%"T@F^8<S70!F9SC$>WD(2H
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M>O%FG_;?$?CN6&Q\/:9(QBD6T+-_9VCVB;2YGG9C+(0HV^9EQNB=%]P_:_\
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M$K'FOQ%_9VTWQ9K7A/5+.UTN.[\(W[WMO;W5L)+>??:R6VQAU78D@*%>%*
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MM:UX7\7Z%K>CZCH]OX<OH[.VN+>739-UO';@QJ+:*WE&?*B#K^]<QN[*%VH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%&ZDW"@!:*"<4FX4 +11NH#9H **** "BBB@ HHHH ***,T %%&<T4 %%%%
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M)Z/-J&J7UGIMA;@&:YNYEAAB!(4;G8@#)( R>215Q) X4J<AAD>XH =1110
MC_=K"\1^-3X;EA7^R=8U+SE+;K&W\T)@XP>16\>13<_-0!R,_P 6_LT>]O#'
MB['3"Z?N/Y!B:C7XSQ, Q\,>,ESZZ0]=EGG_  I: .,/QJAVG_BF_&?_ ()9
M?\*C;XY6JGYO#?C;_P $,Y_DM=N>#1GF@#B'^.MBK[?[!\;9]O#EX?U"4#XZ
MZ?Y98Z'XVX[?\(U?9_\ 1==OC-&V@#BA\<=.=,_V-XT'&<?\(U?9_P#1520_
M&[2GQNTWQA&S=F\+ZCQ^(@(KL,&G8H Y,?&726?;]A\5[O?PQJ6/S\BGGXOZ
M5C_CT\4?^$UJ/_QBNHVXH^[0!RC?&'25&?L?BC_PF-2_^,4G_"Y=(S_QY^*O
M_"7U/_Y'KJ]U*"#0!RG_  N/20,_8_%/_A,:G_\ &*</C#I1&?L?BC_PF=2_
M^,5U6*3% ''R?&#26ND_T7Q1]P\?\(SJ7M_TPIX^-&CJA/V3Q2 O!_XIC4__
M (Q733G%VG/\#?S6I@V: ./D^.FAHI_T;Q5_X2^I_P#R/4?_  O[P[&<,GB-
M>^#X;U(?S@KM <T8.: .-;X_^&PN?^)_^/A[4/\ XQ2CX]^'/^>FLCZZ%?#_
M -HUV=(!_DT <>/CMX=(_P!=J@'^UH]ZO\XJEC^-WAQV*_:[O(Y.=.N1_P"T
MZZMER*-M '*-\;_#:G_C\NNF?^0?<_\ QN@?&OPXR!OMTVUC@$V-P/\ V2NK
MQBDS0!S0^,/AXG'V]L_]>LW_ ,12-\8?#P;;]N;/_7K-_P#$5TPI0* .9'Q>
M\/\ F%?MWS#_ *=Y?_B:)/C%X=A'SZDJ_6"7_P")KIS28]J .5'QO\+'/_$V
MB&TX.8I/_B:%^-_A5C_R&(?QCD_^)KJN]!X'K4Z@<I)\<_"<2,S:W:HJ]2RL
M /TJ(?'_ ,&XY\1:=C_>/^%=?G'MGBEQS0K@<8_[0/@M/O>)-+7ZR8_I0/VA
M? [_ '?$VDG_ +:UVF*;MXIZ@<>?CYX*8;O^$JT%1_M7B+_,TG_#0'@?OXN\
M._\ @='_ (UV6VEQ3 XW_AH#P+G_ )'#PW_X,(O\:='\>O \K,%\8>&\KUSJ
M,0_]FKL,44 <F?C?X+ S_P )=X9_\&</_P 53A\;/!A&?^$N\,X_["D'_P 5
M75;N:.M '*_\+L\&8_Y&[PS_ .#6#_XJG)\:?!__ $-?AG_P:0?_ !5=133Q
M0!S+?&SP>O\ S-?AG_P:0?\ Q5'_  NOP>3@>*_#.?\ L*0?_%5TV<GK2D&@
M#F?^%U>#]V/^$J\,_P#@T@_^*I/^%T^$3_S-7AG_ ,&D'_Q5=,85/I]<4T6R
MKT"_E0!S8^-7@_/_ "-GAG_P:0?_ !5._P"%T>$,_P#(U>&_;_B:0?\ Q5=
M;:*0?=1O^ TV3389%PT,3#T,8- &(?C!X3'_ #-'AW_P90__ !5(?C%X2'_,
MT>'?_!E!_P#%5M?V+:GK;6Y^L0I&T*S<8-I:GZQ+0!BGXR>$<?\ (T^'!_W$
MX/\ XJI4^*?AJ159?$>@LK="+^+G_P >K2;P[8X_X\[/_OPO^%1_\(KIIZZ?
MI_'_ $[)_A0!3'Q0\-G_ )F#0\'H?M\7/_CU.7XE>'G.T:]HK?2^B_\ BJL_
M\(CI;C_D':?M[#[,F!^E(W@W2L?\@S3?_ 5/\* (X/'^B74NV/6=)D;'1;R-
MC^AJP/%6FD_\A+3_ /P(7_&H?^$+T=Q@Z7I;=O\ CU3_  H/@313_P PC2__
M  $C_P * +!\3::/^8A8_P#?]?\ &D/BC3?^@A8_^!"?XU!_P@FC'_F$Z6<=
M,VD?'Z4#P)HO_0'TK_P#C_PH L?\)1IN?^0A8_\ ?]?\:#XETX#_ )"%E_W_
M %_QJJW@'1&ZZ/I/_@''_A0W@'0Y5VMH^DL!S@V<9_I0!:_X273<?\A"R_[_
M *_XTY?$%@_2]LS])E_QJB?ASX?9=IT/1RO<?8H\?RJ&3X5^&9!\WAW06SV:
MPB.?_': -8:[8G_E\M?^_J_XT#6;,_\ +U;'Z2C_ !K%?X0^$IAM;PSX=;/K
MIL)_]EJ-O@KX1(V_\(MX:V^ATN#_ .)H WAK-HS[5NK8MZ>:,T[^U;;=C[3;
M_P#?P5SG_"B_!9.X^#_"Y;U_LFWS_P"@TUO@+X'?[W@WPJWUTFW_ /B*6H'3
MKJ$#_=FB;Z,*<+R(_P#+2/\ [ZKE1\ _ X/_ ")OA3Z?V1;_ /Q%(WP!\#L.
M?!?A(_\ <'M__B*%?J!UJR*R[@P*GH?6G5R(^ G@=55?^$-\)[5[#2+?'_H-
M.'P(\$]_!_A7_P %%O\ _$TP.LS0#FN3_P"%#^!\_P#(F^$__!1;_P#Q%'_"
MB?!(^[X/\*C_ +A-O_\ $4 =917*?\*+\%_]"CX6_P#!3;__ !%*WP,\%XY\
M(^%__!3;_P#Q%3=@=51FN57X%^"UZ>$?"_\ X*8/_B:#\#_!8'/A'PM_X*8/
M_B:>H'59Q1FN3_X4AX*ZKX1\+>G_ "";?_XFFR? [P23\W@_PNQ]M*@_^)I7
M8'7;L"FR?-'WKS:?P1\*XKE83IO@2.>1S&B*MM&S/_=P /F]L$UUO@[X>Z'X
M'69]%TK3]+6[ ,OV6!8_.VYVYQUQN./K1Z@<SX GA^&>KZMH=\L=F-0U>[U*
MPN9,1PW_ -IE>X9 W3S4=W7:?F*JK $9*ZFLP:]KEM+#?3:9X=LVRKSVET]Q
M<.I!&$=TC6%O1L2'!.-I :NFN[*&^A:&:*.:&3&Y)%#*V,<8/'85FVGP\T"Q
MF>2WT71X9)&WNT5E$K.W4$_+^M%K <=K.E_V_!I8\%1V5C<:3$+2TU62V\RP
MMK7"@PJH*F="43"QL%#(K;U*[6Y;]HCXL6O[-'[+OCK7-7TZZA_L_2IVEO)+
ME)X=0NY5$4.Z8;7S)+)&F6C4+G"J$5:]R2+9G]#FJ7B'POI_BW3S:ZII]CJ5
MH6#F"[@2:,D'(.ULC(IVN!X!_P $_OAGK'P[^!-KJ6I:>[^-OB)=GQ5XHO[J
M$V\?VF[/FF$1G#DPQLL80 *&5SN&><7]DKPI=>+?B+XH^,FOB;4_%'C.>72_
M"MC*=K:5HD$S1HYX_="=U,SMSA?+50S$J_U,%91CKZ53L/#EII#3?8[:VM?M
M#M)+Y42IYC$DEFVXRQ)//YY-%M+ ?-?[)/@.XU;QKXJ^,.O0R:EXR\>3/9>'
MX+D>6=,T&"0QP9'S"%9BGVA\%AAHU4%@0:G[&^G:E%H'B+XP>/KBX\5?$/Q+
MJ>HZ5I=M%%LFL[*TNYH(M/LX&;;#O>%I'PP&"IE<E'D/U#I_A^UT<3?9+>WM
MO/=I9/*C5-['DL<#DDY.3SDGUJ/3/"MAI-_<W5M8V=M=79)GFBA59)R>[,.6
M/NV33 \'^+WQ8D_9K_9Z'B3Q5937VH1[4T_086S-X@UVZD>01*BY.TSR'RT&
M=B N065-N5\"/V8M:M="\-ZM\0M/B\1>+(I)?$BPW+QO8Z=K5Y*[3W$BYRTD
M*-''%M&R-%VI\V9&^BM8\(:?K^H65U?:?8WESILAFLY9X$D>S<C!>,D91B.Z
MD&M!82JL/6@GE/E"QUW5/VF_VLU\/^&YI(_ OPGOVG\2Z\%'_$Z\0^68TMX^
M3N^RHY;:<K'($RN(H@[OV=&\2>+O%7BKXK3VLTES?6MWHW@/PW*["*RTF*7+
MWUP<%S)>3P)(6;<[!(P&(/R?4'ASPEIO@[3?L6DZ=8Z79F1I?(M;=88]S'+-
MM4 9).2<<]_6G:5X=L]"29;.SL[,7$AFE\B!8Q)(3DLP4<L3SD\U/*4?+WP7
M^%.K>-OV?H]:\7ZDL?B+XMV(N-=OXS]HU2YM+A-ZZ58)@+:PI$VT8W[?WKD!
MV:5=#]K73]>\1MX7^&6D,NFW'Q"@N1X@U0M^X\->'+3R!=QQ-P%>030P[_XC
M(Q. $,?T3I/A#2_#5Q++8Z9IUG-<9\Q[>U2)GRQ8[BH&<L<G/<YKS/XH?$T:
MYX=76-#TNQU#R9/LV@W<\223ZQ>2<)%8[P0J,5#-<D% D;.$=!O5I6!GEOQ+
M>X_:D_:AL/#<\#?\*S^$\MMJ-YIPAW3>(M;9?,L[)P^!B*+;.Z'(59$,A&[$
M7U=IQD:RA:81K,R NL;EU#=P&(!(SW(&?05PO[/7P&LO@?X'@LQ,VHZU>%KW
M6-3D):34[Z8A[B<D] [C(48  4<X&/0 ,-_]>F ZBBB@!&/';\:X[QQ\;="\
M ^./"_AN^>ZDUSQE<RV^F6EO;M-)((DWRRM@82)%QEFP!G'6M+XH_$;1_A)X
M%U3Q'KUY'I^D:/;/=74S'[B(,G'J>*^8_@;>:3;>&/$G[3'QF:/PN_BBT7^R
M+6ZN)6/AK0LA[>V"@[FN+EB)G2-<LTB*%!RI /KE#N.:?G%>=_#[XP76NV7A
MJXO_  W?>';'Q1*;72H-0N5_M)=MO+<+]HA&1&6CAD.WS7=?E#JK;@OH$]RL
M$#2-]U>23Q@>I]* .8^,?QBT#X%^!KKQ%XEO&L]+M9(H<I"\TLTLKK''%'&@
M+R.SL %4$\^E=)97'VJVBDVR1^8H<K(-K+D="/4="*^5O#&LVO[<W[2E[XIG
M\Y/A-\'+U[72I3=/#%KNO1C][>D!@HAM(V*(W5GD<[L+M'I?B/\ :=T'X3Z[
MJ6CZA9ZLJV'A^7Q*L8FDO+^2'[0EO%'Y3Y82W,LFVWBW%G9'!5& 4SS >R;A
M1O [UY$_[5=IH6@^#[?6_#NN:;XZ\<AVT[P;&\%QJ^U<EWD*N(8D2/#N[R*B
M$[,ER%+O^&FD@^.VC_#=M%FN_%=Y!)J.H)I]V+BTT2P5%VW4\K*A'F2.(TCV
MABRL>% 8OF0'K>\4;AFO//B%\?\ 2_ .NZ#:W2LUKKFKC18[D2!=T_ERR-L4
M@[TB6%S*Y*H@#8+,K*IH_P"T'H^K?'!/ :1W U:;0I=?Y(#06Z3PP RH>8_,
M:;,8;YF$,V53:I=@>B9S5/7M9M?#^B7>H7MQ%:6-E ]Q/<2,%2"-%+,[$\ *
MH))]!7+Q>-+_ %7XB6=A8QV?]C+:W$]W<2AVFN&1D0)!C"[0S_.[9SC"CJP\
MS^)OB_4OCI\>=.^&^@QVTGA_1HXO$7BN^N'+J\:R9L;-8UQN$TT9D;<RAXK5
MU.4E7< ;_B":_P#B=X=^RSV<\&K>*XL6%E<1#_BG+)OE-W,I/RW&TE@.HD*1
MKPLLE>NP#"_Y->*I^TKX3\'Z#XLU+2([[Q+IW@XM_P )#K<15XI[N/"O:128
M'VF\Y5%AA78K,(BT;;4KMOBO\:]+^#^C7&HZ@MQ-9V<L$-S)'M_=R321QQ1C
M)R\KM(H5%!)RN=N02 =N'!/Z4I-</X ^--K\2?'WBC1M-TO6'L_"DZV4VM21
M(FGWEUR)K>!MY>1H6&V0[0JOE<E@<9/[5G[16F_LR_"BZUZZMKK5M2N&6QT?
M2+3/VK6+Z7Y(8(P.1EB-S#.U<G!. 9Y@.BMOBWH.J_%.[\(6^HI-XCTO3DU&
M\M(XW;[+#*^V)G<#8K.48A"P8@9 QS7F7QB^(VN?$_\ :,\/_"_P?J5QI<.D
M1IXB\;:I:,/,LK+)%OIZMSLFNG#,2-K)#&S#[ZFO/M.M(OV!OV>]6\<^,I-0
M\2?%3Q=*=1U2"RN9"VM:K(8X[;3XP&.88M\4"G&"JLP7+!:Z+]E:[L?V?K;0
M='\67%QK'Q*^+VJW-_J^JP1H\5[J*V\D\T4?S%_LMK%&L"LJF)?D (W$+3 ^
ME4X;M^']:=NKB=:^.&CV'Q C\*6,=YK?B)+=;R\L=/",VEVS'"SW#NZQQ(Q!
MVAF\R3:Y17".5U/A=\1].^+'PZT7Q-I(N%TS7+1+RV\]!')Y;C*Y )'3H02I
M&""002 =%N% <$5R7B7QM>1>+=+T?1K>QNYIKK&HR7-P84LX F]U3"DR7!!4
MK'P C;V91L#T]>^/.AZ1\18_!]G]LU[Q7Y O+C2]-"236%L3A9[AG98X5)X7
MS&5I,'8K[6P =SNKGOB3\5/#_P (/##ZSXDU*'2=+CG@M3/*&8&6>5(8D 4$
MEGD=5  [YZ9-<[\._P!HW0?BE\0-=\.Z7!J#WGA:%/[9FD6/[/IMRSNHLW<2
M'=< 1LY"!E5"I+#>@:+X/_M'>&_V@_$/BVQ\.VVH7VG^#]172[C59($73[V[
M"[Y([=MQ:0Q':')55!*E2PYH ]%659%;ZX->)_MF?&/7_"]AX:\#^!+J*U^)
M'Q&OC8:1.T(G71[:,![S4GC8;66"+H&R"\D8PV2IW+#]KCPEK>B:QKFG-?7W
MA'09##?^)8EC728G5PDNR5W4S)%G+R0J\8VN-Y92HXW]D3PWJ'Q<\6:Y\;_$
M%I-9WWC"!=.\,6%RK))I.@1N7AW*>5ENGQ<.#T!C'&"*0'O.B:<^E:=;V\EU
M<7TD$2QO<S[/-G8#!=]BJNYCR=JJ,]@, 7 P-<I\4/'TW@[PVTNGV(U+6+B2
M.VL;66;[/#+/+(D,?G2[6,4(DD0.ZH[ 'Y4=L(W&?M:?M)P_L[_">.Z6TFU;
MQ=X@F32/#VB6D@^T:KJ,V$CC4D#"!F!9R %'H2 6!Z+H_P 0M%\0>+M7T&QU
M.SNM8T 0G4K.*3=+8^<I>+S /N[U!(SU S6SNKYQ^$/@W1OV)/ NE1>+_%VH
M:MXW\::DUYJ)@19[GQ1K$H!F$,$<7F-&N54 !4C10S;!DU[?X;\>VOB"_OK%
MH+JQU+2TBDNK2YV>9"DFXQN2C.A!V/T8\H1UI)@= 6Q39?FC8#!/]:\O@_:Z
M\%WL=K=6]Y<W&BZAK<7ARRU>.'%EJ-_+*85AMV)#7&) 09(5>,;7^?Y'V^=_
MMJ?&/5O%OBO1_@?X#NI(?&GQ B8:IJ,2[AX9T@?\?-RQY'F.A*1KP<MG*DH2
MM .G_9R^+^N?M#_$SQ=XHL[\1_#/2IVT'P_#'#&5UN>%_P#2M1\T L8Q)F&,
M*VPA'8C=T]N!P*\[^$FH^&/A\-)^'?AO2]3M]*T'36@LKF*RD;3E6V9(7A-S
MC89PS#(8[F(DP6*28[O5=6M=$TVXO+RX@M+.UC:6:>:01QPHH)9F8D!5 !))
M. !1$"T&S03Q7$^$?CQH/CBUTN]TUKV;2=<N3:Z9J+6YCMM1<1O+F(MAFC*1
MN5DV^6X7*LP()N>-?BYHO@6/S+Z27RX[FUM)Y(DW+;27,T<,*N<_>9Y4^49;
M# XQS5 =4&S03BN5N/B]H=GX^TOP[)<,NI:R+G[&.-L[6ZAIE7G)*!@6(!"G
M"DAL"NGDD CW=>_K0!4\1>)].\):+=:EJE]9Z=I]BADN+FZF6&&!1U+NQ 4=
M.I[UG^(/B)HWA[X?7GBB]U"WM_#]G8-J4U^6!A2V$?F&7/==HS[U\Z_&BU;]
MM[]H5OAO97UY_P *W\ RQ7WC>2$Q^3JNH!A)::6NY&#JC*)9QRAVHA ;.*/Q
M<\0K^T?\=(?A,NJ7.I> _!]Q;ZKXYO)DB9M4GW;K/1HDAC7>))(_-E 3)2$K
MD<@@'L7[*7C#Q;\5/AS)XM\4QPZ=;^)+M[_0=*$(2;3-,8#[.L[9.^9T_>M_
M=\P+VY]3#9KF/!/Q2T/QIX0N-;L+Z'^R[.:ZM[F:1U1+62UE>*=6;.W"/&X+
M [<+D$CFJ/AGX]^&_%^I:/#8SW$D/B%96TFZ:!HX=4\I [F$M@LH0[P^-CKR
MK-0!VQ.!7FG[5/QV;X"_"]KZQM/[6\3ZQ<)I'AS2\X;4]1F.V&/J/E7EW.1A
M$8YSBO0]0U*#3;626XDCA@C0O))(P5(U'5F)X '<G@5\G?#WXPZ+\7/BD/CA
MXJNFL_ VEZF/!OPWBD@D87EQ--]FN-2,84LIGD'E1D@;(D8L 6S0!]/> -.U
MC2O"&F0^(M0M=4UR*UC6_N[:#[/#//@>8T<9)*)NZ DD#J2>:VMW%<OXJ^+G
MA_P3XDTW0[Z_#:]K 8V&FPQM/>72K]YQ&@)$:\!I&"QKGEA6CI?C73]4T6;4
M%F\NUM7GCN'F C$#PNT<H<G &UD89^Z0-P)7F@#8+8IKME*Y7PE\8_#WCVUL
M+K2+YKW3]5D>.PO5A=;6_=%9V\F1@!(-B,P=<HP5BI;!QY7^VA\<-6T:?1?A
M?X'DDC^(GQ)+V=G=#E?#]F!_I.H28(QY<>[8N<LXX^[@INP&[\$/C1JWQT^,
MGC2\TZ2U7X=>%YET'3Y1%NEUG4H_FO+A9"?^/>+<D*X&'99&WD!17L6[->9_
M!:;P7\&[/1/A3X<>>.;0=)9[>+[)*5DCA=$F=IP@A:8RS*74-OW2D[>N.D\-
M_$#_ (2[QEJUC9V4[:?H_EQ/J+.ODW%PPWM#&N=YV1M&QDQL/F[06*MM8'4T
M;JBN;R.SB:21E2-%+LS' 51U.?05S7AKXS^&_&L=K)I.I+?6NH3M;6EY%#)]
MCO'"NQ$,^WRY1MC?YD9A\IYS0!U#R )GK_A7"ZI\0(]4AU*]A>XCT71Y6MO,
MML";5+E7V-!"2/NA_P!UE2"TF0&4(=V%^TI\7KSPM::3X4\-QWTWC3QM.;'3
M3!"&_L^$+NN;UV9@BB&'<RAC\TC0J1M8D=5X+^&UMX8TW2DDAAQH]NMOI\$3
M-)#IRA=GR%N7D*?*96PS<X"AF% &GX6N[O1? >GS>(+JW^W6]E&VH7!8)%Y@
M0&1L\ +G// ]ATJQKOBS3?#WA*\UR^O;>UTFQM7OKB\=QY,4"+O:0MTV!023
MZ U\Y_'N:?\ :^^-Y^$NDWL!\$^%S!JOCR<1F2.YD#;[72"X8 B0J))HQ@B-
M -X+%6I_&SQ))^T5\68/@W]KAF\)^'Y+;5O'E];PF"!X=P:RT5%W.7DN)%W2
M;",QQE "S,HELGF/8?V7OB1XB^,?PX7Q5KVFV^CVFN7,ESH=DJ.+B+33@6[W
M!9CF:1!YAV@ *ZC&<D^EUB^"_%NE^+/#Z7VE7$<]BDDMON"-'Y;PR-%*C*P!
M4I(C*00,%:H>&_C5X7\7ZE9VNEZO;WS:@)39RQ*S6][Y?$GDS8\N7;WV,V!S
MTIE'4T9J*>[6#KZ9/L.?\*Y'PY^T)X,\6^!=8\4:?X@L;GPWH,EQ'?:K\RV<
M7V?/G,LK +(B8(+H67(/-,#LZAO;V'3;:2::2.&&-2SN[!54#N2> /K7-Z=\
M;/"^JR>%XX=6A:7QK#)<:'&R.CZE&D7FNZ*P!VB,ALG&01CJ*S_%?B#P-\9-
M6\0?#/4I],UZZ6P236M%8&7RK>7&P38X0N,%58AB,$#'-+F [7[7']F$VY?+
M8;@P;*D>N?3WJ)]1A;3A<>9']G*[S('&P+_>STQCG/I7S/\ M+:S=?M#?$NW
M^ /A&[^QZ;]D2Z\>7ML#_P 2;3.#%8JRD8ENN%VC#+%N)X88C_:,\4?\)7XB
MTG]GWP[=6NFV-YIZ77BJ]M!]CB\-^'H]J&W#;F"RW'$*#/RH6)X((7,!ZE^S
M%\9]0_:!T?5_%D=K9V_@V^U"2'PM(H;[5J-I%F-[R0EL;)958QJ%4A K'.^O
M3YKR.WD17D53(VU03]X\G ]3P3CVK"\ W6BKX4M+701;KI>D@:=#;P)M6T\G
M]V(=I *%-H&" 1Q6#9S^ _VBQI.O6K:/XJA\(:M)/I]]$_FQ65[&C1N\;#Y6
M*K(PW E03D'(!!S COPX;I]:6L'3OB-H>IWEU#;ZE:R26,,=S<#>%\J*0N(Y
M3G_EFYBE"N,JQC?!.TXO>'O$]CXKLGN-/N%N(HY7@D(!#1R(<,C*<%6![$ U
M0&A13?,7'6LG7/'&E^&=G]H7:6?F,JCS/X=S!06_NJ6(&YL#)QG- &Q167-X
MQTVVUN#39+R&._NMPB@9L,Y5=Q49_BV_-MZE02!@$B/Q)X\TGP@+;^T[^WLV
MO9/)M4D<>9=R8SY<:?>D? )VJ"< G&* -BBN?T?XI^'_ !#KKZ78ZMI]WJD-
MJM[+9QSJ;B"%CM5WCSN0$Y'S <@CL:M1>-M+GUF33TOH6O(HGF:(')"H0'YZ
M?*60,.J[TSC<N0#6HS63!XVTNYT^:ZCO(Y+>WE\F1U.=K\$+ZY8,I4?Q!U(R
M&!-C1_$%GX@TBUU"QN(;RQOH4N;>XAD5XYHG4,CJP."I4@@CJ#0!>H(R*Q/#
MGQ&T/Q?.T>E:I9ZBR*7S;RK(K*"5+*1PRA@5)7(# J<$$5%+\4/#Z^))M'&J
M6LFJ6Y19[>-M[6A?&SS<9$6_(V[\;LC&<B@#C?VG/CW<?!/0=%L]&TV+7O&/
MB[4XM(T'27F,27,S<R2.P!*0Q1!I'< X  [BNB\0.NK^,])T&Z>-H;BPN-0G
MB&56Z,3P1A<<[H@9BS*3U\O.02#Y+^S?IO\ PT?\==>^-%V?/\/V:2^&O 43
M?ZL622$7NHA3_%<W"%%;"GR($XP_/J7QB^$4OQ%L=/NM,UR\\,^)=#D>72M7
MMHEF:!G&'CFB;Y9[>3"[XFQG:C!D=$=97<#HO$NKZ9X2\*75]JMW8Z?I-A;M
M)=3W$BPV\$0'S%BWRJH7/4XKS7PMJNM>./)U308[KPSX(O'58TDML:A?(V-E
MS;PN"+2(G9E9%9W1BVR!E!E^;9_$7Q:_:V_:MNO NH1?#OQ!X7^"MS;WFO)%
M<7FFZ?KVHR1[K59(REPY\AT:3R<["Z_,[84#Z,M/'VJZEKM]INM^,[!)M+5?
M[0M_"N@W,PTYSDF.>]?ST7*,C%=D4BCY\A3D):L#I/$_A/1TC-C:V-O>^(KB
M(BUN)B9[JTR<?:#*Y,B*C?-D,"6&%RV*[RU0Q1JN\R;>"QZGW_SQ].E96FVN
ME^#M#GG_ '-K9Q@SW%S-+G=@<R22N26.T#+NQX YQ5G0?%NF^)[/[1I=]9:E
M;X!\RTG29>0&'*DCD$$>N1ZU8&EUH)Q66OC/2I;R[MTU"QDN+!=]U$MPA>V7
MGYG&<J.#R<#BN5^)'[2/@_X;_!?4?B!>:Q:W7A?3[62Z%Y8SI<I=A,C9"R-M
MD<L-H /7KC!P7 [T,"<4M>0?LK:CK1\,O?\ CC5F_P"$V\8.=<GT"6\#-X<M
MW5/*L8X205$,;('8*-TCN2<%:]-U[Q=IGA6S6YU34+/3;=V$:RW=PD*,QZ#+
M$#)]* -+/-'6J\>J03V"W4<L;6[H)5E5@49",[@W3;CG/3%9MS\0M#M-%74I
M-8TN/37E%NMVUY$L#2%]@0/NV[B_RXSG/'6@#:H)Q5#5_$VG^'XEDO[RUL8Y
M&V*]Q,D:L>F 6(&?:DA\16=_<R6]O=027$:+(\:2*SQJWW6(SD ]B<9'3UH
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M-7^&OPEL;2U\.?!/2;"34M6>Y8P?VM%9/;K#9,6"_+++(LKD_-((W8X!4O\
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MV>_A+J'PH^#$/ASP]K:WEU##//+X@U2W:\_M75)Y#+-=M&)(R\1D9S@.-V0
MV%+-ZRUHKCYE5L]CS3HH?*_S[8HY6!Y[X:\*?%2QUZSEUCQQX)U'2XW_ -)M
MK7P?<6D\Z<\+*VHR*C9/7RV'&,5XC\0M4OOVF/VDK/X<^%9/,\*^"=3@USQ_
MKY(*W%Y XFLM,C&,.4E19)(_NH(PK$G<K_6AY%01V2QH=JJN3N.!C)HU ^:/
MA'X;U3QS^T[XF\::AYPL?"=Q>>%_!NA/<?<=7$=]JMSCD--(I57;+^5G )=0
MW._ +Q+J7@/X2^/OC;XXCF\5?$::/5Y8M,A(!T?3K"695L81DBWCS S.V"S%
ME!WR!0WUTMJF6;RUW/\ >/<_7_"FBPA+LWE1Y;DG')/J??WHL!\[_LG?#F\^
M$_P@U+5O$VHVL'C#Q9<2^)_'6MF0)#I[MF0VJ.3A5@C.S .V,"1\J67=YSX$
M^.-I)X;\8?M">+K6;2_AO!81:%X"T,1E+G5K$2*4*0X'-[<"(J#G<L<?/EKN
MD^S!I4*V_DB&/R<;=FWY<>F.F/;'IZ4YM.AD*[XHW\MMZ94':W3(]#R1]#19
M@?&6K>%?BIX>_9W\)Z+=:DN@_$_XO:[<OK&JB0>7X-@N(YKJ[>(E@/.BM(E@
MC((*A%"D'?*W2?%CP%K6O>,/@]\*-'633_@Y'ITR:@MS=-!<:U#I\$*PV4LF
MTD1R*P=HB TT<4V=J@U]3W&E6]XBK-;PS*C;U610P5AW .<?6B\TBWU"/R[B
MWAN$SN"R(&4-U!P>]39H#Y9_:@M/%7@WX8^(O%7@'4K5O%=\NG^%[;4HHMNG
MZ!937L<'DV*@$?(9=\EPV_#1A0JA5C@A^-OPR@\&?![PK\#_  &UU96GC#5#
M:>(O$C76V:W@C5KK4;N69CNDNY5C92>0&EPQ4;5KZNETV&XMFAEACDA==K1E
M<H1Z$="/YU7;PY8R0VT;6-JT=FP>!3$NV!E! 9!_"1DX(Q@&GRZW R?A;I-C
MX=\,VFFZ3I\>EZ'IEO%::7;(A4+;H@5< @87   (S@ DG<,=),NY/QYIL5NL
M+?*JC)YP*>XW+_*JMI8#Y._9KTW5/@KI/[2 \J3_ (3:;QOJ&J6"S)EKJ*ZA
MA_LZ7:6&Z%I"R@Y )CE7@J0/:_#'A#3?AIX M_!'AW=>7T=NT4]P_P"\<22D
MF6\NG[R2.S2'/S2.6P,!BO3^.?AYIWCG2Y8;JSLYKGRV2VN)K=9'M&/(=,]"
M&"M@8S@5K6&E0:7:QPVMO#:PPKMCCC0*B#V48 _"A*VP'S5XM\!W_P 6/VWK
MG3/%FHQ_\*O^%_AVPUJTT:4)#:WNH7,EPB7-UDXF2(6LQ 8*JN%(&02WI.ER
M:A?^*_%/B2XCFT#2[ZW@MEOKUT@2VT^T\Z1IRK'<DLCSS8WA52)48D,#&?1M
M0\,:?JM];W5U86=S<V>?L\TD*M)!GKL)&5S[8S3]7T*SU_3+BRO[.VO;.Z0Q
M303Q+)%*C#!5E;(8'H01THMU ^0O@[H&L?MEW/B?QM<Z=J=K\,=>(\-Z#ID4
MH@GU70$:1YIU#E&1+V<1^86(D:%2%(X8S:YILW[2G[4.D?#71;"SLOA_\)6@
MU+7$LXT6QL[Q K6&G( -LCQD>?(%'EAHXT8,J,LOKW[6WQOD_9X^%.GZ;X4L
M[6Y\:>*+B/P]X.TA%"K)>R#",5P0L$"9D<X"JJ $C<*Z+]F;X!V?[.7PBT_P
MW;S-J%\I:]U74I1F;5]0E.^XNI"23N=R< DE5"KDA16>K8'C_P ";+Q!X^^.
MFO?$34(VMM-TN74/#'@7P_YC1M<QK<+'=ZM=N06S/+;@;G4E8TX#LRAJG[)-
MOJ4_A_Q!\9OB5<7/B#QEK6IZAIVAV4$!W:;8V\\MNEG8VQ)\N69H'=L,S,"F
M]SM9J^G]-\,Z?HSW#6=C:VKW<AFG:*)4:=R22[D#+,22=QR<GW-1V/@[2M-U
M&:\M],L+>\N"S2SQ0*DDA8[FRP&3N;DYZGD\UIR@>%_%[XM1_LP_LUC7O%-K
M]LGLXUBLM%ARTGB36;EB\=M"FW>(3,V$0H'5%RR#8 <'X(_LQ>(+SPYX6U;X
MGZ6OBCQ%:N_BC['),B6%GKMU+))+-,I9LF",Q11!4=8E5RH9\./I+5/!VEZ[
M<V,U]IFGWLVF3?:+.2>!9&M)?^>D18$HWN,&M 0+MQMZ4P/C?X0?$34/AK^S
M'J_[0GC^WG\4?$;Q-IDVJ6&FVD;R)I6GE_\ 1+*UC;_4P[6B>:7[S,V6:0JA
M-WPSI&O?L=?LH>)M>C5_$WQ8UY()]9NP!-G493':V&F1Y(&V'S(853.%4/(1
MEU1_JN+P;I<-E=6ZZ78+;WH(N(Q NVXR26WC&&R68\YY8GN:=-X5TZ?2OL+V
M-JUF.D)C!08;<"!TSN ;/J,]>:F*:)4;:GS%'X=U7]B7]CF\TGPO!)XD\?7D
MJ/J=ZC&5M7\1:C*D;,9, EFGD49('EPQJ3@[0U'7O"WB+]B']AK7M+^'LUEJ
MGCP317.LZY/'YJ7>L7UU##/.<CYY09/E# [$BCWACA6^J[KPM87FD+I\EE:O
M9?+_ */Y8\H;2&7"XQPP!!Z@C(YITGA;3IM"?2VT^Q;39(S$UH85,#*>JE,;
M<'TQBCE'8\1@^%EK\+O N@^"]/;4-<\176HV>J^(-6CA>ZO+J6*9+F6XN)"&
MV-/)#Y4?F,JJLAV_)"<<?^UWXUUCQ[XITGX0^'XTOO''CZ!GUIXV_<>$_#V=
MMPYDQA'G'[K?@EBYP.(E/U!IGA^TT2V\FSMX;:+=O(C0+N;IN/J>G)]*JZ7X
M#T;1/$&I:O9Z3I]IJVM&,W][% JW%YY:[4\R0?,VU1A03@#I1K:PSYSBMM<^
M(W[7+2323V?@?X27$8D,:8NO%OB":R)2*-<Y%O:VUP2$W !I"6+@,R?3FG^:
M;:/SD2.0*-Z(VY5.!P#@9_(?ATJG9^#],L=7N=0BT^UAOKP[IYTC DE.U5)9
MNI)5$&>X1<_=%:2)Y84#H.,50#J*** "BC-(&!H 6C-&ZLGQQXYT?X;^%[K6
M]>U2QT72;$*;B\O)EAAAW,$7<S<#+,JCU) H UJ"=HYK)\5^-]'\ >'+K6=?
MU;3=#TBQ4/<WM_<I;6UNN0H9Y'(5020,DXR16=\4?BWH/PD^%NL^,-:OHX=#
MT6Q:_GF1@V^,#*A.?F9SA5 ^\S*!R12N@.E$JD]:=G%>:_LIZKXV\4?"*UUW
MQ_Y5KKWB">34TTN.%8_["MI3F"S) S(\<>W>[?-O9AT45Z0_"FF I<+U-)YB
MR<*<GK7)^*?%LC^+K'P[IKQB^FA-[?3!E/\ 9MFIV[RO.7D<&.,' ^65OF\H
MHT/PAN)-4.K:C"]\VCWUSG33=7#SM<1J &N$+DE8Y'SL53L**KJ ),4 =A'#
ML?=WZ9_STIWF*#C//I39WP@_VN.17B7P$^.?B#]H/XT>,=3TQK>W^%_AB9M"
MTV00*TOB'48R/M5PLA.?L\3 PKM #ON.[ V@ ]P#@G&:6O$OV>OC?X@_:$^,
M?C'5]/:WA^%OA^8Z%H\WE@R:_?1,1=W2N<GR(G A3;\KD.V>,#VOS5W;=PW>
ME #J#S3([B.9<JRLOJ#FG$T 03?\?J?[C?S6K Z57F_X_$_W&_FM6* "BBB@
M HHHH *"<44V0X0T !E4#K2AP3BN.\2^-_-\43:/:W5O:Q:9;"]UJ^<J%TV%
MMWEKE_EWOL=B3D(D1+8WQ[I?@Q?7VK>"TO+Y;A5NKB::R6YS]H6T:1C!Y@."
M':/:Q##<-V&^8&@#K:* V:,T !.!0&S7-_%WXIZ+\%?AGK?BSQ!=?8]&\/VC
MWMW)C<Q1!G:J_P 3L<*JCEF8 9)K&_9Q\6^+?'OPAT77/&VE6.AZ[K$9O7TR
MV63&G12$M##(7.3,L97?P '+   4 =[13=Z@=:/,4]^M #J*CCO89GD5)8W:
M/ <*V2N1D9'N.:<9% 'S#YNGO0 ZB@'BFF15 W,%STR>M #J*:TJI]X@4[=S
M0 4449H ***"<"@ HI V:6@ HHI"VV@!3P*3=DXILL@"?D..M>:>"OC]-\1?
MVBO%'@_1=.M[K0_!-O#%K.LFXX34I1O6QBC"X<I$5=WW?(6"8)S@ ].HHHH
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M7BNU\#_""^^)/Q>D'A.Q\42QWNH:;=@S3!'/EV6G&.-69U2,J/LZ!C)+),S
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MU8]8F93"DBGYE23HSR%;G@_Q!X\^#7[,7Q$^*E_IMO=?$KQ%I*ZNNA$%=/\
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M@#1O'<5E'K6DZ;K$>FWD5_:I>VR3K;W$9)CF0,"%D4D[6'*GD8-;"J0?QHL
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M3]VLS,6>4)G:LCLS,SJ S$Y))YK=HH Y-_@GX7G\41ZU-H6F3:K!<-=PW,D
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M M%%% !0>E%!Y% %>?'VR/GG:W'XK5@=*KS\W,?IM/\ -:L4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!1US2%UFWCCD+>7'/%.0 /F,;JX'YJ*\/
M^&_@A_#/[>GQ1\3:^RQMKFAZ/!X<GF.U#9Q+)]JB0G W"X"NZCD!XB0-P)]\
ME?:AYQQUKB=(^,WP]\?WLEAI_B[P=K5U;LS/;V^JVUS)&1D'Y0Q(P<@^G(H
ML>)M;M_$MO<Z7;W%N]AM/]IW6X>1:0 9>-F/&YDXQD[5)8XP W@?['DMQ^U=
M\>/%'QXU3S&\,PB;PS\/;>3_ %:V"/BZU  @?-<RI@-PP1"O*X->A?M >$;[
MX\: WP_T2ZFT7PQJ)*^)-:M?W8BL0V'L;9@<>?/@HSC*Q1F3=\[(K=MX??3?
M"_ARQ\/^#]/M7L].MX[2T@M?EL=/BC&Q5,@X 78%"KE\CH!DK.X:FEI;K+\2
MM6DC^98;&UMY' R!)OG<IG^\%=&(ZX=#W%5Y?C?X/@L;ZZD\3:+%9:;&\MU=
MR7:):P*C!'+2D[/E9E4_-P6 .,UXE^U5X+USQ7XB^&OPYAUF[TSPUXRU*^N_
M&>H6[&&XOK:VMQ,;82;LQ1S?<*J<K$H4,%4JW/?$[P]!^T%^U#X;\#RZ7_9/
MPE^%NF6NNW=ND2QVOBBZFD9+"TAB7&ZWC:TDDVXVN8@ A4I(36X:GMW[2/[1
M>C_ 3X)WWC"XO(YHUC1-,@BB^T2:M=2C]Q;Q1JP,CR$C 4\#+= 37$_LL?"G
MQ-\$O"6I>*_'_B#05\2>,KH:UXFEFA=!9R.NV*RCF:;8(;==D:@)@D,>"PKF
M=4T&X^.?[:8U3Q79-'X9^#L$+Z78G$@OM>O(Q,FU>1(]M:^6WM+<!E)$6ZCP
MKHWBCXK_ +5/Q"U[Q@VC6]C\,9+:R\*6-W*[6&E23VD5S+J4L7 N)QYHC63S
M$"^7*J%2Q>EJ3J?2ND^+--URQ:ZM+R&>WC9E=U/$97.X-_=(QR#@BN"^*G[5
MW@_X=_"37/%T.J6NM6>C6_F116,GFMJ,S2"&*"%ER':2=DB&W=AG ->(_$7X
M*7WBOXG^"?AW)JE]#X!\42:WXS\:S3M]GOO%7V9K--D[+M6.VDDO(4,(49AA
M"G';5\16,7QR_:]TF2]T]K/P#\$X(9]-MUC*IK>M72*UL(XA@.EM"@=!P=\B
MO@)M8O5Z%'I'['/P3U3X5?#ZYU;Q4T=QX_\ &UT=<\3W"X*K=2*-MNA'_+*"
M,+$HR0-K$'YJ]?JGI,DTMK$US&D,Q7YD5MPC/IGOCID 9Q[5;5@W?..M4 M%
M!.*3=S0 M!Z49H/2@"&;_6IQV.3Z<BIA4,I_?KT^Z>_N*FH **-P]: <T %%
M%% !10#F@T %%!-% !103@44 %%%&: "BC-% !111F@ HHS10 449HH ***3
M=S0 M%)O%+G- !11FC- !12!LTM !1110 444 YH **,T9H **** "BC=1GB
M@ HHSF@G% !12;QZTH.: "B@M@4!@: "B@,#10 449HSF@ HH)Q0&S0 4444
M %%%&Z@ HHHH **,T YH **"<4 YH **** "BBB@ HHHH **** "BBC- !11
M1F@ HI-PI: "BBB@ HHHH **** "BBB@!KKN'I7&7_[.7P_U76)-1NO W@^Z
MU"60RO=3:-;23.YZL7*;B3ZDYKM:* .=TOX4^&]%DC:T\.Z':F%=D9AL(8]@
MZ87"\#'%;D5JL0&WY5484=E'H!_GH*FHH S]4\.6>NHB7UG:7D<4BRHLT2R!
M6&<,-P." 2/;/&*%\-6*ZJE\UG:O?I%Y(NFB4S!"<E=^,X)).!QG/'-:%% &
M<?#%B=9_M'[':KJ!C$+7(B7SF0$D(7QN*@G@9[GUYCO?!6DZIK,.I7.F:?<:
MC;@+#=2VR231 9("N02,;FQCIN/K6K10!GZKX5T[79K>2^L;.\DM&WP-/ LA
MA;&"5W [21P2,9%-7PKIZ:I)?"QL_MLR^7+<>2GG2H!@*SXW, .,$UI44 1O
MN5>!R>_>N0OM:\?1:E*MIX9\(S6:LPCEF\27,4CKG@L@L6"DCL&./6NSHH X
MN/6_B!GY_#'@U1CJOB>Y)]O^7"G0:UX^(7S/#?@\<<A?$MRV/_)'FNRHH Y-
M-7\<^;SX=\*!<=1XBN/_ )"IS:QXV"_\B_X6_P#"@G_^0JZJ@T <BVK>,GFC
MW>'_  QNVDX_M^?';_ISJ;^UO&6?FT'PS^&O3G_VSKHI3^^7KT/\Q4U ',OJ
M_C#'RZ#X;_'7)Q_[:5&^M^,D./\ A'/#[^ZZ[+C];45U5% ')R>(/&: 8\+Z
M*V>N-=?C_P EJC;Q-XU7_F4])/TUX_\ QBNPHH XM_%OC2,G=X+L9-O3RM<5
ML_\ ?42T+XW\8_Q>!Q^&LP_X5VE% '$OXY\81C_D199/9=8M\_KBC_A//%P3
M/_"!W7NHU>US_P"A5VU% '%KX_\ $V[_ )$'5AW)_M*R_P#CM._X3_Q$!_R(
M>NY()XOK X/_ '_%=E10!R,GC_7@R[? OB!O7_3; 8Z?]/%2#QWK&W<W@GQ)
MN]%N=//_ +="NJHH Y8>/=6)_P"1(\4?]_\ 3O\ Y+I?^$[U7_H2?$__ '_T
M[_Y*KJ** .7_ .$ZU8_\R7XF_P"_VG?_ "50OCO5C_S)/B9?;S]._P#DJNHH
MH Y6;Q_JT+?+X'\4R9/\,^FC^=T*C;XBZT!QX"\6?^!&F<_^3E==10!QY^).
MM _\D]\7GCM<:5_\F4P_$[7 W_).O&6,?\_.D_\ R;79T4 <:/B=KF/^2=>,
MO_ G2?\ Y-II^)FM_P#1.O&7_@3I/_R;7:44 <6/B;K0'_).O&7_ ($Z5_\
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M"UFBF$(MW='*[I&W&-P2CX7#$N@+H/VI]$ETWP/<-8ZDJ>-V'EE%5TTY#)'
M))V!P%,\\$(V[B6F!QM5RIS(#JC\6M-#8^R^)/\ PG-1_P#C%-/Q<TO'_'KX
ME_\ ";U'_P",5Q>H_M2-H0\82:EX/UJSM? ]L+G4I?M5I(&#1>;&(@LOS%E(
MY.T#G)XK:^*G[0FG?"O69K"XTW4K^\CMK*=%MO*59?M5_'8QJ'=U (EE4MG
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MUU!=6LEK<6DP57V/'*H8?)(C XVL"""00:Z!$V_YS5 .HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "@]**#TH AE?$R+_LG^E3+TJO,?],3_=;^
M:U8'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;7?@+KFL?$"WUB'^Q-)N/MUC=-JUA<7%OJ-O# (O,LI BA+Z-PDJ+).5V).
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M_&*R^'X\7W@U[QM:^%=0U2PCMM0M%UZ+3VU.T#2!!(K'>!EY%$D>Q\$@/Q@
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M+>2>(-/L='M]?NO$EA=S:G"EO<7=U+=3R8D)VNI:YF(4'H!S\M,URR^'MI\
M=)TV^\1:39^"X39"RU&;5X$@F,$R30@3L=C?/".G7#8]:-4!<\*?$?Q+XPU$
MWUEH6GS>&UUB[T=S]M*W\:V]Q+:R7.UE$90RQ$B-6+&/#@ESY0P?"/[1VI?$
M/4?%EIH.CZ4UUHLGVK3VO=2DCAU?3Q+<6QN0R0MM/VFSG "A@8S"^[]XJAWB
M#PKX%\.^5)>>-(=%TF_NY]?T^Q?5K6WLS=3NTS7D)90TA\Z5YAN=HQ*X?;]T
MC1\&_!OP#X7OK+4/#_\ 9U@WAW1WT:9K":)0]I-' X^TD#+$+#'(CN00"QSA
MVR(#EKC]I_7HK?P.USIO@;2Y_&VBW>NQ/J7B.6"WMH(?L!2/>;8[Y&-[DC
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M[?;\O+7+J!E<M1T[X^ZAJOQ@71;ZQ^'FEZMIDMKIL\.H>*3%J8-U;VEQ,MO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS1H?P'EU.V^%NG>(O NCS7/@CQ5<Z?</':K>6T>E)I6I"S*2RH&DA03VL66
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "@]*** *\W_'XG^Z?YK5@=*KS#_3(_]UOYK5@=* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BB@]* ()C_I:_[I_FM3CI5>;_ (_$_P!T_P UJP.E !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !0>E%!Z4 5YO^/Q/]T_S6K Z57F_P"/Q/\ =/\ -:L#I0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4'FB@]* *\Q_TQ/\ =;^:U8'2J\W_ !^)_NM_-:L4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%!Z4 03?\?T?^XW\UJ>J\W_'ZG^ZW\UJQ0 4444 %%%%
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M7:S>&_%&CZAJOB6X29FF\/K:S6-K*5 X98;J[Q*3C9'%(_\ "5.YKMG\(/\
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M17D^7RY!>2+(1N=?*3:CY..>^'_@OXD?"K4=$U;4-'M?%E\_A\Z-J$6GZA#
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M#Y5Q=-<R:I&(B_G$*$^Q1G<%);<PP.,'09O>!;36?&'Q?U;Q1?>'=7\-VO\
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MTLS$ ,=J$*P%<HN9'/0?#+Q%+\055;/69[JU^)LFN0V$^BK%8?8GG.^Z^W;
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M6_@K4_ /_"-ZI)<WWCR76XM254^P-I\^N'56G,A(VLD;M%Y9&\R(, H=P:W
M[Z]^"_AW7=6M[:;Q/X@N-:\-S-?Q2-K1:\L%N83#A@>5C=4? 88)WX/4#/\
MA7I7PIUC5])A\)^(M#UK4- N;O5$^R>(%U&ZEFN5*3SSMYCO*2)<9<D*"@&
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MSOX=^&VC:+I>B^+O$OA^0:<^CQ2KJT<EQJL >2X&XS(^Z1#),PDC"R 2/\V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(_W32TC#*F@
M#YR^+_Q(\>R?&+QCI/A"]\127WA_2]-FT?2[72[2;3;V[N/M)87LTD>^.$[(
MLLDT;*H8C<< [\WQC\0+\)M6U07=JFH0>/X_#<$GD+M6V?7X;%4*]"WDR%<]
M2<'TKUO3/"&GZ1XBU+5K>UCCU#5UB6\G&=TXB!6//./E#$< =:Y:_P#V;?">
MI^./^$AFT^X;4#>Q:D\/]HW8T^:[C"B.Y>R$OV9YEV(1(T9<%$8-N12 #Q[2
MOV@?$A\;6<9U#7ICJ'CZZ\-):W.AHNAI9Q7<\1(NUC5UE\F(E"9'#3;8RN')
M4T7XS^,M)\2M+KFLZMITVL?VF;.RO-+M9M"NXH[6XGMGTR]M5+-)LB61DNY6
M:2,3LJ+M4#W9_@_X??2/L/\ 9ZK:#6/[?V++(#]M^T_:_.!W9!\[YBN=I!*D
M;216+X7_ &8/!_@_7+>_LM/O%:S:5[2TFU6\N=/T]I59'-O:2RM;P91Y$_=1
MKA))%&%=@9LP.4NOV@KKPSI_P\U36KRTM]&U;PE?>(->G,6WRQ;VMM,74@_(
MH$DA(Y[<X'/F_A#]L'Q7X_\ @'XAET?5?!]]XZL?$6A65M)$AETZ"#5;NS6.
M*7822T(GGMV9<$M;[M@)VU[+H_[(/@70[":SBTO4)[*6U2P2VN]:OKJ"TMEF
M286T"2SLL$!>./,401&6)$*E%51TGB3X+^'?%_B1=7U+3S<:@%LU,IGE3<+2
M[6\MLJK!3Y=PN\$C/+ Y5F!+,#R#4/VA]=^(_A+QUK'AO4AX?_X1#P[!JPMK
MBRCN)[>[5+\75C<!CC='-:HA*G@H^"0P->H>#M"\2ZE\*;83>*%;7+Z&.Y74
M!IL(6WW(A*"(85@/FQDYP>IQFIS\!_"KWWC"Z_L>%;CX@0I;^(6221/[2186
M@ (#?(?+8KN3:>F22,UUEAIZZ980VT*[8K>-8T&2=J@  <DGH.^?QJ@/FOX;
M?$[XC>*M)\#P7/BC2?[3\>/?YN_[%2./2H+1I#)Y:>9^]ED_=!=YP@$C%7VX
M'J'PD\=:Q+XH\9>&=>NK/4KSPC+;RP:G' +9+JWN(3*@E4$JLL95PQ7"LGEL
M NXJ+6H_L]>%[OPWHN@K975G9Z'+)>Z=):7\]O=6$Y;+217"N)5+>;("-V&5
MRC J2IU_!WP?T3P-X>U'3;.VDFM]:E>?4GOKB2^FU&1T6-WGEF9GD)C5(P&)
M"HB* %55 !YQ^SG\6/%7B#Q+9Z5XONVL]>NM):[OM%O-$DL'MKA&B\PV<^6B
MN[9/.5&8.[*?*)(WLHR]$^-'BCQ3\>O$FBQ:IJ5CH^D>)$TJ"&U\$75[;S1"
MVM9',E\I\J,EY)%+'&T >G/?>%_V7O#?A&-UMIO$<P33WTFR>YUV\EFTJT;8
M6AMI3+YD()CBRZMO/EH"V%4"Y%^SWHUEXLOM:M;[Q+8W6I7PU&ZAM=;NH;2X
MG"HI9H0^S#+&@(Q@@=.3E6 R_&NN>)O%WQ0N/"_AO5M/\.Q:3I,&K7M[<Z?]
MN:X:ZEN(H(HUWH@5?LD[2$DL0\87;EC7:^"+S4M0\&Z=)K$FER:J\"_;&TR1
MGM&E'#F(M\VS=G&[D#@YQD\UXJ_9VTOQ5<VUTVJ>*-/U"U^TI]NL-9N+>[EA
MN)C-);O)N):(,1L!YA Q&R G/0>#_AQIO@&TCM=(2:SL;>R@L+>T69VM[:*$
MR;"D;$@.?,.Y_O/M3<3M&&!X;\-_VDO%6O>/?#-K<75A=P^(_%.KZ))8'P]=
M62VUM:/J&V6&^9S#-(!:(610Q?+85-K,-ZT_:)URX^$7P@\0-::4UYX^)_M%
M"C[(A_8>H:A^Z&_(_?6L:_,6^1G'4@CT.W^!V@V-AHMM;V\D,?A_6)]>LCYS
M,T5W,;@RMEB<AOM4XP> KX&,#&'X=_95\,^&KFVV3:Y=6.FPSP:5IUWJ,DUG
MI"S(T<GV="?E/EN\:EBQC1V1-JLP* YSQ=\>M=T?]G7X>>*+7^SH=4\7RZ0E
MV?[+N+^. 7<:O-Y5O"ZRN1D[0&)]<]_0OAIXEU#7/"TEU=2F^N/-<1[M#N]$
M8@ $*8;EFDZG[_"G/ R#GD;3]CS1K7P99Z"/$GCAK'2Y+.73?,U@O)IC6N1$
M87*Y&%.TYSN &<GFN]\ ^!6\":2]HVKZUK7F2M(9]5N?M$XSC"AL#Y1CICJ3
M1J!Y%#\>O&&I?!/4O%,<?A?1M1TC6M2T633&MIM2^W7$.H/8V=O!()H/WDT@
MC3+*%+2K@( :;#^U9?:/^T=X=\#ZI-X49;B&#2M:-K<G[5#K4UI)=JL,9?=]
ME$<6TLZEB]U  >'QZ5:_ G0[2VLH5CG,.GZ_<^)8D>5F4WL[SR.[ GE1)<2.
MJ_PL$((VBJ=]^S9X5U'3[N*;3UDN+S65U^2]/_'Y]LCN4N8G\[[V$>.)57D>
M7&J$%<@E@.'\*?'CQA#HVA>)M6/AN\\-:WXDDT![.RT^:"\T\/J$UE;S>:T[
MI-^\6(.HC3 D9PV$P>L\7_'A;74_!O\ PCJZ-X@TCQ-KRZ/<ZA;:BLJ6A,,L
MIVJF=S?NL?>&W=DYQ@R>&OV9M#\-:OI]U]NUW4+?1[VXU+3K&\O=]K97$S2%
MI%157<P\Z4*7+;/,)'(7'3>)_AMIGBVXT62ZC96T'44U6U\DB,"=8Y(@Q'<;
M9&X^GI2Y0.-^$?QQO?'7Q U71]5@@T>2&[U&&PLY;&[@FO(;2\:W\^.:55BF
M5E$<A\K.P3("2,,?4.O'\C7G]C^SQ;VFM75])XF\67DYM[RUTUI[R-GT..Z<
M/,+>3R_,.2J;3.TI01J$VKQ7H$47E_GG./\ /^15; .*9/X4FTXI]% #<4WR
M\MG\.M244 -*DT!?_P!?K3J* &;#G\<]:0HQ_P ,U)10!'Y;;/4^IIVTX_\
MKTZB@"/8=HZ=!GM_C2[6'^>]/HH 8%QNXZ^G>E(;'O3J* &!-K>OXT%./UP3
M3Z*5@&!,>_\ 2D*-D_Y_S^M244P&;,GI^=*$QC@4ZB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "F@Y:BB@!U!&:**& !<4444 59O^0A#_UR?_T)*M#I
M110 4444 %%%% !1110 4444 %%%% !MH"XHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
